The enzymological characterization of the Inositol Phosphatase Synaptojanin by Knott, Jessica Mary May & Knott, Jessica Mary May
  
 
 
 
The Enzymological 
Characterization of the Inositol 
Phosphatase Synaptojanin 
 
 
 
Jessica Mary May Knott 
Department of Chemistry 
Imperial College London 
 
 
 
 
A Thesis Submitted for a Degree of Doctor of Philosophy 
March 2010 
 
 
 
 
i 
 
DECLARATION OF AUTHORSHIP 
I, Jessica Mary May Knott declare that this thesis, and the work presented in it, is my 
own and that it has been generated by me as the result of my own original research. 
I confirm that: 
1. This work was done wholly or mainly while in candidature for a research degree 
at this University; 
2. Where any part of this thesis has previously been submitted for a degree or any 
other qualification at this University or any other institution, this has been 
clearly stated; 
3. Where I have consulted the published work of others, this is always clearly 
attributed; 
4. Where I have quoted from the work of others, the source is always given. With 
the exception of such quotations, this thesis is entirely my own work 
5. I have acknowledged all main sources of help; 
6. Where the thesis is based on work done by myself jointly with others, I have 
made clear exactly what was done by others and what I contributed myself; 
7. Either none of this work has been published before submission, or parts of this 
work have been published as: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
ABSTRACT 
Synaptojanin is unique in that it is the only mammalian inositol phosphatase to contain 
more than one catalytic domain; a CX5R Suppressor of Actin (Sac) domain and an 
Inositol Polyphosphate Phosphatase Catalytic (IPPc) domain. The enzyme has been 
shown to play a crucial role in synaptic vesicle recycling and its functioning has been 
implicated in the onset of Alzheimer’s disease. Many domains and sub-units in bi- and 
multi-functional enzymes are found to operate in a co-dependent manner. In this work, 
the possibility that the functioning of the Sac and IPPc domains in Synaptojanin are co-
dependent was investigated.  
The kinetic parameters of the IPPc domain were assessed in a double Sac/IPPc 
phosphatase and compared to that in both a double phosphatase where the Sac activity 
had been rendered inactive and a single IPPc phosphatase. It was found that the VMax 
activity of the IPPc domain towards its lipid substrate PI(4,5)P2 is significantly lower 
when the Sac domain is not present or functional. Likewise, it was found that the VMax 
activity of the Sac domain towards PI(4)P is reduced when the IPPc domain is removed 
or its activity rendered inactive. Interfacial recognition and substrate channelling were 
investigated as mechanisms to explain the domain dependency. However, they were 
found not to contribute to the observed differences in VMax.  Instead, it seems likely that 
protein-lipid interactions induce the dependency. In summary, this thesis presents the 
first evidence that the catalytic domains in Synaptojanin act in a co-operative manner 
and probes the mechanism by which the domains interact.  
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Chapter 1 
The Inositol Phosphatase 
Synaptojanin  
A complex system of cell signalling pathways allow cells to respond to changes to their 
environment so that they can repair damage, grow and develop. Cellular signalling 
involves the processes of signal reception, transduction and propagation and defects in 
these processes can lead to the onset of diseases such as cancer and diabetes. Lipid 
signalling forms a vital important part of signal transduction and trafficking with lipids 
such as phosphoinositides, sphingolipids and fatty acids controlling cellular processes 
such as cell proliferation, apoptosis, metabolism and migration[1-4]. Despite their low 
abundance in cellular membranes, the phosphoinositide lipid signalling pathway is 
perhaps regarded as being the most important (Fig 1.1).  
  Phosphoinositides control signalling processes by binding to specific 
phosphoinositide binding modules in proteins such as the Plexstrin Homology (PH)[5-
8], FYVE (named after the first four proteins found with this domain) [9-11], Phox 
Homology (PX)[12-14], Epsin N-Terminal Homology (ENTH)[15-17] and AP180 N-
Terminal Homology (ANTH) domains[1, 14, 18-20]. In this way, they can control the 
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subcellular localization and activation of their various effectors [21-23]. This means that 
the levels and cellular distribution of the various phosphoinositides needs to be tightly 
regulated. This is dependent on the regulation and activation states of all the 
metabolising enzymes, phosphatases, kinases and phospholipases, involved in the 
synthesis and removal of the inositol lipids[18]. Examples of phoshoinositide lipids 
include phosphatidylinositol trisphosphate, PI(3,4,5)P3, phosphatidylinositol 
bisphosphate, PI(4,5)P2 and the phosphatidylinositol monophosphate, PI(4)P.  
PI(3,4,5)P3, is regarded as a very important signalling molecule as it recruits Akt, 
which is involved in cellular survival pathways, to the plasma membrane[24-26]. Once 
Akt is bound to the membrane, it is phosphorylated by phosphoinositide dependent 
kinase 1 (PDK1) and thereby activated [27, 28].  Meanwhile, PI(4,5)P2 controls a 
number of important signalling pathways. The hydrolysis of PI(4,5)P2 by phospholipase 
C produces diacylglycerol (DAG), which activates protein kinase C, and inositol 1,4,5-
triphosphate (I(1,4,5)P3). I(1,4,5)P3 in turn mediates calcium release from internal 
stores [29, 30]. Importantly, PI(4,5)P2 along with PI(3,4,5)P3 has been shown to control 
membrane-cytoskeletal structure. PI(4,5)P2 binds and activates proteins that connect 
the plasma membrane to the actin cytoskeleton and controls the action of enzymes that 
regulate actin polymerisation, such as Cofilin and Gelsolin [34-38]. It is also likely that 
PI(4,5)P2 regulates the activity of various ion channels [31-33]. The 
phosphatidylinositol phosphate PI(3)P localizes proteins to yeast vacuoles and to 
endosomes by binding to proteins, containing FYVE or PX phospholipid binding 
domains, to regulate endosomal trafficking [39-42]. Endosomes are a system of 
membranes that function as crossroads for traffic to and from the plasma membrane.  
PI(3,4)P2 is required for the maintenance of normal vacuole morphology and protein 
sorting destined for degradation [43].  PI(4)P is the most abundant phosphoinositide in 
the Golgi membrane and a deficiency in PI(4)P levels results in changes to the 
functioning and structure of the Golgi[1, 43] .  
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Fig1.1: Biological functioning and regulation of cell signalling by phosphoinositide lipids. 
Phosphoinositide lipids interconvert between themselves through a series of phosphorylations by 
kinases (black arrows) and phosphatases (red arrows).  Phospholipase  C (PLC) cleaves PI(4,5)P2 
to yield I(1,4,5)P3 and diacyglycerol (DAG). I(1,4,5)P3 then acts to mediate calcium release from 
internal stores. PI(4,5)P2 is phosphorylated by a phosphatidylinositol 3-kinase (PI3K) to yield the 
important signalling molecule PI(3,4,5)P3.   Adapted from Whisstock et al[44]  
 
The inositol phosphatase Synaptojanin was first cloned in 1996 and 
characterized as a pre-synaptic inositol phosphatase [1]. The enzyme has since been 
found to play a critical role in cell signalling as its substrates include PI(3,4,5)P3, 
PI(4,5)P2 and PI(4)P. Its action is critical for normal endocytosis and the enzyme has 
been implicated in the onset of Alzheimer’s Disease and Down’s Syndrome [2-8]. The 
characterization of the enzymological functioning of Synaptojanin is therefore regarded 
to be of huge importance.  
Synaptojanin is a particularly interesting inositol phosphatase as it is the only 
mammalian inositol phosphatase to contain two distinct catalytic domains; an Inositol 
Polyphosphate Phosphatase Catalytic (IPPc) domain and a CX5R Suppressor of Actin 
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(Sac) phosphatase. Due to its bifunctional nature, Synaptojanin is named after the two 
faced Greek God Janus. Although the modulation of Synaptojanin’s functioning by 
numerous effector proteins, is well characterized, it is not yet known if the functioning 
of the individual domains within the enzyme is co-dependent. Often, the domains in bi- 
and multifunctional proteins are found to operate in a dependent manner. This thesis 
characterizes the enzymology of the Sac and IPPc domains in Synaptojanin and explores 
the roles of the individual Sac and IPPc domains in the overall functioning of enzyme.  
 
1.1 Inositol Phospholipids  
The importance of inositol phosphatase enzymes and their phosphoinositide substrates 
was first highlighted in the 1950’s , when Hokin and Hokin first observed changes in the 
turnover of membrane phospholipids on stimulation of exocrine tissues and attributed 
these changes to the turnover of phosphoinositide lipid species[1, 45]. Today, the 
metabolism of phosphoinositides by their corresponding phosphatases is known to be 
crucial to numerous important cellular functions. A generic inositol phospholipid 
consists of a polar inositol headgroup connected to two non-polar fatty acid chains via a 
glycerol group (Fig.1.2). PI represents less than 10% of the total phospholipids found in 
eukaryotic cells and phosphoinositides are generally less abundant with PI(4)P and 
PI(4,5)P2 representing the bulk of these lipids in mammalian cells[1, 44, 46, 47].   
PI is primarily synthesized in the endoplasmic reticulum, where 
phosphatidylinositol synthase is thought to catalyse the condensation of CDP-diacyl 
glycerol and myo-inositol to yield phosphatidylinositol and CMP[1, 48]. After synthesis, 
PI is transported to other membranes via vesicular transport or PI transfer proteins[49, 
50] [51-53]. The various phosphoinositide lipids are maintained at steady state levels in 
the membrane by a continuous and sequential series of phosphorylation and 
dephosphorylation reactions by specific kinases and phosphatases respectively. These 
reversible phosphorylations and dephosphorylations generate seven distinct species of 
phosphoinositide species (Fig.1.3)[1, 54].  
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Fig.1.2: The inositol phosphate headgroup can be phosphorylated on the 3-, 4- and 5- positions to 
yield PI(4)P and PI(4,5)P2 phosphoinositides.  The blue arrow represents action of a kinase 
whereas the red arrow represents action of a phosphatase. 
PI PI(4)P PI(4,5)P2 
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Fig.1.3: The generation of the seven phosphoinositide lipids from phosphatidylinositol (PI). 
Reactions indicated with dashed arrows have been shown in vitro, but not in vivo. Adapted from Di 
Paulo et al[1] 
 
Subcellular organelles contain distinct levels of the various 
phosphoinositides[18, 55]. Fig.1.4 shows the predominant subcellular localization of a 
selection of phosphoinositides.  PI(3,4,5)P3 and PI(4,5)P2 are enriched in the plasma 
membrane[56, 57]. PI(3,4)P2 is mostly found at the plasma membrane  and membrane 
fractions associated with early endocytosis [58, 59]. PI(4)P is enriched in the Golgi 
complex, but also found in the plasma membrane [18, 57]. Meanwhile PI(3)P and 
PI(3,5)P2 are predominantly present in endosomal membranes [60]. It is thought that 
the presence of the varying phosphoinositides compositions in the membranes of 
subcellular organelles aids the conferment of subcellular organelle identity[61].  
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Fig.1.4: The conversion of the various phosphoinositides in a selection of subcellular 
organelles. PI(4)P is enriched in the Golgi complex but is also found in the plasma membrane. 
PI(3)P is found in the early endosomal pathway and PI(3,5)P2 is found in the late endosomal 
pathway. PI(3,4)P2 is predominantly found in the plasma membrane and the early endosomal 
pathway. PI(4,5)P2 and PI(3,4,5)P3 are enriched in the plasma membrane.  The cellular location of 
PI(5)P has not yet been fully resolved. Figure adapted from [1]      
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1.2 The Dual Catalytic Inositol Phosphatase Domains within Synaptojanin 
Synaptojanin was first cloned in 1996 and characterized as a pre-synaptic inositol 
phosphatase [62].  Its action has since to be found to be critical for normal endocytosis 
and the enzyme has been implicated in the onset of Alzheimer’s Disease and Down’s 
Syndrome [63-69]. The characterization of the enzymological functioning of 
Synaptojanin is therefore regarded to be of huge importance.  
Synaptojanin is a particularly interesting inositol phosphatase as it is the only 
mammalian inositol phosphatase to contain two distinct catalytic domains; an Inositol 
Polyphosphate Phosphatase Catalytic (IPPc) domain and a CX5R Suppressor of Actin 
(Sac) phosphatase. The IPPc domain can hydrolyse PI(4,5)P2 to PI(4)P whilst the Sac 
domain can hydrolyse PI(4)P to PI. Due to its bifunctional nature, Synaptojanin is 
named after the two faced Greek God Janus. Although the modulation of Synaptojanin’s 
functioning by numerous effector proteins, is well characterized, it is not yet known if 
the functioning of the individual domains within the enzyme is co-dependent. Often, the 
domains in bi- and multifunctional proteins are found to operate in a dependent 
manner. This thesis characterizes the enzymology of the Sac and IPPc domains in 
Synaptojanin and explores the roles of the individual Sac and IPPc domains in the 
overall functioning of enzyme.  
Inositol Phosphatase enzymes are responsible for controlling the levels of the various 
phosphoinositides in cellular membranes and have been implicated in the onset of an 
array of diseases[2].  3-, 4- and 5- inositol phosphatases hydrolyse the 3-,4- and 5-
position from the inositol headgroup ring respectively. Table 1.1 gives examples of 
these phosphatases, along with a summary of their cellular functions.  
 Fig.1.5 shows the domain organization of Synaptojanin along with the substrate 
specificity of the Sac and IPPc domains. As previously outlined, Synaptojanin is the only 
inositol phosphatase class to contain more than one catalytic domain; an IPPc domain 
and a Sac phosphatase. The Sac domain is found between the residues 119-442[44, 70] 
whilst the IPPc domain is found between the residues 500- 899. Both the IPPc and Sac 
domains are found in enzymes other than Synaptojanin and the Sac catalytic motif in 
Synaptojanin is highly homologous to the yeast enzyme Sac1[71, 72]. It is therefore 
interesting that evolution has developed an enzyme such as Synaptojanin that combines 
both of these phosphatase domains. Synaptojanin also contains a non-catalytic C-
terminal proline rich domain between the residues 900-1575 [73-75]. 
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    There are two Synaptojanin isoforms; Synaptojanin 1 and Synaptojanin 2. 
Synaptojanin 1 is predominantly found in the nerve terminals in the brain, whilst 
Synaptojanin 2 is ubiquitously expressed [76, 77]. There are two splice variants of 
Synaptojanin 1; a 145 kDa and a 170 kDa form[78]. The Sac and IPPc catalytic domains 
in Synaptojanin 1 and 2 are highly homologous. However, the proline rich C terminal 
domain is of differing lengths and more divergent[75]. The proline rich domain 
primarily acts a protein-protein interaction domain and is responsible for imparting the 
different specificities and selectivities of the isoforms.  
 The IPPc domain in Synaptojanin is known to be able to hydrolyse the 5- 
position phosphate from PI(4,5)P2 to yield PI(4)P and the 5-position from PI(3,4,5)P3 to 
give PI(3,4)P2 [79-81]. The domain has also been reported to hydrolyse the 5- position 
phosphates from the soluble inositol phosphate headgroups I(1,4,5)P3 and I(1,3,4,5)P4 
[79, 80]. The In Vitro substrate specificity of the Sac domain within Synaptojanin seems 
to be less well characterized than that of the IPPc domain. However, it is known that Sac 
prefers to hydrolyse mono-phosphorylated substrates such as PI(4)P[72, 80] and that in 
yeast, the enzyme is able to act on PI(3)P[71].   
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Table  1.1:  Examples of phosphoinositide-metabolizing enzymes along with their substrates and 
cellular localization. Adapted from Krauβ et al [18]  E, endosome; ER, endoplasmic reticulum; GC, 
Golgi complex;  Mi, mitochondria; MTM1, myotubularin 1; MTMR1-8, MTM1-related proteins; N, 
nucleus; PM, plasma membrane; SV, secretory vesicle; TGN, trans-Golgi network. 
 
Enzymatic 
Activity 
Isoform/gene 
Predominant 
substrate 
Localization Disease References 
 
3-
phosphatases 
PTEN1,2 PI(3,4)P2,PI(3,4,5)P3 PM, GC, N 
Cancer; 
Cowden 
disease 
[82-84] 
 
MTM1 PI(3)P,PI(3,5)P2 PM Myopathy [85-87] 
 
 
4-
phosphatases 
Sac1-3 
PI(4)P 
PI(3)P (yeast) 
ER, GC - [72, 88, 89] 
 Synaptojanin1,2 
 
PI(4)P? - - [72] 
 
 
 
5-
phosphatases 
Synaptojanin1,2 
PI(4,5)P2  
PI(3,4,5)P3 
SV, PM, Mi 
Bipolar 
disorder, 
Down 
syndrome 
[2, 4, 68, 90] 
 
OCRL 
 
PI(4,5)P2 TGN/E/Ly 
Oculocere
brorenal 
syndrome 
of Lowe 
[91-93] 
 SKIP PI(4,5)P2 ER,PM - [94, 95] 
 PIPP PI(4,5)P2 PM - [96] 
 SHIP1 PI(3,4,5)P3 N,PM 
Myeloid 
leukaemia 
[2, 97, 98] 
 SHIP2 PI(3,4,5)P3 N,PM 
Type II 
diabetes 
[2, 98-101] 
 
72kDa 5-
phosphatase 
PI(3,4,5)P3 GC - [102]  
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In addition, interestingly, Minagawa et al recently characterized a novel Sac- 
domain containing phosphatase hSac2 and suggested that it exhibits 5-phosphatase 
catalytic activity[103]. It can be seen from Fig.1.5 that the Sac substrate PI(4)P is the 
product of the IPPc catalysis of PI(4,5)P2. This means that it is possible that 
Synaptojanin hydrolyses PI(4,5)P2 directly to PI without release of the intermediate 
PI(4)P. However, this has yet to be proven. The following section gives an overview of 
the CX5R phosphatase and 5-phosphatase families before the biological functioning of 
Synaptojanin is discussed.  
 
 
 
 
 
Fig.1.5 : Synaptojanin contains a 5-phosphatase IPPc domain between the residues 119-442 and a 
Sac domain which is highly homologous to the yeast enzyme Sac1 between the residues 500 and 
899. In addition, the enzyme contains a non-catalytic proline- rich domain between the residues 
900-1575. The IPPc domain is a 5-phosphatase and can catalyse PI(4,5)P2 to PI(4)P , PI(3,4,5)P3 to 
PI(3,4)P2 and I(1,4,5)P3 to I(1,4)P2 . The Sac domain is a 4-phosphatase and can catalyze PI(4)P to 
PI. The proline- rich domain is a protein-protein interaction domain.  
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1.2.1 CX5R Sac Domain Phosphatases 
The mammalian enzymes Synaptojanin 1 and 2 and the yeast phosphatases In51p, 
In52p and In53p all contain a ~300 amino acid region with a CX5R motif catalytic site 
that is highly homologous to the magnesium-independent yeast protein Sac1p[44, 104].  
The CX5R motif describes an amino acid sequence that contains a cysteine and an 
arginine separated by five arbitrary residues. The CX5R motif is also the signature motif 
of the Protein Tyrosine Phosphatase (PTP) superfamily and the Sac domain was initially 
classified to be part of this family. However, the Sac domain in Synaptojanin was soon 
identified as an inositol phosphatase [71, 105, 106]. Table 1.2 shows the active site 
homology of a selection of enzymes from the PTP family and the Sac1 
phosphatase[107].  
The biological functioning of the Sac domain in Synaptojanin has not been 
extensively characterized. However, it has been shown that yeast Sac1 regulates the 
structure of the actin cytoskeleton[89].  Also, when the Sac domain is mutated in yeast, 
defective Adenosine Triphosphate (ATP) transport occurs and a deficiency in the 
Endoplasmic Reticulum (ER) translocation of proteins is observed[44, 106]. The crystal 
structure of the Sac domain has not yet been resolved.  
 
    
Table 1.2: Active site Motifs of a selection of CX5R phosphatases including “classical” Protein 
Tyrosine Phosphatases (PTPs), Vaccinia H1 (VH1-like) PTPs, the  protein phosphatase Cdc25,   Low 
molecular weight (LMW) PTP’s, Yersinia PTP and the Sac phosphatase [108-112]. 
 
Protein Active Site Motif 
 PTP PIVVHCSAGVGRT 
VH1-like RVLVHCQAGISRSA 
Cdc25   IIVFHCEFSSERGP 
Low Molecular Weight (LMW) PTPS                       SVJFVCLGNICRS 
Yersinia PTP                                HCRAGVGRT 
Sac Phosphatase        RXNCLDCLDRTN 
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Due to the conserved CX5R motifs in the PTP and Sac catalytic sites, Sac 
phosphatases can be expected to share a similar catalytic mechanism to the PTPs and it 
has been shown that another CX5R inositol phosphatase, Phosphatase and Tensin 
Homolog (PTEN), operates via a similar mechanism to the PTPs[113]. Site directed 
mutagenesis experiments on the Yersinia PTP have shown that the cysteine residue in 
the signature motif functions as a nucleophile, attacking the phosphate atom directly 
and displacing the leaving group to form a phosphocysteine intermediate. Substitutions 
of the cysteine residue significantly abolished activity and disrupted the formation of 
the phosphoenzyme intermediate[112] [114].   
The aspartate residue in the Yersinia PTP catalytic site has also been shown to be  
crucial for hydrolysis. The aspartate 356 residue must be protonated for optimal 
hydrolysis of the phosphotyrosine, as substitution of aspartate 356 to asparagine 
dramatically reduced its catalytic activity. This suggests that aspartate 356 acts as a 
general acid during E-P formation (k2) by protonating the ArO- leaving group[115]. 
Besides acting as a general acid, aspartate 356 has another important role in the 
mechanism by acting as a base to activate the water in the E-P hydrolysis step 
(k3)[116].  
Arginine is another crucial invariant motif in the CX5R catalytic site. Experiments 
have shown that when arginine is substituted for lysine and alanine that there is an 
8200-fold decrease in VMax and a 26-fold increase in KM. As will be described later, a 
change in VMax is usually caused by changes to an enzymes conformation whilst the KM 
represents the affinity of an enzyme for its substrate. The difference in VMax between the 
wild type and arginine mutant PTP is larger than that of the KM. This therefore indicates 
that although the active site arginine plays a role in substrate binding, the residue is 
more important for catalysis[115, 117-119].  
Serine and threonine are also often found in the active sites of PTPs next to the 
invariant arginine residue. It has been suggested that the hydroxyl group present in 
these residues is responsible for facilitating the E-P hydrolysis. It is thought that this 
mechanism can be applied to all PTPs as, in addition to having the same catalytic motif, 
the folding of the active site of PTPs is very similar[119].       
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PTEN is an important CX5R inositol phosphatase. The structure of PTEN contains 
an N-terminal CX5R 3-phosphatase domain and a C-terminal C2 domain (Fig.1.6)[120]. 
The phosphatase domain has been shown to hydrolyse PI(3,4,5)P3 both in vivo and in 
vitro whilst the C2 domain has been proposed to be a phospholipid binding domain[82, 
121, 122].  It has been suggested that the phosphatase domain also plays a minor part in 
membrane interactions, as weak binding to phospholipid vesicles still occurs when the 
C2 domain is not present[113].   
PTEN is often described as a tumour suppressor, as PTEN mutations have been 
found in a range of tumours[82, 123]. The PTEN substrate PI(3,4,5)P3 plays a critical 
role in the regulation of cell survival by activation of PDK1 and its target Akt. Akt is an 
oncogene and changes to its activation can induce cancer[124]. Cellular levels of 
PI(3,4,5)P3 and Akt have been shown to rise in PTEN-deficient mouse embryonic 
fibroblasts[113]. PTEN regulates the PI(3,4,5)P3 and Akt signalling pathway and in this 
way influences cell cycle progression and cell survival[83, 84].    
 
 
 
 
 
Fig.1.6: The structure of Phosphatase and Tensin Homolog (PTEN) consists of an N-terminal CX5R 
3-phosphatase domain between the 16 and 187 residue and a C-terminal C2 domain between 
residues 187-350. The carboxy terminal region of the enzyme also contains a site for binding of 
PDZ domain-containing proteins.  
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1.2.2 The Inositol 5- Phosphatase Family 
In addition to a Sac phosphatase, Synaptojanin contains an IPPc domain, which is a 
member of the 5-phosphatase family. The 5-phosphatases are family of phosphatases 
that can remove the 5-position phosphate from PI(3,4,5)P3, PI(4,5)P2 and PI(3,5)P2 to 
form PI(3,4)P2, PI(4)P and PI(3)P respectively[79]. Schmid et al showed that the order 
of specificity of the IPPc domain in Synaptojanin towards its substrates was PI(4,5)P2 
>I(1,4,5)P2 >PI(3,4,5)P3 [79]. In contrast to the CX5R phosphatases, the activity of the 5-
phosphatases is thought to be magnesium dependent.      
The 5-phosphatase family all contain a central 5-phosphatase domain of 
approximately 350 amino acids[44]. The motifs WXGDXNXR and PXWCDRXL, located 60 
amino acids apart, are conserved between the 5-phosphatases[125-127]. Type I 5-
phosphatases are only able to hydrolyze soluble inositol phosphatases whereas Type II 
phosphatases are active against both soluble and lipid phosphoinositides. The IPPc 
domain in Synaptojanin has been characterized as a Type II 5-phosphatase[79, 80] 
  Whisstock et al proposed a mechanism for the 5-phosphatase-mediated 
hydrolysis of I(1,4,5)P3 whereby a nucleophile is generated from the abstraction of a 
proton from a water molecule followed by cleavage of the scissile phosphate[44, 70]. 
The phosphate is polarized via its interaction with histidine and asparagines. Histidine 
is required for activity and forms a hydrogen bond to the oxygen of the phosphate. 
Another asparagine motif has been shown to act as the nucleophile. Mutation studies 
have shown that aspartic acid is important for activity and is orientated by hydrogen 
bonds to the side chain of two asparagine residues. When aspartate is mutated to 
alanine then the activity of the 5-phosphatase is abolished[44, 70, 114]. The metal ion is 
proposed to be directly co-ordinated by the conserved 5-phosphatase glutamic acid 
residue [44, 70, 104].  
Although the crystal structure of the mammalian IPPc domain has not yet been 
reported, Tsujishita et al solved the crystal structure of the yeast Schizosaccharomyces 
pombe (S.pombe)Synaptojanin 5-phosphatase domain (Fig.1.7)[128]. The active site of 
S.pombe  Synaptojanin is located in a funnel-shaped depression formed at the end of two 
β-sheets. The crystal structure contains both N and C terminal extensions that are 
outside the conserved core. The apurinic/apyriminic base excision repair 
endonucleases have been shown to have a similar catalytic site structure and 
mechanism of catalysis to that of the 5-phosphatase family[70, 129].   
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Fig. 1.7: Crystal structure of yeast Schizosaccharomyces pombe Synaptojanin 5-phosphatase 
domain as proposed by Tsujishita et al[128] showing with a bound metal cation (black ball) and 
I(1,4)P2 molecule.  
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The members of the inositol 5-phosphatase family have been implicated in an 
array of diseases[2] (Table 1.1).  Such diverse biological functions as insulin signalling, 
synaptic vesicle recycling and hematopoietic cell function have been attributed to the 
family [4, 63, 101, 130-133]. More than ten human 5-phosphatases have now been 
identified. These include Synaptojanin 1 and 2, Oculocerebrorenal Syndrome of Lowe 
(OCRL) 5-phosphatase[134], Skeletal muscle and Kidney enriched Inositol Phosphatase 
(SKIP)[94], SH2 (src homology 2) containing Inositol 5-Phosphatase 1 and 2 (SHIP1 and 
2)[101], Proline-rich inositol polyphosphate 5-phosphatase (PIPP)[135], 43kDa 5-
phosphatase, 75kDa 5-phosphatase and 107kDa proline-rich 5-phosphatase[44]. Here, a 
brief description of a selection of the 5-phosphatase family is given. Fig.1.8 shows the 
domain structure of these enzymes. 
 OCRL contains a 5-phosphatase domain along with a RhoGTPase activating 
protein (RhoGAP) domain. The RhoGAP domain in OCRL has been suggested to be 
responsible for positioning the phosphatase at the membrane surface[92, 136].  
Mutations of OCRL have been attributed to the onset of Lowe syndrome which is a rare 
disorder characterized by mental retardation, congenital cataracts and Fanconi 
Syndrome of the kidney proximal tubules[91, 134, 137-139].  
SHIP contains a central 5-phosphatase domain, an SH2 domain and a proline-rich 
domain. The src homology 2 (SH2) domain has been shown to be vital in the 
interactions of SHIP with a large number of intracellular proteins[2].   SHIP1 is highly 
homologous to SHIP2 but exhibits sequence divergence in the proline-rich 
domain[140]. Both isoforms are found in hematopoietic cells, but the functioning of 
SHIP2 has been found to be more important in the brain and heart [140, 141]. SHIP2 
regulates the actin cytoskeleton by binding to actin regulatory proteins and along with 
PTEN has been implicated in the insulin signalling pathway. PTEN and SHIP2 are drug 
discovery targets for Type 2 diabetes [120, 142-145]. 
 SKIP contains a SKIP carboxyl homology (SKICH) domain along with its 5-
phosphatase domain. The SKICH domain is thought to be responsible for the localization 
of the enzyme to the membrane[2]. SKIP has been shown to regulate glucose transport 
and actin cytoskeletal rearrangement[2, 94]. PIPP localizes at membrane ruffling areas 
and has been shown to regulate neurite elongation [135, 146]. 
As described previously, Synaptojanin is the only mammalian inositol 
phosphatase to contain more than one catalytic domain; a 5-phosphatase domain and a  
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Sac domain. Like SHIP and PIPP, the enzyme also contains a non-catalytic proline-rich 
domain. The proline-rich domain has been shown to be largely a targeting domain for a 
large range of endocytic proteins[75].  
The reasons why nature has evolved an enzyme with two distinct phosphatase 
catalytic domains has not yet been elucidated. Often domains within bi- and multi-
functional enzymes act in a co-dependent manner (See Section 1.4). However, it is not 
known whether the Sac and IPPc domains function in an independent or co-dependent 
manner. As highlighted above, other phosphatases such as OCRL have been shown to 
contain specific membrane binding domains. It is not clear whether Synaptojanin 
contains a domain that is responsible for the binding of the enzyme to the membrane.  
 
 
 
Fig.1.8: Domain structure of a selection of 5-phosphatases: (a) Oculocerebrorenal 
Syndrome of Lowe (OCRL), (b) Synaptojanin (c)SH2 Domain Containing Inositol 5-Phosphatase 
(SHIP), (d) Skeletal muscle and kidney enriched inositol Phosphatase (SKIP),(e) Proline-rich 
inositol polyphosphate 5-phosphatase (PIPP). All domains except the 5-phosphatase and Sac are 
non catalytic.  Synaptojanin is the only mammalian inositol phosphatase to contain more than one 
catalytic domain. 
 
 
 
(b) 
(a) 
(c) 
(d) 
(e) 
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1.3 The Role of Synaptojanin in Synaptic Vesicle Recycling 
Studies have shown through the use of Synaptojanin knockouts in mice that 
Synaptojanins enzyme activity is important for normal synaptic vesicle recycling and 
neurological functioning [2, 63, 147]. Synaptojanin-deficient mice exhibit neurological 
defects and die shortly after birth[132].  
The recycling of synaptic vesicles in nerve terminals is crucial for synaptic 
transmission[148]. Neurons communicate with each other through neurotransmitters 
that are released from neighbouring neurons through exocytosis. The 
neurotransmitters are transported in synaptic vesicles, which can fuse with the 
membrane after which they are absorbed into the neuron. Synaptic vesicles dock at the 
active sites of synapses where they undergo a priming step that makes them competent 
for calcium-dependent fusion. After exocytosis their membranes are retrieved from the 
cell surface in a reaction that requires the GTPase Dynamin and they are used to 
regenerate new synaptic vesicles[149].      
Endocytosis is an important part of the synaptic vesicle cycle and Synaptojanin 
has been implicated in this stage of the cycle. A number of endocytic mechanisms have 
been proposed to run in parallel in nerve terminals, including clathrin coat and “Kiss 
and Run” endocytosis[150, 151]. Kiss and run endocytosis refers to a mechanism where 
vesicles connect only briefly to the plasma membrane without full collapse. The role of 
Synaptojanin in clathrin coat endocytosis is more established and therefore this section 
focuses only on the role of the enzyme in this model. 
    The process of clathrin coat endocytosis involves multiple steps and employs 
an array of proteins that alter the shape and composition of the membrane, regulate 
membrane coat interactions and influence actin polymerization[64]. The clathrin coat is 
made up of the three legged protein clathrin. Clathrin binds to the membrane through 
interactions with Adaptor Protein (AP) complex AP2. The protein AP180 has also been 
found to aid clathrin coat assembly[152].   
Synaptic vesicles are enriched in levels of PI(4,5)P2 and it has been shown that 
PI(4,5)P2 has a direct role in synaptic vesicles endocytosis. Fig.1.9 depicts the role of 
PI(4,5)P2 in synaptic vesicle recycling. Mutagenesis experiments have shown that the 
interaction of AP2 and AP180 with PI(4,5)P2 is crucial for the formation of membrane- 
associated clathrin coats[153]. It has been postulated that localized pools of PI(4,5)P2 or 
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“Rafts” are responsible for the recruitment[37]. However, the existence of lipid rafts in 
vivo remains a controversial subject.    
After the clathrin coat vesicle is formed, membrane invagination occurs. This is 
thought to be driven by actin assembly coordinated by proteins such as profilin and 
syndapin[154]. PI(4,5)P2-rich vesicles through Wiskott-Aldrich syndrome protein 
(WASP) activation may promote actin comet tail assembly which supports the 
propulsion of the vesicle away from the membrane[155-158]. It is thought that N-WASP 
is recruited to the membrane through the Rho-family G-protein Cdc42. WASP binds 
then to the Arp2/3 complex and in doing so stimulates its ability to nucleate actin 
polymerisation [157, 159]. As described earlier, the GTPase Dynamin has been also 
implicated in the tubulisation of membranes [160-162]. Dynamin forms a ring around 
the vesicle neck and as GTPase hydrolysis occurs, the ring becomes tighter until the 
membrane pinches off from the original membrane[162, 163].   
  It is then thought that Synaptojanin hydrolyses PI(4,5)P2 and this decreases the 
affinity of the clathrin coat adaptor proteins for the synaptic membrane[65, 76, 164]. It 
has been proposed that the adaptor protein endophilin is required to localize and 
stabilise Synaptojanin during this process[165]. The clathrin is then freed and the 
vesicles are directed back to the vesicle cluster from which they can be mobilised for 
subsequent rounds of release[1].  
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Fig.1.9 : Synaptic vesicle cycle (a) synaptic vesicle fuses with membrane through PIP2 binding 
protein (b) Clathrin is recruited to membrane through adaptor protein. The adaptor protein AP2 
and AP180 interact with the membrane through PI(4,5)P2 (c) vesicle pinches off from the 
membrane via the action of  Dynamin and actin based comet assembly. Cdc42 recruits WASP to the 
membrane which in turn recruits Arp 2/3 which nucleates actin polymerization. The interaction of 
clathrin with the membrane is disrupted by the hydrolysis of PI(4,5)P2 by Synaptojanin (d) the 
vesicles are directed back to the vesicle cluster from which they can be mobilized for subsequent 
rounds of release. Adapted from  [37] 
 
 
 
 
 
 
 
 
 
 
Synaptojanin 
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The regulation of coat membrane interactions may not be the only function of 
Synaptojanin in synaptic vesicle endocytosis. As described earlier, actin polymerization 
may be a mechanism that supports the clathrin coated vesicle detachment and 
movement away from the membrane[154].  The lipid PI(4,5)P2 has been implicated in 
the formation of the actin cytoskeleton and given that PI(4,5)P2 is a substrate of 
Synaptojanin, this implicates the enzyme in the pathway[38].    
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
1.4 Multifunctional enzymes 
Nature has developed an array of bi- and multi-functional proteins including tryptophan 
synthase, carbamoyl phosphate synthase, glutamine phosphoribosoyl pyrophosphate 
amidotransferase, cyclic nucleotide gated channel and Synaptojanin[166-169]. Often the 
distinct domains and sub-units in these enzymes communicate together so that the 
overall functioning of the enzyme is optimised[167, 170]. For example, interdomain 
interactions have been implicated in the functioning of the cyclic nucleotide gated 
channel, which is a multimeric protein complex. The activity of the channels has been 
shown to be regulated by interactions of the amino acid terminal domain and the 
carboxy- terminal ligand binding domain[171-173].  
 Besides Synaptojanin, there is another enzyme that is named after the two faced 
Greek God Janus. The Janus Protein Tyrosine Kinases (JAK’s) are involved in signal 
transduction and have been implicated in cellular survival, proliferation, differentiation 
and apoptosis[174, 175]. The domain structure of a JAK can be seen in Fig.1.10. The 
domains in the kinase are often referred to as the JAK homology domains and the 
enzyme contains seven JAK domains (JH1-JH7). JH1 has been shown to be a functional 
kinase catalytic domain. However the kinase also contains a “pseudokinase” domain, 
JH2. The amino acids in this domain are homologous to kinase catalytic domains but the 
domain lacks any observable tyrosine kinase activity[175, 176].     
 
 
 
 
 
Fig 1.10: Structural organization of the seven domains in the Janus Kinase(JAK). JH1 is a catalytic 
kinase domain whilst JH2 is thought to be a pseudo-kinase domain[175].   
 
 
Interestingly, it has been shown through mutagenesis and deletion of the JH2 
domain that the JH2 domain negatively regulates the activity of the JH1 domain in JAK2. 
This has been proposed to occur through an interaction with the kinase domain. It has 
been proposed that the pseudokinase domain may have a role in the regulation of JAK2-
substrate interactions[177].  
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     Synaptojanin is the only mammalian inositol phosphatase to contain two 
distinct catalytic domains. It is as of yet unknown whether the domains operate in an 
independent or a dependent manner. If they were to operate in a co-dependent manner, 
then this would be expected to occur through mechanisms such as allosteric 
communication. It is also possible that Synaptojanin operates via a substrate 
channelling mechanism [178, 179].   
Substrate channelling is the process by which a product of a one particular 
domain mediated catalysis is a substrate for a sequential catalysis by another domain. 
As can be seen from Fig.1.5, the substrate of the IPPc domain hydrolysis of PI(4,5)P2 is 
PI(4)P. PI(4)P is a substrate for the Sac domain. Therefore, it is possible that 
Synaptojanin can hydrolyse PI(4,5)P2 directly to PI, without accumulation of the 
intermediate PI(4)P.       
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1.5 Conclusion and Project Aims 
Given the role of Synaptojanin in synaptic vesicle recycling, an understanding of its 
enzymological mechanism is crucial for the development of future therapeutic options 
for neurological disorders such as Alzheimer’s Disease. Whilst the protein-protein 
interactions of Synaptojanin have been extensively investigated, it is still unclear 
whether the functioning of the Sac and IPPc domains is co-dependent.  
If the domains in Synaptojanin were to operate in a co- dependent manner, they 
could do so via a number of mechanisms.  A variety of bi- and multi-functional enzymes 
have been shown to exhibit mechanisms such as allosteric communication and 
substrate channelling. It is possible that that substrate channelling occurs in 
Synaptojanin as the product of the IPPc hydrolysis of PI(4,5)P2, PI(4)P, is a substrate of 
the Sac domain.   
It is clear that the functioning of the CX5R Sac domain in Synaptojanin has not yet 
been fully characterized. Whilst the 5-phosphatase domain in Synaptojanin is widely 
known to hydrolyse both lipid and non-lipid substrates, it is not clear whether the Sac 
phosphatase can hydrolyse soluble phosphates. Additionally, it is not known if either of 
the domains in Synaptojanin contributes to the recruitment of Synaptojanin to the 
membrane in the same way as the C2 domain in PTEN. 
 This thesis explores the enzymological functioning of Synaptojanin and aims to 
elucidate whether the catalytic domains in Synaptojanin act in an independent or 
dependent manner. To do this, a full enzymological analysis of the kinetic parameters of 
the Sac and IPPc mediated hydrolysis of their corresponding substrates was 
undertaken. 
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2.1 Materials and Methods 
2.1.1 Materials 
PI(3,4,5)P3, I(1,4,5)P3, I(1,4)P2 and I(1,3)P2 were obtained from CellSignals Inc 
(Columbus, U.S.A), PI(4,5)P2(Nat), PI(4)P(Nat), DOPC, DOPE and DOPS were obtained 
from Avanti Lipids Inc (Alabama, U.S.A). Alkaline phosphatase (Calf Intestine) and PTP- 
β were purchased from Sigma (Dorset, U.K). 7-nitro-2-carboxylic acid was obtained 
from Gold Biotechnology Inc (St Louis, U.S.A).                                                         
 
2.1.1.1 Buffers 
Ampicillin   
100 mg/mL ampicillin  
Stored at -20OC for 3 months 
 
LB Boullion  
LB Boullion    25g  
dd H2O             1000mL 
 
PhenylMethaneSulphonylFluoride (PMSF) 
100mM PMSF  in 70% ethanol 
 
10X Lysis Buffer 
Tris base                                     500 mM 
EDTA                                            20 mM     
Benzamindine                           100mM 
 DTT                                              10 mM    
Triton X-100                              10% (v/v)      
Soya bean trypsin inhibitor  100 µg/mL 
pH 7.4 Stored at 4oC 
 
Isopropyl β-D-thiogalactoside IPTG 
200 mM in 50% glycerol 
Stored at -20oC  
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Tris Glycine SDS Polyacrylamide Gel Running Buffer (10 x) 
Tris base                            250 mM 
Glycine                               1.9 M 
SDS                                      288 mM 
pH 7.4 
 
Coomassie Stain  
Coomassie Blue                       3 mM 
Methanol                                   45.4 % (v/v) 
Acetic Acid                               9.2% (v/v) 
 
Destaining Solution 
Isopropanol                            20% (v/v) 
Acetic acid                               7% (v/v) 
Glycerol                                    3% (v/v) 
 
Tris Buffered Saline (TBS 1X)      
NaCl          138 mM 
KCl            2.7 mM 
Tris-HCl   1M 
pH 7.4 
 
TBS-Tween 
Tween 20                              0.05% 
TBS                                         99.95%  
pH 7.4 
 
Column Equilibration Buffer 1 
Tris        50 mM  
NaCl      140 mM 
KCl        2.7 mM 
DTT       1 mM      
pH 7.4 
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Column Equilibration Buffer 2 
Tris      50 mM  
NaCl     500 mM 
KCl       2.7 mM 
DTT      1 mM      
pH 7.4 
 
Elution Buffer 
Tris                           50 mM 
Glutathione            20mM 
NaCl                          250 mM 
β-mercaptoethanol (10 µL/50 mL) 
Glycerol                    50% 
pH 7.4 
 
Tris - Glycine SDS Polyacrylamide Gel Loading Buffer 
Tris-HCL (pH 6.8)       11 % 
SDS (10%)                     29% 
Glycerol (100%)          14%  
β- mercaptoethanol     7% 
bromophenol blue        29% 
pH 6.8 
 
Western Transfer Buffer 
Tris base          300 mM 
Glycine             2M 
SDS                    1%  
 
Malachite Green Phosphate Dye (2x) 
Malachite Green (oxalate)    6 mM 
Ammonium molybdate         19 mM        
Bismuth (III) citrate              77 mM 
Conc HCL                                   17% (v/v) 
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2.1.2 Transformation of Synaptojanin Plasmids into E.coli Bacteria 
The Sac/IPPc, Sac/IPPc-, Sac-/IPPc, Sac and IPPc constructs were prepared by Dr Erika 
Rosivatz and Dr Annette Schmid (Imperial College London).  The phosphatase domain 
constructs were cloned into a PGEX-4T2 expression vector (Pharmacia). The boundaries 
of the double phosphatase, Sac/IPPc, are 0-1016.  The IPPc domain in Sac/IPPc- was 
rendered inactive through a single amino acid substitution of Asp808 to Ala. The Sac 
domain in Sac-/IPPc was rendered inactive through the mutation of Cys404 to Gly. The 
boundaries of the single 5-phosphatase IPPc domain are 470-1016 and the boundaries 
of the single Sac domain are 0-494. To transform the plasmids into bacteria, 100 µL of 
XL-1 Blue strain of Escherichia coli (E.coli) bacteria, in a 1.5 mL eppendorf, were 
defrosted on ice for 15 minutes. 1 -100 ng of the appropriate phosphatase plasmid was 
then added before being incubated on ice for 30 minutes. The bacteria were heat-
shocked at 42o for 90 seconds before incubation on ice for 2 minutes. The bacteria was 
then spread onto an LB agar plate, containing ampicillin antibiotic and incubated at 
37oC overnight.    
 
2.1.3 Expression and Purification of Phosphatases 
To prepare pre-cultures, bacterial colonies were picked from an agar plate and 
incubated in 10 mL of LB Broth (containing with 0.1 mg/mL ampicillin) overnight at 37 
oC. 1L of LB broth containing 0.1 mg/ml ampicillin was then inoculated with the cultures 
and grown for a further 6 hrs at 37 oC.  After this, the cells were induced with 100 mM 
IPTG and incubated at 18 oC for 24hrs. The bacteria were harvested by centrifugation at 
4600rpm for 40mins at 4 oC and 2 mg/mL lysozyme added before storage at -20 oC. To 
lyse the cells, lysis buffer, 0.1 mM PMSF and soya trypsin inhibitor were added whilst 
the cells thawed on ice. A probe tip sonicator was used to complete lysis with 6 cycles of 
1 minute each, and 2 minutes rest between cycles on ice. To remove cellular debris, the 
suspension was centrifuged at 115000 rpm at 4 oC for 60 minutes. A column, loaded 
with 3 mL of GST beads, was used to purify the protein. 30 mL of equilibration buffer 
was run through the column in order to equilibrate the beads. The supernatant was 
filtered through a 0.45 µM filter before loading it onto the column. To remove unbound 
protein, the column was washed twice with the equilibration buffer and then twice with 
the higher salt equilibration buffer. To elute the protein from the beads, 1.5 mL of 
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elution buffer was incubated with the beads and before being collected in 1.5mL 
eppendorf tubes containing 50% glycerol.  
 
 2.1.4 Bradford Assay for Protein Concentration Determination 
Bradford dye was used to quantify the total amount of protein obtained for the 
expression and purification of the phosphatase. 0-500μg/ml of Bovine Serum Albumin 
(BSA) was used to calibrate the absorbance of the dye for varying concentrations of 
protein (Fig.2.1).  
 
Fig.2.1: Calibration of the absorbance of Bradford dye at 595nm with increasing levels of Bovine 
Serum Albumin (BSA). Y=0.016x 
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2.1.5 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Western blot analysis was used to confirm protein size and the presence of Glutathione 
–S-transferase (GST) tag. To do this, it was necessary to run an SDS PAGE gel. Glass 
plates were cleaned and set up in SDS-PAGE equipment (BioRad vertical gel kit). 
Running and stacking gels were made up, with compositions shown in Table 2.2. 
Running gel was loaded first and left to set for approximately 30 mins.  Stacking gel was 
then loaded and left to set again for 30 mins. The comb was then removed and the gel 
loaded with relevant molecular weight marker. Protein samples were combined with 
sample lysis buffer and denatured on a heating block before loading. The samples were 
then run through the stacking gel at 150 V. Once the samples reached the running gel 
the voltage was increased to 200 V. Staining of the gel is performed by incubation with 
coomassie blue for 15 minutes and destaining overnight. 
 
Table 2.1: Acrylamide percentages showing relative compositions for analysis of proteins. TEMED 
and APS are the polymerisation agents for the gel and must be added last. 
 
 Running Gel 
(8%) 
Stacking Gel 
(5%) 
Water 9.3 mL 5.5 mL 
Acrylamide 
(30%) 
5.3 mL 1.3 mL 
Tris 
(1.5M pH 8.8) 
5 mL 1 mL 
SDS (10%) 200 µL 80 µL 
APS (10%) 200 µL 80 µL 
TEMED 16 µL 8 µL 
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2.1.6 Western Blot and Chemiluminescent Detection 
Once the proteins are separated by SDS-PAGE the proteins were transferred out of the 
gel and onto a nitrocellulose membrane and probed using antibodies specific to the GST 
protein. To transfer the protein for the gel to the membrane, the membrane was placed 
on top of the gel, and placed in a transfer cassette, which was then placed in an 
electroblotting chamber. The membrane was briefly wetted in transfer buffer. Transfer 
was completed at 4oC at 110 V (400 mA) for 1 hour or 10 V (40 mA) overnight.  To 
prevent interactions between the membrane and antibody used for detection of the 
target protein, membranes were washed with (Tris Buffered Saline) TBS-Tween buffer 
three times for 10 minutes and blocked using 5% dried milk powder/BSA in TBS-Tween 
for 30 mins. Once blocked, the membrane was washed again three times with TBS-
Tween. Primary antibody solution with 5% milk/BSA in TBS-Tween with 1:5000 
dilution of anti-GST antibody from mouse was prepared.  It was then incubated with 
gentle agitation with blotted membrane overnight at 4° C. The membrane was then 
washed with TBS-Tween 3 times for 5 minutes. Secondary polyclonal antibody was 
prepared in TBS-Tween containing 2 – 5 % milk/BSA and 1:5000 anti-mouse antibody. 
The membrane was incubated with the secondary antibody for 30 mins. The membrane 
was again washed in TBS-Tween 3 × 5 min. Protein bands were detected using an 
Enhanced Chemiluminescence (ECL) Advance Western blotting Detection Kit 
(Amersham).  The membrane was exposed to chemiluminescence for between 30 
seconds and 30 minutes.  
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2.1.7 Malachite Green Activity Assay  
The malachite green assay is a well established assay that is used to measure levels of 
free phosphate generated from the action of phosphatases[79, 180-182]. Reactions 
were carried out in a 96 well plate with buffer containing 4 mM MgCl2, 100 mM Tris (pH 
7.4) in a total volume of 80 µL. Lipid substrates such as PI(4,5)P2 and PI(4)P were dried 
down before addition to the assay using N2(g), resuspended in 1% octylglucoside (OG) 
and placed in a sonication bath for 15 minutes. Octylglucoside was chosen as a 
detergent with which to solubilise the lipids, due to the fact that the detergent does not 
interfere with the assay. The system was confirmed as being micellar through 
tensiometry studies[183]. The assay was typically started by addition of the enzyme 
and the plate incubated at 37 oC for 30 minutes. Control reactions were carried out 
using denatured enzyme instead of active enzyme. Enzyme was denatured by heating 
active enzyme at 95°C for 10 minutes. In order to achieve assays that were linear over 
time, the reaction was optimised with regard to time and enzyme concentration.  To 
stop the reaction 80µL of malachite green dye was added before incubation at 25 oC for 
ten minutes. Optical densities were measured using a SPECTRAMAX 340PC 
spectrometer (Molecular Devices) at a wavelength of 625 nm.  To calibrate the levels of 
free phosphate produced in the assays, varying concentrations of KH2PO4 were 
incubated with malachite green dye and the absorbance of the dye read at 625 nm. A 
typical calibration graph is shown in Fig.2.2. Saturation of the malachite green dye 
occurred at higher phosphate levels and therefore levels of enzyme activity were always 
limited to within the linear regime of the calibration curve.  
To measure the Michaelis Menten KM/VMax parameters, ascending concentrations 
of up to 300 µM of lipid in 0.25% (w/v) octylglucoside were incubated with enzyme at 
37 oC.  In order to ensure that the activities of the enzyme towards the substrate were 
linear with respect to time, the assay time and enzyme concentration was optimized. 
Michaelis Menten parameters were calculated using Origin ® software. The Michaelis 
Menten equation is as follows[184]:  
 
𝑅𝑎𝑡𝑒 =
𝑉𝑀𝑎𝑥  [𝑆]
𝐾𝑀 +  [𝑆]
 
 
Where VMax is the maximal rate of the enzyme and KM is the Michaelis Menten constant.  
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Fig 2.2: Calibration of absorbance levels of a sample of malachite green dye at 625nm with 
increasing concentrations of KH2PO4.Equation of slope was found to be Y=0.78x+0.022. 
Error bars represent the standard error of triplicate repeats. 
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2.1.7.1 Evaluation of the Magnesium Dependency of the Phosphatases 
To evaluate the magnesium dependency of the double phosphatase Sac/IPPc, increasing 
concentrations of MgCl2 were incubated with the enzyme in 100 mM Tris for 15 minutes 
and the activity measured towards 100 µM I(1,4,5)P3, PI(4,5)P2 and PI(4)P. For the 
ethylenediaminetetraacetic acid (EDTA) control, 10mM magnesium and increasing 
levels of EDTA were incubated with the phosphatases for 15 minutes before the 
addition of substrate. The EDTA solution was buffered before use to prevent changes to 
the final assay pH.  
 
2.1.7.2 Inhibition Studies 
To measure the extent of inhibition, compounds were incubated with enzyme for 15 
minutes before the addition of substrate. Assays to assess the inhibition of the 
Synaptojanin phosphatases were carried out in buffer containing 4 mM MgCl2, 100 mM 
Tris (pH 7.4) in a total volume of 80 µL. Unless otherwise stated, Lineweaver-Burke 
plots were constructed to assess the mechanism of inhibition[185].  
 To assess the inhibition of PTP-β (human)(Sigma), para-nitrophenylphosphate 
(pNPP) was used as a synthetic substrate. The buffer used for this assay was 25 mM 
Hepes (pH 7.4), 50 mM NaCl, 5 mM DTT, 2.5 mM EDTA and 100 µg/mL BSA. The linear 
absorbance of pNPP was monitored through absorbance intensity at 410 nm[186].  
 
2.1.7.3 Effect of Sac Inhibition on IPPc domain Activity 
To assess the effect of Sac inhibition on the activity of the IPPc domain activity, 1 µM of 
BpV(OH)pic was incubated with Sac/IPPc for 15 minutes before the addition of 
increasing concentrations I(1,4,5)P3 or PI(4,5)P2 substrate. Buffer contained 4 mM 
MgCl2, 100 mM Tris (pH 7.4).  
 
2.1.7.4 Effect of IPPc Phosphatase on the Activity of the Sac Domain 
The single IPPc phosphatase was incubated with the Sac phosphatase for 15 minutes 
before the activity of the Sac domain was measured towards 100 µM of PI(4)P 
substrate. The assay time was 30 minutes.  Buffer contained 4 mM MgCl2, 100 mM Tris 
(pH 7.4).  
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2.1.8 Fluorescein DiPhosphate (FDP) Activity Assay  
All assays were conducted at 37OC. Absorbance change was detected on a Cary UV/Vis 
spectrophotometer. The formation of fluorescein from fluorescein monophosphate 
(FMP) was monitored by absorbance at 490 nm and the formation of FMP from FDP was 
monitored by absorption at 445 nm[187]. Buffers contained 100 mM Tris (pH 7.4) and 4 
mM MgCl2. The reaction was initiated by addition of Fluorescein DiPhosphate (FDP) and 
monitored continuously afterward. Michaelis Menten parameters were calculated by 
Origin ®. Control reactions were carried out by adding the appropriate amount of 
denatured enzyme (active enzyme was heated at 95°C for 10 minutes) in place of active 
enzyme. Error bars represent the standard error of triplicate repeats. The 
concentrations of FMP and fluorescein generated in the assays were calculated using 
their molar absorption extinction coefficients. The extinction coefficients for FMP and 
fluorescein are 34,000/M/cm and 90,000/M/cm respectively.    
 
2.1.9 O-Methyl Fluorescein Phosphate (OMFP) Activity Assay  
All assays were conducted at 37oC. Fluorescence was detected on a Cary Eclipse 
Fluorimeter (Varian). The formation of O-Methyl Fluorescein (OMF) from O-Methyl 
Fluorescein Phosphate OMFP was monitored at an excitation of 485nm and emission of 
525nm[188, 189].  Buffer contained 100 mM Tris (pH 7.4) and 4 mM MgCl2. The 
reaction was initiated by addition of OMFP and monitored continuously afterward. The 
assay wells were thoroughly pipetted to ensure even mixing. Control reactions were 
carried out by adding the appropriate amount of denatured enzyme ) in place of active 
enzyme. To denature the enzyme, active enzyme was heated at 95°C for 10 minutes.   
The reaction was initiated by addition of OMFP and monitored continuously afterward. 
Michaelis Menten parameters were calculated using Origin ® software. Error bars 
represent the standard error of triplicate repeats.  
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2.1.10 Preparation of Lipid Vesicles 
Lipids were dissolved in cyclohexane and frozen under liquid nitrogen before 
lyophilizing for at least 24hrs. They were then dissolved in chloroform and dried in a 
round-bottomed flask under a stream of nitrogen.  The lipid film was then resuspended 
in Tris (pH 7.4). Buffered lipids were then extruded 15-20 times through a 0.1 µM 
polycarbonate filtration membrane (Avanti Lipids) to produce vesicles 100 nm in size. 
Dynamic Light Scattering (DLS) was used to measure the polydispersity and size of 
vesicles. It was necessary to check that the particle size of the vesicles does not change 
in the presence of magnesium as charged particles can sometimes cause such systems to 
condense [190]. Therefore it was necessary to check that the particle size of the vesicles 
was stable. An example is shown in Fig 2.3, where 4 mM MgCl2 was incubated with 200 
µM of 100 nm 60:40 PC:PE vesicles for 20 minutes in 100 mM Tris. It can be seen that 
the presence of magnesium does not influence the particle size of this system. 
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Fig. 2.3: Particle size 50 µM 200 nm 60:40 PC:PE vesicles in the absence and presence of 4 
mM MgCl2. 
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2.1.11 Effect of Large Unilamellar Vesicles on the Malachite Green Assay  
As with all assay work, the interference of any new component to an assay needs to be 
evaluated for its ability to interfere with the measurement under consideration. 
Previous literature has shown that large unilamellar vesicles can interfere with 
absorbance measurements through scattering light [191]. Therefore, it was necessary to 
assess the interference of the absorbance of the malachite green dye by the presence of 
lipid vesicles. To do this, increasing levels of 100 nm vesicles of varying compositions 
were incubated with the malachite green dye and the absorbance of the dye measure.  It 
can be seen from Fig.2.4, that increasing levels of vesicles decrease the absorbance 
intensity of the dye.  The differences in interference levels between the different 
samples are likely to be due to the error in the concentration as there does not seem to 
be a systematic effect of increasing levels of DOPE on the levels of absorbance. Fig.2.5 
shows the absorbance of the dye in the presence of 25 µM of lipid with increasing 
concentrations of DOPE. It can be seen that at this concentration, no interference to the 
levels of absorbance is observed.  
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Fig.2.4 : Effect of increasing concentrations of 100 nm unilamellar vesicles on the 
absorbance of malachite green dye in the presence of 5 µM of inorganic phosphate. 
Phosphate levels were measured through the malachite green assay (2.1.7). The control 
corresponds to the absorbance of the dye in the absence of vesicles.    
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Fig.2.5: Effect of 25 µM of 100 nm unilamellar vesicles with increasing DOPE mol fractions 
on the absorbance of the malachite green dye in the presence of 5 µM of inorganic 
phosphate. Phosphate levels were measured through the malachite green assay (2.1.7). 
The control corresponds to the absorbance of the dye in the absence of vesicles   
 
Evidently, a method of removing the interference needed to be found before the 
influence of vesicles on the functioning of Synaptojanin could be evaluated.  
Centrifugation of vesicles and the addition of detergent to vesicles are often cited as 
methods to remove the presence of vesicles from assays[180]. However, in this work, 
these methods were found not to remove vesicular interference.    
However, another method was proposed by which an aliquot of the assay 
solution is taken at the end of the assay and then diluted before the addition of the 
malachite green dye. Through taking an aliquot of the original solution and diluting it, 
the concentration of vesicles can be diluted to a level where they do not interfere with 
the assay. However, because the assay is very sensitive towards the levels of phosphate, 
levels of phosphate can still be detected after dilution.  
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To test this method, aliquots were taken from a solution containing the vesicles 
and inorganic phosphate and diluted to a concentration of 25 µM, before measurement 
of the phosphate levels. The results from this were compared to that of a solution 
containing phosphate but no vesicles. It can be seen from Fig.2.6 that the levels of 
phosphate detected from each concentration of vesicles examined were identical. This 
confirms that this method removes the observed interference from the vesicles. 
However, for concentrations of vesicles above 200 µM, this method is not suitable for 
removing interference. The dilution factor would be too large with which to detect the 
phosphate levels.  
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Fig. 2.6:Variation of the  absorbance intensity of malachite green dye with increasing levels of 
DOPC. The X-axis refers to the original concentration of DOPC vesicles before dilution to 25 µM. 
Phosphate levels were measured through the malachite green assay (2.1.7).  Levels of 
phosphate detected from each original concentration of vesicles examined were identical. 
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2.1.12 Effect of Large Unilamellar Vesicles on the OMFP Assay  
Fig.2.7 shows the background hydrolysis time profile of OMFP in both the presence and 
absence of 100 nm vesicles. It can be seen that there is no significant difference between 
the profiles, showing that vesicles do not interfere with the OMFP assay.   
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Fig.2.7: The background hydrolysis time profile of OMFP in both the presence and absence of 100 
nm vesicles. Details of the OMFP assay can be found in Section 2.1.9.Error bars represent the 
standard error of three repeats.  
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Chapter 3 
Characterization of the Sac 
Phosphatase Activity 
CHAPTER ABSTRACT 
To assess the substrate specificities of the Sac and IPPc domains in Synaptojanin, it was 
necessary to evaluate their activity towards both lipid and non-lipid, soluble substrates. 
I(1,4,5)P3 is a well established non-lipid soluble substrate of the Sac phosphatase. 
However, non-lipid substrates of the Sac phosphatase had not been identified. This 
work investigated I(1,4)P2, I(1,3)P2, Fluorescein DiPhosphate (FDP) and O-
methylfluoresein phosphate (OMFP) for their potential to be non-lipid substrates for 
the Sac domain in Synaptojanin. The Sac phosphatase was found to hydrolyse PI(4)P but 
not its corresponding inositol phosphate headgroup I(1,4)P2, indicating that the domain 
holds a preference for lipid substrates. (OMFP) was identified as a novel soluble Sac 
substrate that was specifically hydrolysed by the Sac domain in the double phosphatase 
Synaptojanin.  
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3.1 INTRODUCTION 
As described previously, nature has evolved an array of enzymes that are multi- and bi-
functional and the catalytic domains within these enzymes are often found to function 
in a dependent manner [192-194]. Synaptojanin is unique in that it is the only inositol 
phosphatase in its class to contain more than one catalytic domain, in that it contains 
both a CX5R Sac phosphatase and an IPPc domain. The reasons as to why nature has 
evolved a bifunctional inositol phosphatase are as of yet unclear.  In this work, we 
wanted to compare and contrast the catalytic functioning of the Sac and IPPc domains 
and investigate whether the domains exhibit domain-domain communication.    
 A common method used to evaluate the functioning of catalytic domains in multi 
or bi-functional enzymes is to mutate a particular domain and monitor the effect on the 
functioning the other domains [106, 192, 195-197]. To apply this approach to 
Synaptojanin, a series of Synaptojanin phosphatases were expressed. Fig 3.1 shows the 
domain structure of each the phosphatases expressed, Sac/IPPc, Sac/IPPc-, Sac-/IPPc, 
IPPc and Sac.  Sac/IPPc is a double phosphatase which contains both fully functioning 
IPPc and Sac phosphatases. Sac/IPPc- is a mutant of Sac/IPPc, where the IPPc domain 
was rendered inactive through a single amino acid point substitution of aspartate to 
alanine[44, 104, 114]. Sac-/IPPc is a mutant where the activity of the Sac phosphatase 
was inactivated through a single amino acid substitution of cysteine to glycine[112, 
114]. The IPPc and Sac phosphatases are single phosphatases, encoding the IPPc and 
Sac domain respectively. Comparing the kinetic parameters of the Sac and IPPc domains 
in the Sac/IPPc to that of the domains in the mutants and single phosphatases allows 
the enzymological functioning of each of the domains to be characterized and the 
possibility of domain co-operativity occurring in Synaptojanin to be evaluated.   
   In order to conduct a full enzymological characterization of the domains and to 
establish their substrate specificities, it was necessary to determine the activity of the 
Sac and IPPc domains to both lipid and non-lipid substrates. As described previously 
PI(4,5)P2 and PI(4)P are known to be lipid substrates of the IPPc and Sac domain 
respectively. The IPPc domain can also hydrolyse the inositol phosphate headgroup 
I(1,4,5)P3. However, the activity of the Sac phosphatase towards inositol phosphate 
headgroups or non-lipid substrates had not been determined. Therefore, this work 
investigated a series of non-lipid soluble compounds for their ability to be substrates for 
the Sac phosphatase.    
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Fig 3.1: Domain structure and boundaries of the series of Synaptojanin phosphatases expressed in 
this work (a) Sac/IPPc, where both the Sac and IPPc domain are functional (b) Sac/IPPc-,where 
the IPPc domain is rendered inactive by mutation of aspartate to alanine (c) Sac-/IPPc where the 
Sac domain is rendered inactive by mutation of cysteine to glycine (d) IPPc, a single IPPc domain 
phosphatase.  The boundaries of this phosphatase are 470-1016 (e) Sac, a single Sac domain 
phosphatase. The boundaries of this phosphatase are 0-494.  
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3.2 RESULTS 
3.2.1 Characterization and Validation of Enzyme Activities  
In order to evaluate the functioning of the Sac and IPPc phosphatases within 
Synaptojanin, we wanted to fully characterise the enzymology of the IPPc and Sac 
domains. To do this, the series of phosphatase enzymes shown in Fig. 3.1 were 
expressed using E.coli bacteria. Aliquots of protein were eluted from a column 
containing glutathione sepharose beads and the concentration of each aliquot 
determined through the Bradford assay (Section 2.1.4). A typical elution profile is 
shown in Fig.3.2. The fractions containing the highest protein levels were combined for 
use in the assays.  
0 2 4 6 8 10
0.0
0.1
0.2
0.3
0.4
 
 
S
a
c
/I
P
P
c
 (
m
g
/m
L
)
Elution Fraction Number
 
Fig.3.2: Example of an elution profile obtained for the purification of Sac/IPPc. 1.5 mL of 
elution buffer was loaded and fractions were collected in 1.5 mL eppendorfs containing 
50% (v/v) glycerol.  
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The phosphatases were characterized for their integrity and attachment of GST 
tag by Western Blotting. Fig 3.3 shows the Western blots obtained for (a) Sac/IPPc, (b) 
Sac/IPPc-, (c) Sac-/IPPc (d) and IPPc (e) Sac.  It can be seen that lanes (a), (b) and (c) all 
contain bands at 124 kDa, which confirms the preparation of these enzymes. The band 
at 73 kDa in lane (d) confirms the preparation of the single IPPc phosphatase. The Sac 
band at 85 kDa proves that the preparation of the single phosphatase was successful.  It 
can be seen that the phosphatases all contain smaller fragments at 28 kDa, which 
correspond to free GST. Free GST is not catalytic and is known not to not to interfere 
with phosphatase mediated catalysis.  
 
   
 
 
 
 
 
                    
 
 
 
 
 
 
 
 
Fig. 3.3: Anti GST Western Blots of Sac/IPPc, Sac/IPPc-, Sac-/IPPc (124 kDa) IPPc(73kDa) and Sac 
(85kDa) phosphatases. 
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3.2.2 Validation of the Inactivation of the IPPc and Sac Catalytic Domains within 
Sac/IPPc- and Sac-/IPPc  
It was necessary to confirm that the activity of the IPPc domain in Sac/IPPc- and the Sac 
phosphatase in Sac-/IPPc had been successfully rendered inactive through their 
respective point mutations. In order to do this, the activity of Sac in Sac-/IPPc and IPPc 
in Sac/IPPc- were evaluated towards their corresponding substrates.    
                  A variety of assays have been developed to measure the activity of 
phosphatase enzymes. For example, radio–labelled phosphoinositides are often used as 
phosphatase substrates [88, 198, 199]. However, assays based on radioactivity are 
complicated and time consuming. Instead, in this work, an assay based on a malachite 
green dye is used to evaluate the activity of the phosphatases towards their 
phosphoinositide substrates.  Assays based on malachite green have been widely used 
in the literature to evaluate the activity of inositol phosphatases [79, 113, 180-182, 
200]. The detergent octylglucoside is often utilized as a detergent with which to 
solubilise inositol phosphates as it is has been shown not to interfere with absorbance 
measurements[79, 181, 201].    
The malachite green assay is based on measuring the levels of free phosphate 
released from the phosphatase catalysed hydrolysis of substrate. Malachite green can 
exist in two forms; chromatic and non chromatic. Levels of the chromatic form of the 
dye increase with increasing levels of phosphate in the presence of molybdate. Since the 
chromatic form displays absorbance at a wavelength of 625 nm, this enables levels of 
free phosphate to be quantified[180] [202]. 
To confirm the inactivation of IPPc in Sac/IPPc-, the activity of the IPPc domain 
in Sac/IPPc- towards I(1,4,5)P3 was compared to that of IPPc in Sac/IPPc. Likewise, to 
validate the inactivation of Sac in Sac-/IPPc, the activity of the Sac domain in Sac-/IPPc 
towards PI(4)P was compared to that of Sac in Sac/IPPc (Fig. 3.4). It can be seen that, 
within the detection limits of the assay, there was no observable activity of the IPPc 
domain in Sac/IPPc- or of the Sac in Sac-/IPPc thus confirming the successful 
inactivation of the IPPc and Sac domains in the corresponding mutants. 
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Fig 3.4: Activity of the IPPc domain in Sac/IPPc- as a percentage of the activity of 
the IPPc domain within Sac/IPPc towards 100 µM of I(1,4,5)P3 and activity of the Sac 
domain in Sac-/IPPc as a percentage of the activity of the Sac domain within Sac/IPPc 
towards 100 µM of PI(4)P. Phosphate levels were measured through the malachite green 
assay (Section 2.1.7).  Error bars represent the standard error of triplicate repeats. Assay 
time was 30 minutes. 
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3.2.3 Identification of a Non-lipid Sac Substrate  
The lipid PI(4)P is known to be a Sac phosphatase substrate, whilst PI(4,5)P2 is a lipid 
substrate for the IPPc domain [72, 75, 88]. Sac1p in yeast has been shown to hydrolyse 
PI(3)P[88]. The IPPc domain has also been shown to hydrolyse the inositol phosphate 
headgroup I(1,4,5)P3 in previous work[79]. However, as of yet, it is unknown whether 
the Sac phosphatase can hydrolyse inositol phosphate headgroups in addition to 
phosphoinositide lipids.  
The positioning of the phosphate groups on PI(4)P is analogous to those in 
I(1,4)P2. Likewise, the positioning of the phosphates on PI(3)P is analogous to that in 
I(1,3)P2. This means that I(1,4)P2 and I(1,3)P2 are likely to have the ability to interact 
with the Sac active site. Therefore, the possibility of I(1,4)P2 and I(1,3)P2 being 
substrates of the Sac phosphatase was investigated. Fig.3.5 shows the activity of 
Sac/IPPc towards I(1,4)P2 and I(1,3)P2 as a percentage of the Sac/IPPc activity towards 
PI(4)P. It can be seen that within the detection limits of the assay, negligible levels of 
phosphate were produced during the assay time, indicating that I(1,4)P2 and I(1,3)P2 
are not substrates for the Sac domain.  
Given that the Sac domain was found not to act on inositol headgroups, 
alternative compounds were explored as possible non-lipid Sac substrates. As described 
previously, PTP’s and the Sac phosphatase are both members of the CX5R phosphatase 
family and are thought to act via similar catalytic mechanisms[44, 72, 107]. To exploit 
this homology, PTP substrates were investigated for their potential to be substrates for 
the Sac domain in Sac/IPPc.  
                Substrates of the PTP family tend to be artificial surrogate compounds as often 
the actual cellular substrates of PTP’s are not known[203]. Non continuous PTP activity 
assays include radiometric assays where the release of [32P] phosphate from 
phosphotyrosyl proteins is measured[204] and HPLC [205, 206]. Antiphosphotyrosine  
monoclonal antibodies have also been used to evaluate the phosphate release from 
proteins or peptides[206].  Continuous activity assays for PTPs are typically based on 
the hydrolysis of an arylphosphate moiety from a synthetic substrate which yields a 
spectroscopically active product[203]. For example spectroscopic assays have been 
developed based on p-nitrophenyl phosphate (pNPP)[207, 208], 4-methyl-7-
hydroxycoumarinyl phosphate (MUP)[209, 210], 6,8-difluoro-4-methylumbelliferyl 
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phosphate (DiFMUP)[210, 211], 3,6 fluorescein diphosphate (FDP)[187, 188, 212], 3-O-
methyl fluorescein phosphate (OMFP)[188] and phosphotyrosine peptides[206]. 
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Fig.3.5: The activity of Sac/IPPc towards 200 µM of I(1,4)P2 and I(1,3)P2 as a percentage 
of that of Sac/IPPc towards PI(4)P. Phosphate levels were measured through the 
malachite green assay (Section 2.1.7). Assay time was 30 minutes. Error bars represent the 
standard error of triplicate repeats.  
  
                        A summary of the advantages and disadvantages of the various established 
PTP substrates is given in Table 3.1. Phosphotyrosine peptides have been shown to 
have good catalytic efficiency and have the advantage of mimicking the natural 
substrate of PTP but to have low specificity and detection sensitivity and a susceptibility 
to colour interference. pNPP and MUP are widely used as PTP substrates as they are 
more sensitive than the peptides and have no colour interference. However they are 
limited by their pH operating range as both pNPP and MUP require buffers with a pH 
above 7. Assays based on FDP and OMFP have been found to have good sensitivity, no  
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Table 3.1: Summary of the advantages and disadvantages of a selection of PTP artificial 
substrates: p-nitrophenyl phosphate (pNPP), 4-methyl-7-hydroxycoumarinyl phosphate (MUP), 
6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP), 3,6 fluorescein diphosphate (FDP), 3-O-
methyl fluorescein phosphate (OMFP) [187, 188, 207, 209-212]. 
 
 
 
Structure Advantages Disadvantages 
pNPP 
N+
-O
O
O P
O
OH
OH  
No colour 
Interference. 
High pH 
operating range 
Low sensitivity 
MUP 
O OOP
O
HO
OH
 
Sensitive. 
No colour 
Interference. 
High pH 
operating range 
DiFMUP 
 
 
O
F
F
OOP
O
HO
OH
 
 
Sensitive. 
No colour 
Interference. 
Low pH 
operating range 
FDP 
O
O
O
OPO3H2H2O3P  
Good pH 
operating range. 
High catalytic 
efficiency. 
Photobleaching 
when exposed to 
intense light 
Hydrolytic in 
water 
OMFP 
O
O
O
OPO3H2MeO  
Good pH 
operating range 
High catalytic 
efficiency 
Simpler enzyme 
kinetics than dual 
phosphate 
substrates 
Photobleaching 
when exposed to 
intense light. 
Hydrolytic in 
water 
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colour interference and to have a wide operating pH range. They also have the 
advantages of being substrates that can be monitored in a continuous fashion.  
 
3.2.3.1 Investigation of Fluorescein DiPhosphate ( FDP) as a Sac Phosphatase 
Substrate 
FDP has been shown to be a substrate for a variety of PTPs, including leukocyte 
phosphatase CD45 (leukocyte common antigen), PTP1B and leukocyte common 
antigen-related protein LAR [187, 212]. Hydrolysis of FDP by a PTP is a two step 
process, with FDP first being converted to fluorescein monophosphate (FMP) and then 
to fluorescein (Fig.3.6). Purified FDP has a weak absorbance at 330nm. When the first 
phosphate is hydrolysed, and FDP converted to FMP, a large increase in absorbance is 
observed at 445nm. Further removal of the remaining phosphate group generates 
fluorescein and a further increase in absorbance at 490nm.  The kinetics of the 
hydrolysis can be followed by monitoring the levels of absorption at 445 and 490 nm. 
The absorption spectra of FDP, FMP and fluorescein formed from the hydrolysis of a 
PTP is shown in Fig. 3.7. 
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OPO3H2H2O3P O
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O
OPO3H2HO OHO OH
COOH
Pi Pi
 
 
 
 
Fig.3.6: The stepwise hydrolysis of Fluorescein DiPhosphate (FDP) to Fluorescein by a Phosphatase. 
FDP is first converted to Fluorescein Monophosphate (FMP) before further hydrolysis to 
Fluorescein.  
 
 
 
 
FDP FMP Fluorescein 
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Fig.3.7: Time course of CD45-catalyzed hydrolysis of FDP to FMP and fluorescein (A) 
monitored by repeated absorption scans (B) variation of FDP during the assay time course. 
Figure taken from [187].  
 
 
As described earlier, the PTP-mediated catalysis of the commercially available 
compound FDP has been shown to be highly efficient [187, 212]. FDP is likely to be a 
substrate for the Sac domain but not the IPPc domain due to its aromatic nature and 
similarity to other CX5R phosphatase substrates.  It was therefore investigated for its 
potential to be a Sac phosphatase substrate.   
Due to the fact that FDP hydrolyses in water, preparations of FDP are rarely 
pure.  This means that stock preparations of FDP need to be calibrated for background 
levels of both FMP and fluorescein in order to control for levels of background 
hydrolysis. Alkaline phosphatase is known to have the ability to hydrolyse phosphate 
groups from many types of molecules including nucleotides, proteins and alkaloids[213] 
and has been shown to exhibit a high catalytic efficiency towards numerous synthetic 
substrates, including FDP. Therefore, in order to convert FDP to FMP and fluorescein, 
alkaline phosphatase was incubated with FDP. Fig.3.8 shows absorbance scans of 400 
µM of FDP in the absence and presence of alkaline phosphatase between the 
wavelengths of 380 and 560 nm. It can be seen that there is an absence of absorbance at 
445 and 490 nm for the pure FDP sample, confirming that the preparation of FDP does 
not contain detectable levels of FMP or fluorescein.  
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Fig.3.8: Comparison of the absorbance scans of 400 µM fluorescein diphosphate (FDP)(red)and 
400 µM FDP hydrolysed by alkaline phosphatase (black) between the wavelengths of 380 and 
560nm. See Section 2.1.8 for FDP assay method.    
 
 
  
 In order to compare the kinetic parameters of the hydrolysis of FDP with that 
cited in the literature the hydrolysis of FDP by alkaline phosphatase was first studied as 
a model system and positive control. To assess the kinetics of the alkaline phosphatase- 
catalysed hydrolysis of FDP, alkaline phosphatase was incubated with increasing 
concentrations of FDP and the absorbance of FMP and fluorescein measured over time 
(Fig.3.9).  
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Fig 3.9: Time course of the alkaline phosphatase (0.4 µg/mL) mediated hydrolysis of 400 µM of 
fluorescein diphosphate (FDP). The data taken at 445nm represent the conversion of FDP to FMP 
whilst the data at 490 nm represent the hydrolysis of FMP to fluorescein. The control consisted of 
denatured alkaline phosphatase. See Section 2.1.8 for FDP assay method. Error bars represent the 
standard error of three repeats.  
 
 To construct a Michaelis-Menten curve, the absorbance intensity of each FDP 
concentration at a fixed time point was plotted against FDP concentration. The 
Michaelis-Menten curve is shown in Fig.3.10. Fitting with Origin software showed that the 
KM is 111 ± 48µM. This corresponds well with the literature value of 95 µM (Sigma).    
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Fig 3.10:Michaelis-Menten curve of the alkaline phosphatase (0.4 µg/mL)  mediated hydrolysis of 
fluorescein diphosphate (FDP). See Section 2.1.8 for FDP assay method.The KM was calculated to be 
111 ± 48 µM . Error bars represent the standard error of three repeats. 
 
Having shown that the KM value in the literature for the alkaline phosphatase -
mediated hydrolysis of FDP is reproducible in the conditions used in this work, the 
possibility of FDP being a substrate for the Sac domain was investigated. To do this, 
Sac/IPPc was incubated with 400 µM FDP for 60 minutes and the absorbance of FMP 
and fluorescein monitored. It can be seen from Fig 3.11 that no increase in FMP or 
fluorescein levels were detected over this time period, suggesting that FDP is not a 
substrate for Sac in Sac/IPPc. At this concentration of Sac/IPPc, detectable activity of 
the Sac domain towards PI(4)P is observed. The hydrolysis of FDP by Sac/IPPc was also 
investigated by monitoring the fluorescence intensity of FMP and fluorescein. Again, no 
detectable activity was recorded.   
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Fig. 3.11 Time course of the Sac/IPPc (62 µg/mL) mediated hydrolysis of 400 µM of fluorescein 
diphosphate (FDP).  The data taken at 445nm represent the conversion of FDP to FMP whilst the 
data at 490 nm represent the conversion of FMP to fluorescein. See Section 2.1.8 for FDP assay 
method. Error bars represent the standard error of three repeats.  
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3.2.3.2 Investigation of O-Methyl Fluorescein Phosphate (OMFP) as a Sac 
Phosphatase Substrate 
Since the Sac phosphatase was found not to have the ability to hydrolyse FDP, the 
possibility of OMFP being a Sac substrate was investigated. OMFP has been shown to be 
a substrate for various PTPs including CDC25B, ATPase, and the mitogen activated 
protein kinase phosphatases, MKP-1 and MKP-3 [189, 214, 215]. Hydrolysis of the 
phosphate group from OMFP yields O-methyl fluorescein (OMF) (Fig. 3.12). In contrast 
to the two step hydrolysis of FDP, the removal of a phosphate from OMFP is a one step 
process with an absence of intermediates. This means that the analysis of the reaction 
kinetics is simpler for OMFP than FDP.  
The kinetics of OMFP hydrolysis can be monitored by the rate of formation of 
OMF, which can be determined by examining fluorescence levels at an excitation 
wavelength of 485 nm and emission of 525 nm[188].   
 
 
OMeO OH
COOH
PiO
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O
OPO3H2MeO
 
 
 
 
Fig.3.12 : Hydrolysis of the phosphate group from O-methyl fluorescein 
 phosphate (OMFP) by a phosphatase yields O-methyl fluorescein (OMF). OMF can be detected by 
fluorescence at 525 nm.  
 
 
 
 
 
 
 OMFP OMF 
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 In order to know much phosphate is produced during the enzyme-mediated 
hydrolysis of OMFP, it was first necessary to calibrate the levels of OMF produced in the 
assays. Hydrolysis of OMFP by excess alkaline phosphatase overnight produces a 
complete turnover of OMFP to OMF thus allowing the fluorescence levels of known 
concentrations of OMF to be measured. Fig.3.13 shows a plot of OMF fluorescence 
intensity versus OMFP concentration.  
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Fig.3.13: Variation of the fluorescence intensity of OMF with increasing levels of OMFP allowing the 
calculation of phosphate levels in the assay from the fluorescence intensity. OMFP was taken to 
completion levels of OMF by excess levels of alkaline phosphatase. Emission slit width = 5nm, 
excitation slit width=2.5nm. Equation of the linear fit was found to be Y=1.541x. See Section 2.1.9 
for OMFP assay method. Error bars represent the standard error of three repeats.   
 
 The alkaline phosphatase-catalysed hydrolysis of OMFP was used as a model 
system. To optimise the concentration of alkaline phosphatase required to give a 
response, the fluorescence intensity of varying concentrations of alkaline phosphatase 
towards 200 µM of OMFP was measured (Fig.3.14). It is advantageous to use the lowest 
concentration of enzyme that gives a detectable, linear release of product.  Fig. 3.14 
shows that the production of OMF by a concentration of 0.25 µg/mL alkaline 
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phosphatase is linear up to a time point of 25 minutes. Therefore, this concentration 
was used for the alkaline phosphatase assays described here onwards.  
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Fig.3.14: Measurement of the OMF fluorescence intensity over time for the hydrolysis of 250 µM of  
O-methylfluorescein phosphate(OMFP) by increasing concentrations of alkaline phosphatase. See 
Section 2.1.9 for OMFP assay method. 
 
 
To generate a Michaelis-Menten plot for the alkaline phosphatase hydrolysis of 
OMFP, the hydrolysis of varying concentrations of OMFP was measured over time 
(Fig.3.15).  The fluorescence intensity of each OMFP concentration was then plotted 
against OMFP concentration at a fixed time point (Fig.3.16). The KM of the alkaline 
phosphatase hydrolysis of OMFP was calculated as 135 ± 33  µM. This is the first 
reported value of the alkaline phosphatase hydrolysis of OMFP and therefore, there are 
no values in the literature with which to compare this.    
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Fig 3.15: Time profile of the alkaline phosphatase (0.25 µg/mL) hydrolysis of varying levels of 
OMFP. See Section 2.1.9 for OMFP assay method.  
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Fig 3.16: Michaelis-Menten plot of the alkaline phosphatase mediated hydrolysis of OMFP(0.25 
µg/mL) at 30 minutes. The KM was calculated as 135 ± 33 µM. Data were taken from Fig 3.15 in 
order to construct this plot.  Error bars represent the standard error of three repeats. See Section 
2.1.9 for OMFP assay method. 
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To investigate whether OMFP is a substrate for the Sac phosphatase, 62 µg/mL of 
Sac/IPPc was incubated with increasing levels of OMFP and the fluorescence intensity 
of OMF measured over time (Fig.3.17). It can be seen that levels of OMF increase 
linearly over time for all OMFP concentrations examined, showing that OMFP is a 
substrate for the Sac phosphatase. This is the first reported non-lipid substrate of the 
Sac domain. To construct a Michaelis-Menten plot, the slope of each time profile was 
plotted against OMFP concentration. Fig.3.18 shows the Michaelis-Menten curve for the 
hydrolysis of OMFP by Sac/IPPc at a time point of 30 minutes. The KM was found to be 
106±41.  
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Fig 3.17: Time profile of the Sac/IPPc (62 µg/mL) mediated catalysis of varying levels of 
OMFP. Error bars represent the standard error of three repeats. See Section 2.1.9 for OMFP assay 
method. 
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Fig 3.18: Michaelis-Menten plot of the Sac/IPPc (62 µg/mL). Data were taken from Fig 3.17. The 
KM was calculated to be 106±41. Error bars represent the standard error of three repeats. 
 
Due to the fact that Synaptojanin contains an IPPc domain in addition to the Sac 
phosphatase, it was necessary to confirm that OMFP is specifically hydrolysed by the 
Sac domain and is not an IPPc substrate. 200 µM of OMFP was incubated with Sac/IPPc- 
, Sac-/IPPc and IPPc (62 µg/mL) and the formation of OMF monitored over time. From 
Fig.3.19 it can be seen that Sac-/IPPc and IPPc did not display any detectable activity 
within the time range examined whilst the formation of OMF increased linearly with 
time in the presence of Sac/IPPc-. This confirms that the hydrolysis of OMFP is specific 
to the Sac domain in Sac/IPPc.  
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Fig 3.19: Time course of the hydrolysis of 200 µM of OMFP by 62 µg/mL of Sac/IPPc, Sac-/IPPc and 
IPPc. Error bars represent the standard error of three repeats. See Section 2.1.9 for OMFP assay 
method. 
 
 
As described previously, the lipid PI(4)P is known to be an in vivo substrate for 
the Sac phosphatase[89]. To compare the activity of the Sac domain to OMFP with that 
of PI(4)P, Sac/IPPc was incubated with 50 µM of each of PI(4)P or OMFP and the 
activity of Sac measured (Fig. 3.20). The activity of Sac towards OMFP was evaluated 
through the fluorescent measurement of OMF levels, whereas the activity towards 
PI(4)P was assessed using the malachite green assay. A full analysis of the substrate 
specificities of the Synaptojanin phosphatases can be found in Chapter 4.    
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Fig 3.20: Activity of the Sac phosphatase in Sac/IPPc towards 50µM of OMFP as a percentage of the 
activity of the Sac domain activity towards 50µM of PI(4)P  at a time point of 30 mins. Error bars 
represent the standard error of three repeats. The activity of the enzyme towards PI(4)P was 
measured by the malachite green assay (2.1.7), whilst the activity towards OMFP was measured 
according to the OMFP assay method (See Section 2.1.9) 
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3.4 DISCUSSION 
Comparing the behaviour of phosphatases towards phosphoinositide lipid substrates 
with that towards their corresponding headgroups can be used to give an indication of 
the interfacial preferences of the enzyme[216]. The IPPc domain in Synaptojanin is 
known to hydrolyse both PI(4,5)P2 and the inositol headgroup I(1,4,5)P3 [75, 80, 105]. 
In contrast, in this work it has been shown that the second catalytic domain in the 
enzyme, the Sac domain, has the ability to hydrolyse PI(4)P but not the corresponding 
inositol phosphate headgroup analogue I(1,4)P2.  
This indicates that the Sac phosphatase has a greater preference for lipid 
substrates, whereas the activity of the IPPc domain is less specific. However, it has been 
shown  that the VMax activity of the IPPc domain has been reported to be higher towards 
PI(4,5)P2 than I(1,4,5)P3[79], suggesting that the IPPc hydrolysis of lipids is more 
efficient. Therefore, it seems that both the Sac and IPPc domain show a catalytic 
preference towards lipid substrates. Lipid molecules are amphiphilic meaning that the 
aggregate into interfacial mesophases. This means that it could be possible that they 
functioning of the catalytic domains within Synaptojanin is sensitive to the interface 
that they act on. The response of an enzyme to the presence of an interface can be 
described as interfacial recognition.    
Further evidence to suggest that the Sac and IPPc domains show interfacial 
recognition can be found by examining the literature. The Sac domain in SP 
Synaptojanin has been found to be sensitive to the substrate presentation of 
PI(4)P[105] whilst the IPPc domain has also been shown to be sensitive to the fatty acid 
composition of its lipid substrates both in vitro and in vivo[65, 79]. It has also been 
found that octylglucoside decreases the VMax activity of the IPPc domain towards 
I(1,4,5)P3, indicating that the detergent can bind to the active site of the enzyme[79]. 
The effect of various interfaces on the functioning of the enzyme is investigated later in 
this thesis (See Chapter 6).  
   Despite the fact that the Sac domain cannot hydrolyse inositol phosphate 
headgroups, the aromatic molecule OMFP was found to be a soluble substrate for the 
Sac domain. This is the first reported non-lipid substrate of the Sac phosphatase and 
allows the kinetic parameters of the Sac phosphatase towards a non-lipid substrate to 
be assessed in a continuous manner.  The fact that the Sac domain can hydrolyse the 
PTP substrate OMFP can clearly be attributed to the fact that the Sac domain shares 
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catalytic site homology with the CX5R family. Dr Lok Hang Mak (Imperial College 
London) has also shown that OMFP is a substrate for PTEN, suggesting that OMFP may 
be a generic substrate for CX5R phosphatases.  Interestingly, the activity of the Sac 
domain towards OMFP was significantly lower than that of PI(4)P again indicating that 
the Sac domain preferentially hydrolyses lipid molecules. 
 The structures of OMFP and FDP are both fluorescein analogues and differ 
only in that OMFP contains a methoxy group whereas FDP contains an additional 
phosphate group. OMFP was found to be a Sac substrate whereas FDP was not and this 
indicates that the methoxy group in OMFP promotes the association of OMFP to the Sac 
active site whereas the additional phosphate in FDP acts to disrupt the interaction.  
 In summary, a series of phosphatase enzymes have been expressed and a 
novel non-lipid substrate for the Sac phosphatase has been identified. It seems that the 
Sac and IPPc domains both preferentially hydrolyse lipid substrates, providing evidence 
to support the fact that the domains exhibit interfacial recognition. To gain a full 
understanding of the differences between the hydrolysis of lipid and non-lipid 
substrates, an analysis of the kinetic parameters these processes was required. Chapter 
4 describes the enzymological characterization of the catalytic domains within 
Synaptojanin.   
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Chapter 4 
Enzymatic Characterization of 
the Sac and IPPc Domains within 
Synaptojanin 
CHAPTER ABSTRACT 
The kinetic parameters of the Sac and IPPc domains in a series of phosphatases; a 
double phosphatase Sac/IPPc, an IPPc mutant, Sac/IPPc-, a Sac mutant Sac-/IPPc, and 
single IPPc and Sac phosphatases were characterized in order to deduce whether the 
domains in Synaptojanin function in a co-dependent manner. It was found that the VMax 
activities of the Sac and IPPc domain are co-dependent when they act on lipid 
substrates. Several possible mechanisms are proposed to explain these observations, 
including substrate channelling and interfacial recognition. In addition, an analysis of 
the substrate specificities of the Sac and IPPc domains confirms that both phosphatases 
preferentially hydrolyse lipid substrates.  
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4.1 INTRODUCTION 
The domains and sub-units in bi- and multi-functional enzymes are often found to 
function in a co-dependent manner. Mechanisms by which the domain co-dependency is 
found to operate include that of substrate channelling and/or conformational changes 
which act to control the functioning of the domains [168, 194, 217]. The synaptic 
enzyme Synaptojanin is unique in that it is the only mammalian inositol phosphatase to 
contain more than one catalytic domain; a 4-phosphatase Sac domain and a 5-
phosphatase IPPc domain. However, the reasons as to why nature has evolved a bi-
functional inositol phosphatase containing both Sac and IPPc domains are as yet 
unclear.  
A series of Synaptojanin phosphatases were expressed in Chapter 3. These 
included a double phosphatase, Sac/IPPc, a mutant of Sac/IPPc that rendered the Sac 
domain inactive, Sac-/IPPc, an IPPc mutant Sac/IPPc- and single IPPc and Sac 
phosphatases. Having also identified a soluble non-lipid substrate of the Sac 
phosphatase in Chapter 3, a full enzymological characterization of the Sac and IPPc 
domains in these phosphatases could be carried out.   
 Comparing the kinetic parameters of the IPPc phosphatase in Sac/IPPc to that of 
the Sac mutant, Sac-/IPPc, allows any influence of the Sac domain on the functioning of 
the IPPc domain to be elucidated. Likewise, evaluating whether the inactivation or 
removal of IPPc activity has an effect on the catalytic functioning of the Sac domain, 
enables the extent of influence that the IPPc domain has on the Sac phosphatase to be 
determined.  The activities of the domains were measured towards both lipid and non-
lipid substrates in order to probe the substrate specificities of the phosphatases.  
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4.2 RESULTS 
To elucidate whether the activities of the Sac and IPPc domains are co-dependent, the 
KM/VMax parameters of the Sac- and IPPc- mediated hydrolysis of their substrates were 
evaluated in each of the Synaptojanin phosphatase constructs (see Fig 3.1). The IPPc 
domain activity was measured towards PI(4,5)P2 and I(1,4,5)P3. The activity of the Sac 
domain was measured towards PI(4)P and OMFP.  
   
4.2.1 Enzymological Analysis of the IPPc Domain-mediated Hydrolysis of PI(4,5)P2 
and I(1,4,5)P3 
First, we wanted to evaluate whether the functioning of the Sac domain influences the 
activity of the IPPc domain towards the IPPc lipid substrate PI(4,5)P2. To do this, the 
activities of the IPPc domain within Sac/IPPc, Sac-/IPPc and the single IPPc 
phosphatase constructs were measured towards increasing levels of PI(4,5)P2. 
Phosphatase activity was measured by monitoring levels of free phosphate through the 
malachite green assay.  The corresponding Michaelis-Menten plots can be seen in Fig.4.1 
and the KM, VMax and KM/VMax values are given in Table 4.1. Here, the VMax values 
correspond to turnover number, kcat, and kcat = VMax/[E]o where EO is the concentration 
of active sites in solution. The value of kcat reflects the turnover of substrate molecules 
each enzyme site converts to product per unit time.   
Interestingly, the VMax activity of the IPPc domain towards PI(4,5)P2 was found to 
be approximately 3 fold higher in the double phosphatase, Sac/IPPc, than in both Sac-
/IPPc and the single phosphatase IPPc. This indicates that the Sac domain has an 
influence on the VMax functioning of the IPPc domain towards PI(4,5)P2. Interestingly, 
there is no significant difference in the VMax for Sac-/IPPc and the single IPPc 
phosphatase, suggesting that the physical presence of the Sac protein is not responsible 
for the effect. Instead, it is likely that the influence of the Sac domain is kinetic. 
    The KM value of the single IPPc phosphatase hydrolysis of PI(4,5)P2 was 
calculated as being 136 ± 37 µM. This correlates well with that of previous work, which 
characterized the KM as being 100 µM ± 43[79].  Through comparing the KM values of 
Sac/IPPc, Sac-/IPPc and IPPc, it can be seen that there is no significant change in KM 
between the phosphatases. Therefore, it can be assumed that the functioning of the Sac 
domain does not influence the KM of the IPPc domain towards PI(4,5)P2.  
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 Changes in KM can be attributed to a change in the enzyme’s affinity towards its 
substrate, whilst changes to the VMax reflect an alteration to the enzymes ability to turn 
over its substrate. The effect of Sac inactivation, through both mutation (Sac/IPPc-) and 
removal (IPPc), does not seem to be on the affinity of the IPPc domain towards 
PI(4,5)P2.  Instead, the effect is mainly a VMax one, implying that the presence of a 
functional Sac phosphatase somehow aids the IPPc’s ability to turn over the lipid. The 
KM /VMax ratio is often used to denote an enzyme’s efficiency. The smaller the ratio, the 
higher the efficiency the enzyme has towards the substrate.  It can be seen from Table 
4.1 that the KM /VMax ratio of Sac/IPPc towards PI(4,5)P2 is notably lower than that of 
Sac-/IPPc or the single IPPc phosphatase.           
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Fig.4.1: Comparison of the Michaelis-Menten plots of the IPPc domain in Sac/IPPc, Sac-/IPPc and 
IPPc towards PI(4,5)P2 dissolved in 0.25% octylglucoside. The KM and VMax values are given in Table 
4.1. Phosphate levels were measured through the malachite green assay (Section 2.1.7). 
Assay time was 30 minutes. Error bars represent the standard error of triplicate repeats.  
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Having established that the Sac domain influences the VMax activity of the IPPc 
domain towards PI(4,5)P2, it was investigated whether the Sac domain also influences 
the IPPc domain hydrolysis of the non-lipid substrate I(1,4,5)P3. To do this, the activity 
of the IPPc domain in Sac/IPPc, Sac-/IPPc and IPPc was measured towards increasing 
levels of I(1,4,5)P3 substrate. The corresponding Michaelis-Menten plots can be seen in 
Fig.4.2. 
 There is no significant difference in the VMax activity of the IPPc-mediated 
hydrolysis of I(1,4,5)P3 by Sac/IPPc, Sac-/IPPc and IPPc. Likewise, as can be seen from 
Table 4.1, no significant difference in KM was observed between the three phosphatases. 
Therefore, in contrast to when PI(4,5)P2 is used as a substrate, the IPPc domain is not 
dependent on the Sac domain when it acts on I(1,4,5)P3. Again, the KM value for the 
single phosphatase IPPc catalysis of I(1,4,5)P3 correlates well with earlier work[79]. 
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Fig. 4.2: Michaelis-Menten plots of the IPPc domain catalysis of I(1,4,5)P3  by Sac/IPPc, Sac-/IPPc 
and IPPc Assay time was 30 minutes. The KM and VMax values are given in Table 4.1. Phosphate 
levels were measured through the malachite green assay (Section 2.1.7). Error bars represent the 
standard error of triplicate repeats. 
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Table 4.1: Summary of the kinetic parameters, KM, VMax(kcat) and KM/VMax,, for the catalysis of 
PI(4,5)P2 and I(1,4,5)P3 by Sac/IPPc, Sac-/IPPc and the single IPPc phosphatase. Units of KM are 
µM. Units of VMax are nmolphosphate/min/µg enzyme.   
 
 PI(4,5)P2 I(1,4,5)P3 
Phosphatase KM VMax  KM/VMax 
(x1000) 
KM VMax KM/VMax 
(x1000) 
 
Sac/IPPc 
 
165± 45 
 
 
0.03082 
± 0.00026 
 
5 ± 2 
  
 
122±47 
 
0.00836 
±  
0.00078 
 
15±0.03 
 
 
Sac-/IPPc 
 
 
187±63 
 
0.01042 
± 0.00057 
 
18 ± 7 
 
 
147±48 
 
0.00613 
±  
0.00057 
 
23 ± 10  
 
 
IPPc 
 
136±37 
 
 
0.01099 
± 0.00093 
 
12 ±4 
 
136±54 
 
0.006001 
±  
0.00055 
 
22 ± 11 
 
 
It is unlikely that the mutation used to render the Sac domain inactive in Sac-
/IPPc would cause a change in conformation to the enzyme as it is a single amino acid 
substitution. However, the single IPPc domain was prepared from “cutting” from the 
double phosphatase Sac/IPPc (work by Dr Erika Rosivatz see Fig. 3.1 for boundaries). 
This can sometimes lead to changes in protein folding. However, if there was a change 
to the global conformation of the enzyme caused by mis-folding, then changes in the 
VMax would be expected to occur with all substrates. As aforedescribed, significant VMax 
changes were not observed with I(1,4,5)P3 as an IPPc substrate supporting the notion 
that protein misfolding is not responsible for the decrease in VMax. As a control, it is 
possible to compare the PI(4,5,)P2 activity of the IPPc domain in each phosphatase as a 
percentage of its activity towards I(1,4,5)P3 (Fig 4.3). It can be seen that the VMax change, 
relative to the activity of I(1,4,5)P3 is still significant.  
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Fig 4.3: VMax activity of the IPPc-mediated catalysis of PI(4,5)P2 in 0.25% octylglucoside by 
Sac/IPPc, Sac-/IPPc and IPPc  as a percentage of the corresponding VMax activity  towards 
I(1,4,5)P3 . Phosphate levels were measured through the malachite green assay (Section 
2.1.7). Error bars represent the standard error of triplicate repeats. Assay time was 30 minutes.  
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4.2.2 Enzymological Analysis of the Sac Domain- mediated Hydrolysis of PI(4)P and   
          OMFP 
Having established that the Sac domain has an influence on the VMax functioning of the 
IPPc domain towards PI(4,5)P2, it was investigated whether the catalytic functioning of 
the Sac domain is influenced by the IPPc phosphatase domain.  To do this, the kinetic 
parameters of the Sac domain-mediated hydrolysis of PI(4)P by Sac/IPPc, the IPPc 
mutant Sac/IPPc- and the single Sac phosphatases were compared. The activity of Sac 
was measured towards increasing levels of PI(4)P and Michaelis-Menten plots 
constructed (Fig.4.4).  Again, interestingly, it can be seen that the VMax activity for the 
Sac domain in Sac/IPPc is significantly higher than that in both Sac/IPPc- and the single 
Sac domain. This shows that the VMax of the Sac-mediated catalysis of PI(4)P is 
influenced by the functioning of the IPPc domain.  
The removal of the IPPc domain seems to affect the functioning of the Sac 
domain to a greater extent than its inactivation through mutation, with the single 
phosphatase displaying a notably lower VMax than Sac/IPPc- (See Fig 4.5). This indicates 
that both the enzymological functioning and the physical presence of the IPPc domain 
are important for the activity of the Sac domain. Also, it can be seen that the difference 
in VMax between the phosphatases is more severe than that observed for the IPPc 
domain catalysis of PI(4,5)P2 (Fig. 4.1). This suggests that the functioning of the IPPc 
domain is more important for the Sac-catalysed hydrolysis of PI(4)P than the Sac is for 
the IPPc catalysis of PI(4,5)P2. 
  As can be seen from Table 4.2, in contrast to the IPPc domain catalysis of 
PI(4,5)P2, the change in KM between Sac/IPPc and Sac/IPPc- is also significant. This 
indicates that the inactivation and removal of the IPPc domain in the double 
phosphatase affects the affinity of the Sac domain for PI(4)P as well as the ability of the 
Sac domain to catalyse the lipid.  
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Fig 4.4 : Michaelis-Menten plots of the Sac domain catalysis of PI(4)P in 0.25% octylglucoside by 
Sac/IPPc, Sac/IPPc- and Sac. Assay time was 30 minutes. The KM and VMax values are given in Table 
4.2. Phosphate levels were measured through the malachite green assay (Section 2.1.7).  
Error bars represent the standard error of triplicate repeats. 
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Fig 4.5 : Michaelis-Menten plots of the Sac domain catalysis of increasing concentrations of PI(4)P 
in 0.25% octylglucoside  by  Sac/IPPc- and Sac. Error bars represent the standard error of 
triplicate repeats. 
 
Having shown that the Sac domain does not influence the IPPc catalysis of the 
non-lipid headgroup I(1,4,5)P3, the effect of IPPc functioning on the Sac-mediated 
hydrolysis of the non-lipid Sac substrate, OMFP was evaluated. To do this, the activity of 
Sac in Sac/IPPc, Sac/IPPc- and Sac were measured towards increasing concentrations of 
OMFP. The activity of the phosphatases weas evaluated by measuring the increase in 
fluorescence levels generated by the formation of OMF[188]. Michaelis-Menten plots of 
the Sac domain hydrolysis of OMFP by the three Synaptojanin phosphatases were 
constructed (Fig.4.6). The KM  and VMax values are given in Table 4.2.   It can be seen that 
the difference in VMax and KM values for Sac/IPPc and Sac/IPPc- are minimal and this 
implies that the IPPc domain does not influence the Sac-mediated catalysis of OMFP. In 
contrast, for the single phosphatase Sac, no detectable activity was observed towards 
OMFP suggesting that the Sac domain is required for IPPc domain activity. However, it 
could be that the low activity of the single Sac domain towards its substrates is a result 
of protein mis-folding cannot be ruled out. This means that the use of the double 
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phosphatase IPPc mutant is likely to be a more reliable method of assessing the effect of 
the IPPc domain on the catalytic functioning of the Sac domain.       
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Fig. 4.6: Michaelis-Menten plots of the Sac domain catalysis of OMFP by Sac/IPPc and Sac/IPPc- . 
The activity of the single Sac phosphatase towards OMFP was found to be negligible. The KM and 
VMax values are given in Table 4.2. See Section 2.1.9 for OMFP assay method. Assay time was 30 
minutes. Error bars represent the standard error of triplicate repeats. 
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Table 4.2: Summary of the kinetic parameters, KM, VMax(kcat) and KM/VMax,  for the catalysis of 
PI(4)P and OMFP by Sac/IPPc, Sac/IPPc- and the single Sac phosphatase. Units of KM are µM. Units 
of VMax are nmol phosphate/min/µg enzyme. Assay time was 30 minutes. 
 
 PI(4)P OMFP 
Phosphatase KM VMax  KM/VMax 
(x1000) 
KM VMax KM/VMax 
(x1000) 
 
Sac/IPPc 
 
66 ± 30 
 
 
0.00457 
± 0.0006 
 
 
14± 8 
 
106 ± 
44 
 
0.00063 
± 
0.00006 
 
 
168 ± 84 
 
Sac/IPPc- 
 
 
202 ± 21 
 
0.000914 
± 0.00004 
 
 
221 
± 32 
 
88 ± 33 
 
0.00044 
± 
0.00006
24 
 
 
200 ±86 
 
Sac 
 
302 ± 46 
 
 
0.000187 
± 
0.000006 
 
 
 
1614 
± 83 
 
0 
 
0 
 
0 
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The VMax activity of Sac domain towards PI(4)P for each of the phosphatases can 
be given as a percentage of that towards OMFP (Fig 4.7). It can be seen that the change 
in VMax can be considered to be significant.  
 
 
Fig 4.7: VMax of the Sac-mediated catalysis of PI(4)P by Sac/IPPc and Sac/IPPc-as a percentage of 
the VMax activity towards OMFP. Assay time was 30 minutes. Error bars represent the standard 
error of triplicate repeats.   
 
 
It was found that the functioning of the IPPc domain in Synaptojanin is 
dependent on the Sac domain when it acts on lipid substrates but not non-lipid 
substrates. However, it seems that the functioning of the Sac domain is dependent on 
the IPPc domain for both lipid and non-lipid substrates.  This can clearly be seen from 
Fig.4.8, which shows the activity of the Sac and IPPc domains in the mutant and single 
phosphatases as a percentage of the activity of the corresponding domain in the double 
phosphatase.  
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As described previously, it has been found in past work that the presence of 
octylglucoside decreased the VMax activity of the single IPPc domain towards I(1,4,5)P3, 
indicating that the IPPc domain may exhibit interfacial recognition [79].  Therefore it 
could be that the sensitivity of the domain dependence towards lipid and non-lipid 
substrates is due to the fact that Synaptojanin displays interfacial recognition towards 
octylglucoside. This has been investigated and the results are presented in Chapter 6.    
 
Fig. 4.8: The VMax activity of the Sac and IPPc domains in each of the Synaptojanin 
phosphatases as a percentage of the VMax activity of the corresponding domain in the double 
phosphatase Sac/IPPc. The activities of the phosphatases towards PI(4,5)P2, I(1,4,5)P3 and 
PI(4)P were measured through the malachite green assay (Section 2.1.7). Details of the 
OMFP assay can be found in Section 2.1.9.  Error bars represent the standard error of triplicate 
repeats.   
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4.2.3 Analysis of the Substrate Specificity of the Phosphatases 
To examine the substrate specificity of the phosphatases in more detail, a graph 
summarising the VMax activities of the Sac and IPPc domains in each of the phosphatases 
was constructed. The graph shows the activities of the domains in each of the 
phosphatases towards their corresponding substrates as a percentage of the Sac/IPPc 
activity towards PI(4,5)P2 (Fig 4.9). The order of VMax substrate specificity for Sac/IPPc  
can be seen to be  PI(4,5)P2 > I(1,4,5)P3> PI(4)P >OMFP. For the mutant Sac-/IPPc and 
the single IPPc phosphatase, even though the VMax of the hydrolysis of PI(4,5)P2 is lower 
compared to that of Sac/IPPc, the IPPc domain is still most efficient at catalysing 
PI(4,5)P2 compared to I(1,4,5)P3. Previous literature has compared the specificity of the 
single IPPc domain towards a KM concentration of PI(4,5)P2 and I(1,4,5)P3 [79].  It was 
reported that the IPPc domain has a higher activity towards PI(4,5)P2 than I(1,4,5)P3, 
correlating well with the results presented here.  
Interestingly, the  VMax activities of the Sac phosphatase towards PI(4)P and 
OMFP  are lower than that of the IPPc domain hydrolysis of PI(4,5)P2 and I(1,4,5)P3 . 
This shows that the Sac domain is much less efficient at catalysing its substrates than 
the IPPc phosphatase.  
 As described in Chapter 3, comparing the activity of the headgroup I(1,4,5)P3 
with the lipid PI(4,5)P2 can be used to give an indication of the preference of IPPc for 
the presence of a fatty acid chain in its substrates.  The positioning of the phosphates in 
PI(4,5)P2 and I(1,4,5)P3 are similar, with the 1- phosphate in I(1,4,5)P3 positioned 
similarly to the phosphate group linker in the lipid molecule.  The IPPc phosphatase in 
Sac/IPPc preferentially hydrolyses PI(4,5)P2 over I(1,4,5)P3 showing that the VMax 
activity of the enzyme is sensitive to the presence of a fatty acid chain. Table 4.1 and 4.2 
show that the IPPc domain in Sac/IPPc, Sac-/IPPc and IPPc  all have similar KM values 
for PI(4,5)P2 and I(1,4,5)P3. Therefore, although the enzyme holds a similar affinity 
I(1,4,5)P3 and PI(4,5)P2, it is able to catalyse PI(4,5)P2 more effectively than I(1,4,5)P3.  
Interestingly, the KM of the double phosphatase towards PI(4)P is significantly 
smaller than that of the IPPc domain for PI(4,5)P2. This indicates that although the Sac 
domain cannot hydrolyse PI(4)P as effectively as the IPPc can PI(4,5)P2, its affinity for 
its lipid substrate is stronger.  
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Fig. 4.9: The VMax activity of the Sac and IPPc domains in each of the phosphatases as a percentage 
of the VMax activity of the Sac/IPPc activity towards PI(4,5)P2 . Error bars represent the standard 
error of triplicate repeats. Assay time was 30 minutes. 
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4.2.4 Characterization of the Magnesium Dependencies of the IPPc and Sac 
Phosphatases 
The activity of the members of the inositol 5-phosphatase family, including SHIP, SKIP 
and the 5-phosphatase in SP Synaptojanin have been reported to be magnesium 
dependent[80, 90, 218, 219]. In the absence of magnesium, the 5-phosphatase cannot 
hydrolyse I(1,4,5)P3 because the cation facilitates the binding of I(1,4,5)P3 to the active 
site[128]. In contrast to I(1,4,5)P3, the activity of the IPPc domain towards PI(4,5)P2 is 
thought to be magnesium independent[105]. Meanwhile, CX5R phosphatases are also 
widely reported to be magnesium independent [75, 106].  
The magnesium dependencies of the activities of the Sac and IPPc phosphatases 
in the double mammalian Synaptojanin phosphatase have as of yet, not been fully 
characterized. Therefore the effect of magnesium on the Sac and IPPc domains in the 
double phosphatase was investigated.  To do this, the activities of the Sac and IPPc 
domains in Sac/IPPc were measured towards 100 µM I(1,4,5)P3 , PI(4,5)P2 and PI(4)P in 
the presence of increasing levels of magnesium. A control was required to account for 
the possibility that residual levels of magnesium are present in the enzyme 
preparations. Therefore, in a separate experiment, increasing concentrations of the 
magnesium complexing molecule EDTA were incubated with 10 mM magnesium and 
the activity of the domains measured towards their corresponding substrates. 
Fig.4.10(a) shows the activity of Sac/IPPc towards PI(4,5)P2, I(1,4,5)P3 and 
PI(4)P in the presence of increasing levels of magnesium. Fig 4.10(b) shows the activity 
of the IPPc domain towards PI(4,5)P2, I(1,4,5)P3 and PI(4)P in the presence of 10 mM 
magnesium and increasing levels of EDTA. The X-axis in this graph refers to the 
concentration of un-complexed free magnesium. For example at a concentration of 6 
mM free magnesium, the assay well contained 10 mM magnesium plus 4 mM EDTA. A 
concentration of -5 mM magnesium refers to the assay containing 10 mM magnesium 
and 15 mM EDTA.  
It can be seen that in the absence of magnesium, the IPPc domain is unable to 
hydrolyse I(1,4,5)P3. Addition of magnesium raises the activity to a maximum at 2 mM 
after which the activity slowly decreases. This correlates well to the results observed by 
Chi et al for SP Synaptojanin[80]. It was suggested that the decline in activity in the 
presence of larger levels of magnesium is due to the ions binding to a secondary metal 
binding site that is inhibitory. 
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  Chung et al reported that the activity of Synaptojanin is magnesium independent 
when it acts on PI(4,5)P2[105]. However, it can be seen from Figs. 4.10(a) and (b) that 
although the IPPc domain is able tohydrolyse PI(4,5)P2 in the absence of magnesium, 
the activity rises with magnesium concentration to a maximum at 2 mM after which it 
slowly declines. Therefore, in this work, the activity towards PI(4,5)P2 can also be 
described as being magnesium dependent. This indicates the activity of the IPPc domain 
towards PI(4,5)P2 is also regulated by binding to a secondary metal ion binding site. The 
differences in the results presented here to those reported by Chung et al can perhaps 
be attributed to the differing buffer conditions in the assays.     
 As described previously, CX5R phosphatases are thought to be magnesium 
independent. Interestingly, in contrast, it is evident in this work that the Sac domain in 
Sac/IPPc cannot hydrolyse PI(4)P in the absence of magnesium. The response of Sac to 
increasing levels of magnesium seems to mirror that of the IPPc domain towards its 
substrates, with the characteristic decrease in activity observed at higher 
concentrations. It could therefore be that the activity of the Sac domain is also 
influenced by the binding of magnesium to this secondary site.  
To confirm this, the activity of the single Sac domain towards 100 µM PI(4)P was 
measured in the presence of increasing levels of magnesium and compared to that of 
Sac in Sac/IPPc. The concentration of Sac was optimised to match the activity of Sac in 
Sac/IPPc through measurement of their activities towards PI(4)P. It can be seen that the 
magnesium response of the single Sac domain differs to that of Sac in Sac/IPPc 
(Fig.4.11). The activity does not reach a maximum within the magnesium concentration 
range examined. Therefore, it seems that the decrease in Sac activity in the double 
phosphatase, Sac/IPPc, is a direct result of a binding event on the IPPc domain. This 
provides yet more evidence that the IPPc domain influences the Sac domain functioning.  
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Fig. 4.10  Activity of the Sac and IPPc domains in Sac/IPPc towards their corresponding substrates I(1,4,5)P3 (IPPc), PI(4,5)P2 (IPPc) and 
PI(4)P (Sac) (a) in the presence of increasing levels of MgCl2 (b) in the presence of 10 mM MgCl2 pre incubated with increasing levels of 
EDTA.  Error bars correspond to standard error of triplicate repeats. Assay time was 30 minutes. 
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Fig 4.11: Comparison of the activity of the Sac domain in Sac/IPPc with the single Sac phosphatase 
in the presence of increasing levels of  MgCl2. Phosphate levels were measured through the 
malachite green assay (Section 2.1.7). The concentrations of the phosphatases were 
optimised so that the activities were the same at 4mM MgCl2.  Preparations of both 
enzymes were confirmed as having negligible levels of residual magnesium. Error bars 
correspond to standard error of triplicate repeats. Assay time was 30 minutes.  
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4.4 DISCUSSION 
The VMax activitiy of the IPPc domain was found to be dependent on the Sac 
domain when it hydrolysed its lipid substrate PI(4,5)P2 but not when it acted on 
the soluble substrate I(1,4,5)P3. Interestingly, the VMax activity of the Sac domain 
was also found to be dependent on the IPPc domain when it acted on its lipid 
substrate PI(4)P. However, it is unclear whether the Sac domain activity is 
influenced by the IPPc domain when it acts on its soluble substrate OMFP. The 
Sac domain in the double phosphatase IPPc mutant was not affected by the 
inactivity of the IPPc domain. In contrast, the single Sac domain activity was 
found to be negligible towards OMFP indicating that both the presence and 
activity of the IPPc domain is required for OMFP catalysis. However, the 
possibility that the low activity of the single Sac domain is a result of protein mis-
folding cannot be ruled out.  
Through acting in a co-dependent manner towards their lipid substrates, 
the Sac and IPPc phosphatases are likely to be able to finely tune their output to 
optimise the biological functioning of the enzyme. There are two distinct types of 
mechanism that can explain the observed domain dependency; those that are 
based on the kinetic turnover of the substrates by Synaptojanin, such as 
substrate channelling and those that are dependent on protein-lipid and/or 
protein-protein interactions.  
 
4.4.1 Substrate Channelling as a Mechanism of Domain Dependency 
It is possible that substrate channelling occurs within Synaptojanin(4.12(a)). 
Substrate channelling can be described as the process of sequential catalysis by 
one or more sub-units in a monomeric or multimeric enzyme complex, without 
the release of intermediate into the bulk[217]. Many multifunctional enzymes 
such as Tryptophan Synthase, carbamoyl-phosphate synthase (CPS), glutamine 
phosphoribosoylpyrophosphate amidotransferase (GPATase) and thymidylate 
synthase have been shown to operate via substrate channelling 
mechanisms[167, 168, 170, 179, 220, 221].  
Such a mechanism is of fundamental importance to the overall control 
and catalytic efficiency of such enzymes and provides numerous advantageous. 
For example, it allows enzymes to protect their intermediates from being 
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released back into the bulk and this ensures that the intermediates are not 
consumed by competing reactions. Substrate channelling also reduces the time 
with which the intermediates reach the next catalytic site[178, 217]. If substrate 
channelling were to be a mechanism by which Synaptojanin operates, the 
observed changes in VMax between the domains in Synaptojanin could be a 
consequence of changes to the chemical turnover of the substrates rather than a 
result of domain or lipid interactions. 
If substrate channelling does not occur within Synaptojanin, then the 
product of the IPPc domain hydrolysis of PI(4,5)P2, PI(4)P, will be released back 
into the membrane bulk (Fig. 4.12(b)). The Sac domain could then possibly 
hydrolyse the PI(4)P from the bulk to PI.  However, the activity of the Sac domain 
towards bulk PI(4)P has been shown to be relatively low and phosphate levels 
produced from the hydrolysis of bulk PI(4)P to PI are likely to be insignificant.  
If Synaptojanin were to operate via a substrate channelling mechanism, 
then the Sac domain would hydrolyse the same PI(4)P that is released from the 
IPPc active site to PI (Fig. 4.12(a)). The local concentrations of PI(4)P in this 
model would be sufficiently high to cause significant levels of phosphate to be 
produced by the Sac domain. Mutation of the Sac domain activity in the double 
phosphatase would mean that the Sac domain would be unable to hydrolyse 
PI(4)P to PI(Fig. 4.12(c)). This in turn would result in a reduction of the levels of 
phosphate produced, thus explaining why lower levels of phosphate are 
generated in the mutant and single phosphatases. Likewise, rendering the IPPc 
domain inactive would be expected to lower the total levels of phosphate 
produced (Fig. 4.12(d)).  
A method that could be used as a control with which to investigate 
whether Synaptojanin exhibits substrate channelling is to chemically inhibit one 
particular domain and monitor its effect on the catalytic activity of the 
other[222]. If substrate channelling were to occur, then a reduction in the levels 
of total phosphate produced would be expected, in the same way as shown in 
Figs 4.12 (c) and (d). Previous work has found that the bisperoxovanadate 
compound, BpV(OH)pic, is an inhibitor of the Sac domain in Synaptojanin[223]. 
However, inhibitors of the 5-phosphatase domain have not yet been identified. 
This issue has been addressed and the data are presented in Chapter 5.     
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Fig.4.12: (a) If Synaptojanin operates via a substrate channelling mechanism, then the 
product of the IPPc catalysis of PI(4,5)P2 , PI(4)P will be transferred to the Sac domain 
active site for further hydrolysis to PI. (b) If substrate channelling does not occur, then the 
PI(4)P will be released from the active site of the IPPc domain back into the bulk. The Sac 
domain could possibly hydrolyse the PI(4)P from the bulk to PI. However the activity of the 
Sac domain towards bulk PI(4)P is relatively low. (c) If substrate channelling occurs and 
the Sac domain is rendered inactive, then  PI(4)P will not be hydrolysed to PI(4)P and less 
total  phosphate will be produced. (d) If  substrate channelling occurs and the IPPc domain 
is rendered inactive then the supply of PI(4)P from the IPPc domain will be reduced. 
 
(a) (b) 
(c) (d) 
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4.4.2 Interfacial Recognition as a Mechanism of Domain Dependency 
The fact that the domain dependency was specific to lipid substrates points to 
the possibility that the dependency is controlled by enzyme-lipid or enzyme-
interface interactions.  The lipid substrates are suspended in micellar 
octylglucoside in order to solubilise them. It was shown in previous work that 
octylglucoside decreases the VMax activity of the single IPPc domain towards 
I(1,4,5)P3, indicating that the IPPc domain exhibits interfacial recognition[79].  
It is common for the functioning of soluble proteins to be controlled by 
the interfaces that they act on.  For example, phospholipase A2 (PLA2) has been 
shown to bind to anionic phospholipids, which mediates the binding of the 
enzyme to the bilayer[224, 225]. Anionic lipids such as PI(4,5)P2 have also been 
found to increase the activity of PTEN towards it substrates[216, 226]. However, 
as in this work, it is unclear whether this effect is a result of the interface or the 
result of direct protein-lipid interactions. The effect of octylglucoside micelles 
and vesicles on the functioning of Synaptojanin is explored in Chapter 6.      
As previously described, Synaptojanin plays a crucial role in synaptic 
vesicle endocytosis. Recently, Mani et al[114] showed that that the dual action of 
the Sac and IPPc domains is required for normal synaptic vesicle internalization 
and re-availability. Mutants of the IPPc and Sac domains in a double 
Synaptojanin phosphatase were used to show that defects in these processes 
occur when either domain is inactive. 
Given that in this work it was shown that inactivating the IPPc domain 
activity by mutation causes the VMax Sac domain activity to decrease and vice 
versa, it could be that the endocytic defects observed by Mani are due to the 
activity of both Sac and IPPc domains decreasing as a result of the 
mutation[114]. However, Mani et al showed that the activities of the Sac and IPPc 
domains within the wild type and mutant phosphatases did not differ by 
measuring their activities towards water soluble short chain C8 phosphoinositide 
lipids[114]. 
It was shown in the present work that the Sac and IPPc domains are co-
dependent when they act on phosphoinositides with predominantly C18 fatty acid 
chains but not when they act on soluble non-lipid substrates. Mani et al showed 
that the activities are not dependent when they act on C8 lipids. C8 
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phosphoinositide chains are soluble in aqueous solution and this provides 
further evidence that domain dependency is sensitive to the exact nature of the 
substrate that the domains act upon[227]. The differences in the results 
presented in this work compared to Mani et al could also be due to the fact that 
octylglucoside was not included in their system.  
However, even if the results reported by Mani et al are due to differences 
in the VMax activities of the domains, the suggestion that both domains are 
required for efficient endocytosis is likely to be true, as without a functional Sac 
domain, the biological activity of the IPPc domain will decrease and vice versa. 
 
4.4.3 Direct Domain Interaction as a Mechanism of Domain Dependency 
It could be that a conformation exists by which the Sac domain supports the IPPc 
domain hydrolysis of its substrates and the IPPc phosphatase supports the Sac 
catalysis of its substrates.  For example, the domains could hold a conformation 
whereby both interact with the lipid substrate (Fig.4.13). Given that the 
dependency is lipid specific, this interaction would only occur for lipid molecules 
or interfaces. It is possible that mutating or removing one domain could disrupt 
this interaction and hinder the hydrolysis of the substrates of both domains.  Of 
course, there is no direct evidence for this as the crystal structure of the full 
length mammalian Synaptojanin has yet to be solved.  
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Fig.4.13: Proposed conformation whereby both domains interact with the lipid 
substrate (represented by blue ball).  
 
4.4.4 Substrate Specificity of Synaptojanin 
The fact that the Sac domain hydrolysis of PI(4)P to PI has a lower turnover than 
the IPPc hydrolysis of PI(4,5)P2 means that accumulation of significant levels of 
PI(4)P in synaptic vesicles is possible. It has been suggested that the presence of 
PI(4)P in the synaptic vesicles may be important for endocytosis as PI(4)P is 
known to be important for the budding from the trans-Golgi network [228, 229]. 
Another possibility is that the Sac domain contributes to the recruitment of the 
Synaptojanin to the membrane.  Having an enzymatic activity that is comparably 
slow may enable Sac to bind to the phosphoinositides for significant periods of 
time. The enzymatic activity of the Sac domain could act as a “timer” with which 
to control the timescale of the interactions of Synaptojanin with the membrane.   
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4.4.5 Magnesium Dependency of Synaptojanin 
The single Sac phosphatase exhibited a different magnesium dependency profile 
to that of Sac in Sac/IPPc, indicating that the IPPc domain plays a part in the 
magnesium regulation of Sac activity. At large concentrations, magnesium is 
thought to bind to a secondary site on the IPPc domain which inhibits the 
enzyme’s activity[80]. However, the location of such a site has not yet been 
identified. It could be that the binding of magnesium causes a conformational 
change to the enzyme that controls the functioning of both the Sac and IPPc 
domains. It is not unusual for cations such as magnesium to induce changes to an 
enzyme’s conformation. For example, the interfacial binding of the 
diacylglycerol(DAG)kinase DgKB has been shown to be dependent on a 
magnesium-dependent conformational change[230].  
However, it is unlikely that magnesium effects are the cause of the 
observed domain dependency. At the magnesium concentration (4 mM) used to 
evaluate the kinetic parameters of the domains, binding of magnesium to this 
putative inhibitory binding site is likely to be insignificant. Also, the IPPc domain 
was rendered inactive through the mutation of Asp to Ala. This mutation would 
not be expected to interfere with magnesium binding at the active site of the IPPc 
domain because the Glu residue in the IPPc active site has been shown to be 
responsible for the binding of the active site to the metal cation[104].  
 It should be noted that the presence of differing magnesium 
concentrations might cause changes to the electrostatic environment of the 
phosphatase assays. Phosphoinositide lipids are known to bind magnesium and 
therefore increasing levels of the ions could change the screening levels of the 
charges between active site and substrate.  
In summary, this work has shown that the VMax activities of the Sac and 
IPPc domains are co-dependent when they act on lipid substrates. The remainder 
of this thesis seeks to gain an understanding of the mechanism of this domain 
dependency. The possibility that Synaptojanin exhibits interfacial recognition 
and/or substrate channelling is explored in Chapter 6. However, in order to 
investigate whether the Sac and IPPc domains participate in substrate 
channelling, selective chemical inhibitors of each of the domains needed to be 
identified. As described previously, inhibitors of the Sac domain in Synaptojanin 
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have been reported[223]. However, there are no known inhibitors of the 5-
phosphatase IPPc domain. Therefore, a variety of compounds are tested for their 
ability to inhibit the IPPc domain in Chapter 5.  
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Chapter 5 
Small Molecule Inhibitors of 
the Catalytic Domains in 
Synaptojanin  
CHAPTER ABSTRACT 
To explore whether Synaptojanin operates via a substrate channelling 
mechanism, it was necessary to identify selective inhibitors of the IPPc and Sac 
domains. BpV(OH)pic was confirmed as a selective inhibitor of the Sac domain.  A 
variety of compounds were evaluated for their ability to inhibit the 5-
phosphatase IPPc domain. These included inositol phosphate analogues, inositol 
phosphate peptides and stibonate compounds. Although a variety of these 
compounds were found to inhibit the IPPc domain at micromolar concentrations, 
their selectivity over the Sac domain was found to be inadequate. Nevertheless, a 
variety of carboxy-stibonate compounds were found to be potent and selective 
inhibitors of PTP-β, with a selection of the compounds exhibiting inhibition at 
nanomolar concentrations. Therefore a novel class of PTP inhibitors has been 
identified.  
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5.1 INTRODUCTION 
In the previous chapter evidence was presented which implied that the activities 
of the Sac and IPPc domains within Synaptojanin are co-dependent when they on 
lipid substrates. A number of possible models were proposed to explain this lipid 
based Sac/IPPc domain co-dependence (Section 4.4), including substrate 
channelling an interfacial recognition. 
Substrate channelling can be described as the process of sequential 
catalysis by one or more sub-units in a monomeric or multimeric enzyme 
complex, without the release of intermediate into the bulk. If substrate 
channelling does not occur within Synaptojanin, then the product of the IPPc 
domain hydrolysis of PI(4,5)P2, PI(4)P, will be released back into the membrane 
bulk. The Sac domain will then catalyse the bulk membrane PI(4)P to PI.  
However, if Synaptojanin were to operate via a substrate channelling 
mechanism, then PI(4)P would be directly transferred to the Sac phosphatase 
from IPPc. The Sac domain could then hydrolyse PI(4)P  to PI , thus allowing the 
hydrolysis of PI(4,5)P2 directly to PI (Fig 4.12).   
 As described in Chapter 4, a variety of bifunctional enzymes have been 
shown to operate via substrate channelling mechanisms [178, 179, 217]. Such 
mechanisms can be identified through studying the effect of the chemical 
inhibition of a particular catalytic domain on the activity of secondary catalytic 
domains[222]. This approach was therefore applied to Synaptojanin. To do this, 
selective chemical inhibitors of both the IPPc and Sac domains needed to be 
identified.   
                Besides providing a tool with which to probe the domain dependence, it 
has been suggested that the inhibition of the IPPc domain in Synaptojanin could 
offer a novel therapeutic option for the treatment of Alzheimer’s disease. Aβ 
oligomers have been shown to destabilize levels of PI(4,5)P2 in neuronal cells 
and to alter both the signalling properties and permeability of synaptic 
membranes[69, 231, 232].  Preventing the decrease in PI(4,5)P2 levels by genetic 
means reduces the synapse impairing actions of Aβ oligomers[69]. Therefore, the 
inhibition of the 5-phosphatase domain in Synaptojanin could be used to raise 
neuronal PI(4,5)P2 levels and alleviate the symptoms of Alzheimer’s.  
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5.1.1 Small Molecule Inhibitors of the Sac Phosphatase  
Vanadium compounds are well established inhibitors of the CX5R protein 
tyrosine phosphatase family [233-238]. However, it has since been shown that a 
variety of vanadate and bisperoxovanadium complexes (Fig.5.1) can also inhibit 
a range of other CX5R phosphatases, including PTEN and the Sac phosphatase 
within Synaptojanin[223, 239].  The bisperoxovanadium compound, BpV(OH) 
pic, was found to be the most potent Sac inhibitor, with an IC50 of 0.06 µM  (Table 
5.1)[223].  
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Fig.5.1: Structures of a selection of bisperoxovanadium compounds. 
 
Table 5.1 : Inhibition of PTEN and Sac by a selection of vanadate and bisperoxovanadium 
compounds. Data taken from Rosivatz et al  [223]. 
Compound IC50 PTEN (nM) IC50 Sac (µM) 
VO-OH pic 35  ± 2 >10 
Bpv-OH pic 14 ± 2.3 0.06 ± 0.01 
Bpv-pic 31 ± 1.7 0.99 ± 0.01 
Bpv-phen 38 ± 2.4 0.08 ± 0.01 
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5.1.2 Small Molecule 5-Phosphatase Inhibitors     
There are few examples of inhibitors of Type II 5-phosphatases cited in 
the literature.  Woscholski et al[90] reported the inositol phosphate analogue, 
InsS6, and PI(4)P as inhibitors of the Synaptojanin IPPc domain. However, InsS6 
showed only weak inhibition and PI(4)P would not be a suitable inhibitor for this 
work because of its role as a Sac substrate. The chemical inhibition of other 5-
phosphatase enzymes has been more extensively investigated. Mills et al [240] 
synthesized a library of benzene phosphates and evaluated them for their 
potential to act as Type I 5-phosphatase inhibitors. They found that the most 
potent trisphosphate benzene was benzene (1,2,5) trisphosphate (IC50 = 14 
µM)(Fig 5.2(a)) and that benzene(1,2,4,5) tetrakisphosphate could inhibit the 
IPPc domain (IC50 = 4 µM) (Fig.5.2(b)).  Biphenyl (2,3,4,5,6)-pentakisphosphate 
was found to be the most potent 5-phosphatase inhibitor(IC50=1 µM) (Fig.5.2(c)). 
However, these compounds are not commercially available. In the present work, 
molecules including inositol phosphate analogues, inositol peptides and 
stibonate compounds are assessed for their ability to inhibit the IPPc domain in 
Synaptojanin.  
 
 
 
 
   
 
 
 
Fig.5.2: (a) benzene( 1,2,5) trisphosphate  (b) benzene 1,2,4,5-tetrakisphosphate (c) 
biphenyl (2,3,4,5,6)-pentakisphosphate 
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5.2 RESULTS 
Two approaches were taken in order to find a selective IPPc domain inhibitor; 
that of testing substrate analogues as inhibitors and that of testing inhibitors of 
enzymes that have analogous catalytic site structures to IPPc.  
 
5.2.1 Testing of IP3 and IP4 Analogue Compounds as Inhibitors for the IPPc 
Domain in Sac/IPPc 
A common approach in inhibitor development is to investigate compounds that 
are analogues to the natural substrate of the enzyme under investigation. 
Functional moieties are often used to disrupt the hydrolysis mechanism so that 
the compounds do not act as substrates.  
Non-aryl inositol phosphate compounds were investigated for their 
ability to be inhibitors of the IPPc domain. A small library of  I(1,4,5)P3 and 
I(1,3,4,5)P4 analogue compounds were synthesized by Joanna Swarbrick and 
Samuel Cooper of Imperial College London (Fig.5.3). The Sac phosphatase is 
thought to only hydrolyse lower phosphorylated inositol lipids, such as PI(4)P. 
The IPPc domain, meanwhile, can act on higher phosphorylated inositols, such as 
I(1,4,5)P3 and PI(3,4,5)P4. Therefore, it was thought that the I(1,4,5)P3 and 
I(1,3,4,5)P4 based compounds would be likely to interact to a greater extent with 
the IPPc domain rather than the Sac domain.  
First, it was necessary to assess whether the compounds were substrates 
for Sac/IPPc. Levels of free phosphate released from the hydrolysis of the 
compounds were measured through the malachite green assay. 200 µM was 
selected as a suitable concentration with which to test the compounds because, 
at this concentration, the IPPc domain hydrolysis of I(1,4,5)P3 is near its VMax. 
Therefore, if the compounds are IPPc substrates, they would be likely to show 
activity in this concentration regime. The activity of Sac/IPPc towards the 
compounds was compared to that of the Sac/IPPc domain towards I(1,4,5)P3 
(Fig.5.4).   
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Fig. 5.3: Library of  I(1,4,5)P3 and I(1,3,4,5)P4  analogue compounds synthesized by 
Joanna Swarbrick and Samuel Cooper of Imperial College London. 
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It can be seen that levels of free phosphate produced by the compounds 
were negligible within the detection limits of the assay.  Therefore, it can be 
assumed that they are not substrates for Sac/IPPc. Evidently, the functional 
various moieties on the inositol ring have the ability to interfere with the IPPc 
hydrolysis mechanism. 4-C-methyl IP4 and 4-C-Pentyl IP4 were omitted from 
further testing due to the high levels of background phosphate found in these 
compounds (Fig.5.5). At high levels of background phosphate, the malachite dye 
is saturated, decreasing the sensitivity of the assay.  
Fig. 5.4: Levels of phosphate produced from the incubation of Sac/IPPc with 200 µM of 
inositol phosphate analogue compound as a percentage of the activity of Sac/IPPc towards 
I(1,4,5)P3. Phosphate levels were measured through the malachite green assay (Section 
2.1.7). Error bars represent the standard error of triplicate repeats. 
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Fig. 5.5: Optical density of the background levels of free phosphate as determined by the 
malachite green assay found in 200 µM of the inositol phosphate analogue compounds. 
Phosphate levels were measured through the malachite green assay (Section 2.1.7). Error 
bars represent the standard error of triplicate repeats. 
 
 
Next, the compounds were tested for their ability to inhibit the IPPc 
domain in Sac/IPPc. The compounds were incubated with Sac/IPPc before 
measurement of the IPPc activity towards I(1,4,5)P3. Fig.5.6 shows the activity of 
the Sac/IPPc phosphatase in the presence of each analogue as a percentage of the 
control. The control consists of the IPPc domain activity towards I(1,4,5)P3 in the 
absence of a potentially inhibitory compound. It can be seen that 4-C-ethyl IP4, 2-
O-propyl IP4, 2-O-hydroxyethyl IP4 and 4-C-pentyl IP3 inhibit the IPPc domain by 
more than 50% at 100 µM, with 4-C-pentyl IP3 causing the greatest decrease in 
activity. Interestingly, the I(1,4,5)P3 compound containing the bulkier pentyl 
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group was more successful at inhibiting the IPPc domain than the methyl and 
ethyl functional compounds. However, the aromatic phenyl IP3 was found to be a 
less potent inhibitor than the straight chain non–aromatic pentyl.  
To investigate the inhibition mechanism by which the most potent 
inositol phosphate inhibitors operate, the extent of inhibition was tested at 
increasing concentrations of I(1,4,5)P3. The resulting data were plotted in 
Lineweaver- Burk plots (Fig.5.7)[185]. As previously described, if a molecule 
inhibits an enzyme in a competitive manner, then a shift in KM will be observed. 
The VMax will remain unchanged. A Lineweaver-Burk plot comparison of an 
uninhibited enzyme catalysis with a competitively inhibited enzyme will show 
the plots crossing at the (1/V) axis. However, the plots will intercept the (1/[S]) 
axis at different points. In contrast, a non-competitive inhibitor will cause the 
VMax to lower but the KM will remain the same. Therefore, in this case, the plots 
will cross at the (1/[S]) axis but not the (1/V).  From Fig.5.7, it can be seen the 
mechanism of IPPc inhibition by 2-O-hydroxyethyl IP4 and 4-C-pentyl IP3 is 
clearly competitive in nature.  
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Fig.5.6 : The Activity of Sac/IPPc towards 100µM I(1,4,5)P3 in the presence of 100 
µM of each of the inositol phosphate analogues as a percentage of the control. The control 
describes of the hydrolysis of I(1,4,5)P3 in the absence of an inositol phosphate compound. 
Phosphate levels were measured through the malachite green assay (Section 2.1.7).The 
assay time was 30 minutes. . Error bars represent the standard error of triplicate repeats. 
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Fig.5.7 : Lineweaver Burk plots of the Sac/IPPc-mediated hydrolysis of I(1,4,5)P3 in the 
presence of 100 µM 4-C-pentyl IP4 (red), 2-O-hydroxyethyl IP4 (blue) and absence of a 
inhibitor (black). Phosphate levels were measured through the malachite green assay 
(Section 2.1.7). Assay time was 30 minutes. Error bars represent the standard error of 
triplicate repeats. 
 
Next, it was necessary to investigate whether the inositol phosphate- 
based inhibitors act in a dose-dependent manner and establish whether a wipe-
out of activity could be achieved at higher inhibitor concentrations. Increasing 
concentrations of 4-C-ethyl IP4, 2-O-propyl IP4, 2-O-hydroxyethyl IP4 and 4-C-
pentyl IP3, were incubated with Sac/IPPc and the activity of the IPPc domain 
measured towards I(1,4,5)P3 (Fig.5.8). It can be seen that 4-C-ethyl IP4 and 2-O-
propyl IP4 inhibit up to 50% of IPPc activity, where the level of inhibition 
plateaus at a concentration of ~100 µM. 2-O-hydroxyethyl IP4 was the only 
compound found to have the ability to inhibit 100% of IPPc’s activity. Above a 
concentration of 200 µM, 2-O-hydroxyethyl IP4 and 4-C-pentyl IP3 contained too 
high a level of background phosphate for measurement.   
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 Fig.5.8: Dose response of 4-C-ethyl IP4 , 2-O-propyl IP4, 2-O-hydroxyethyl IP4 and 4-C-
pentyl IP3 as inhibitors of the IPPc domain activity in Sac/IPPc towards 100 µM of 
I(1,4,5)P3. Phosphate levels were measured through the malachite green assay (Section 
2.1.7). Assay time was 30 minutes.  Error bars represent the standard error of triplicate 
repeats. 
 
  It was vital to find an inhibitor that was selective to the IPPc domain over 
the Sac phosphatase. To assess the selectivity of the most potent inositol 
phosphate-based compounds, Sac/IPPc was incubated with the compounds (100 
µM) and the Sac activity measured towards both OMFP and PI(4)P. The degree of 
Sac inhibition was also measured for the mutant, Sac/IPPc- and the IPPc 
inhibition for the Sac mutant, Sac-/IPPc.  
Fig.5.9 shows a comparison of the inhibition of the Sac hydrolysis of  
PI(4)P and OMFP with that of the IPPc hydrolysis of I(1,4,5)P3 for Sac/IPPc, Sac-
/IPPc and Sac/IPPc-. 4-C-ethyl IP4 and 2-O-propyl IP4 inhibit the Sac/IPPc 
hydrolysis of PI(4)P by ~30% whilst 2-O-hydroxyethyl IP4 and 4-C-pentyl inhibit 
~ 40% of the control. Therefore, it can be concluded that these compounds show 
  
109 
 
poor selectivity towards the IPPc domain. Interestingly, the extent of Sac 
inhibition is much less when the activity is measured towards the artificial 
substrate OMFP. The inhibition of the IPPc domain in Sac-/IPPc was comparable 
to that in Sac/IPPc for all compounds. This indicates that the compounds do not 
inhibit the IPPc domain by allosterically binding to the Sac domain. Likewise 
there was no difference in the extent of Sac inhibition towards PI(4)P between 
Sac/IPPc -and Sac/IPPc, indicating that the Sac inhibition was not the result of 
the compounds binding to the IPPc domain.   
Fig.5.10 shows a comparison of the extent of inhibition of both the Sac 
and IPPc domains by increasing levels of 2-O-hydroxyethyl IP4 and 4-C-pentyl 
IP3. It can be seen that the extent of Sac inhibition is lower than that of the IPPc 
domain for all concentrations examined. However, the difference in inhibition is 
not high enough with which to evaluate the effect of Sac inhibition on the IPPc 
domain activity.     
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Fig. 5.9: Comparison of the inositol phosphate analogue inhibition of the Sac and 
IPPc domains. The extent of Sac inhibition in Sac/IPPc and Sac/IPPc was measured by 
monitoring the activity of the enzymes towards 100 µM PI(4)P in 0.25% octylglucoside and 
100 µM OMFP. The extent of IPPc inhibition in Sac/IPPc and Sac-/IPPc  was measured by 
monitoring the enzyme’s activity towards 100µM I(1,4,5)P3 . The activities of the enzymes 
towards I(1,4,5)P3 and PI(4)P were measured using the malachite green assay (2.1.7). 
Details of the OMFP assay can be found in 2.1.9.  Assay time was 30 minutes.  Error bars 
represent the standard error of triplicate repeats. 
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Fig. 5.10: Comparison of the inhibition of  the Sac and IPPc domains in Sac/IPPc by 
increasing concentrations of 2-O-hydroxyethyl IP4 and 4-C-pentyl IP3 . The activity of the 
Sac and IPPc domains were measured towards 100 µM PI(4)P in 0.25% octylglucoside  and 
I(1,4,5)P3 respectively. Phosphate levels were measured through the malachite green assay 
(Section 2.1.7). Assay time was 30 minutes.  Error bars represent the standard error of 
triplicate repeats. 
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5.2.2 Phosphatidylinositol Chimera Inhibition of the IPPc Domain 
Peptide-based compounds are often found to be inhibitors of enzymes. For 
example, a variety of peptides have been shown to be inhibitors of Protein 
Tyrosine Phosphatases (PTPs)[241-243]. Such compounds are designed to form 
interactions with the amino acids in an enzyme’s active site. A set of inositol 
phosphate peptides, synthesized by Dr William Heal of Imperial College London, 
were tested for their ability to inhibit the IPPc domain. As can be seen from 
Fig.5.11, the compounds all contain an inositol headgroup attached to differing 
peptide backbones. The compounds therefore mimic a phosphatidylinositol lipid.  
For clarity, the compounds are labelled with their amino acid chain sequence.   
 
 
 
 
 
 
 
 
    
 
 
 
 
Fig. 5.11:Library of Inositol peptide compounds synthesized by Dr William Heal of Imperial 
College London 
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The inositol peptides were tested for their ability to inhibit the IPPc 
domain by incubating them with Sac/IPPc and then measuring the activity of the 
IPPc domain towards I(1,4,5)P3. Due to the low amounts of the compounds that 
were synthesized, an in depth characterisation into the mechanism of inhibition 
could not be carried out. Instead, to gain a indication of the inhibition 
mechanism, the activity of the IPPc domain was measured at both a KM and VMax 
concentration of I(1,4,5)P3. If an inhibitor is competitive, then raising the 
substrate concentration whilst maintaining a fixed inhibitor concentration will 
decrease the extent of inhibition. However, if the inhibition is non-competitive 
then raising the substrate concentration would be expected to not affect the 
levels of inhibition. 
Fig.5.12 shows the activity of the IPPc domain in Sac/IPPc in the presence 
of each of the inositol peptides as a percentage of a control, which consisted of 
the hydrolysis of substrate in the absence of a potential inhibitor. It can be seen 
that compounds KRRSG-Ins and FYRRG-Ins both inhibit the IPPc domain activity 
at a concentration of 100 µM. KRRSG-Ins inhibits 100% of the activity at a KM 
concentration and 50% at a VMax concentration. FYRRG-Ins inhibits 50% of the 
activity at a KM concentration of I(1,4,5)P3 and 15% at a VMax concentration. At a 
higher concentration of substrate, the inhibition of the IPPc domain by FYRRG-
Ins is significantly reduced, indicating that this inhibitor acts in a competitive 
manner with the substrate. Meanwhile, for KRRSG-Ins, raising the level of 
substrate increases the activity of the IPPc domain, although it does not abolish 
inhibition. Therefore, this inhibitor may well operate via a mixed mode of 
inhibition. 
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Fig. 5.12: Inhibition of the IPPc in Sac/IPPc by 100 µM of each member of the  
inositol phosphate peptide compound library. The compounds are labelled according 
to their peptide sequence. Their structures can be seen in Fig. 5.11. The inhibition of 
the IPPc domain was measured towards I(1,4,5)P3 at a KM (50 µM) and VMax (200 
µM) concentration. Phosphate levels were measured through the malachite green assay 
(Section 2.1.7). Assay time was 30 minutes.  Error bars represent the standard error of 
triplicate repeats. 
 
Fig.5.13 shows the IPPc inhibition as a function of increasing levels of 
FYRRG-Ins. It can be seen that the activity plateaus at a concentration of 100 µM 
of FYRRG-Ins. A dose response of KRRSG-Ins could not be carried out due to 
limiting stock amounts of this compound. Low compound amounts also meant 
that the selectivity of the compounds for the IPPc domain could not be 
established. However, because of the similarity of the inositol peptide 
compounds to the product of the Sac domain hydrolysis PI, these compounds 
could prove to be inhibitors of the Sac domain. The compounds are currently 
being re-synthesized to allow further testing.  
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Fig.5.13: Activity of the IPPc domain in Sac/IPPc towards hydrolysis I(1,4,5)P3  (100 µM) in 
the presence of increasing levels of the inositol peptide compound FYRRG-Ins. Phosphate 
levels were measured through the malachite green assay (Section 2.1.7). Assay time was 30 
minutes.  Error bars represent the standard error of triplicate repeats. 
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5.2.3 Testing of Inhibitors of Enzymes that Share Homology with the IPPc 
Domain 
The second approach to finding an IPPc domain inhibitor involved the testing of 
inhibitors of enzymes that hold catalytic site homology to the IPPc domain. The 
IPPc catalytic site has been shown to share homology with both the 
Apurinic/Apyrimidic Endonuclease 1 (APE1) and DNAse family (Fig.5.14)[129]. 
5-phosphatases have been shown to share a similar mechanism of catalysis to 
APE, with both classes of enzymes hydrolysing their distinct substrates through a 
metal-ion dependent process[70].   
APE inhibitors have received particular attention in the literature due to 
their role in sensitising cells to various chemotherapeutic agents[244, 245]. A 
variety of APE inhibitors have been reported in the literature. Madhusaden et 
al[246] reported 7-nitro-1H-indole-2-carboxylic acid as an APE 1 inhibitor, 
although these findings have since been disputed[247].  Arylstibonic acids have 
also been shown to be inhibitors of both APE1 and human topoisomerase 1B 
[247, 248]. Therefore, 7-nitro-1H-indole-2-carboxylic acid and a library of 
arylstibonic compounds were tested for their ability to inhibit the IPPc domain. 
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Fig.5.14 : The catalytic sites of APE1 and DNase1 are homologous to that of the IPPc 
domain in Synaptojanin. The motifs common to DNase1 and Synaptojanin form a similar 
catalytic site, with the substrate directed to the top of the β-strands and the metal ion 
binding site. Figure was taken from Schein et al[129] 
 
 
5.2.3.1 Evaluation of 7-nitro-1H-indole-2-carboxylic acid as an IPPc Domain 
Inhibitor 
The inhibition of the IPPc domain by 7-nitro-1H-indole-2-carboxylic acid was 
tested by incubating 100 µM of the compound with Sac/IPPc and evaluating the 
activity of the IPPc domain towards a KM concentration of I(1,4,5)P3. Fig.5.15 
shows that at this concentration, 7-nitro-1H-indole-2-carboxylic acid inhibits the 
activity of the IPPc domain by 31%. This is significantly lower than the reported 
inhibition of APE 1 by 7-nitro-1H-indole-2-carboxylic acid (IC50=3.06 µM) [246].  
Therefore any further investigation into this compound as an IPPc inhibitor was 
not pursued.    
hAPE1 DNase 1 IPPc 
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Fig.5.15: Activity of the IPPc domain towards 50 µM I(1,4,5)P3 in the presence of 7-nitro-
1H-indole-2-carboxylic acid (100 µM) as a percentage of the control. The control consisted 
of the hydrolysis of I(1,4,5)P3 in the absence of an inhibitor. Assay time was 30 minutes.  
Phosphate levels were measured through the malachite green assay (Section 2.1.7). Error 
bars represent the standard error of triplicate repeats. 
 
5.2.3.2 Evaluation of Aryl Stibonates as IPPc Domain Inhibitors   
A 39 member library of aryl stibonates was obtained from Prof. John Stivers 
(John Hopkins University School of Medicine) (Fig.5.17). This library was 
previously tested by Kim et al[248] for its potential to inhibit human 
topisomerase 1B.  Here, the library was screened for their ability to inhibit the 
IPPc and Sac phosphatases in Sac/IPPc. Due to their structural similarity to the in 
vivo substrate of PTPs, tyrosine phosphate, they were also assessed for their 
ability to inhibit PTP-β. PTP-β was selected as a suitable PTP with which to work 
as it was used by Rosivatz et al[223] to evaluate inhibition by vanadium-based 
compounds.  
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The screening of Sac and IPPc inhibition was carried out using KM 
concentrations of PI(4)P and I(1,4,5)P3 respectively. As described previously 
pNPP is a well established substrate of PTPs and was chosen as the substrate 
with which to monitor PTP-β activity[207, 208]. To determine the KM of the PTP-
β-catalysed hydrolysis of pNPP, a Michaelis-Menten plot was constructed 
(Fig.5.16). The KM was calculated as 0.97±0.048mM, which is in good agreement 
with the literature value of 1 mM(Sigma). 1mM of pNPP was used to screen the 
library for PTP-β inhibition.  
Fig. 5.16: Michaelis-Menten plot of the PTP-β- catalysed hydrolysis of pNPP. Assay 
time was 30 mins. KM was calculated as 0.97±0.048mM.The pNPP assay method is outlined 
in Section 2.1.7.2. Error bars represent the standard error of triplicate repeats. 
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Fig. 5.17: Library of arylstibonate compounds 
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5 µM of each stibonate compound was evaluated for its ability to inhibit 
the Sac, IPPc and PTP-β phosphatases, as this concentration was shown to give 
significant inhibition of the human topisomerases. Fig.5.18 shows the results of 
the screening of the library against the phosphatases. Six of the arylstibonate 
compounds gave > 30% inhibition of the IPPc domain, 13755, P6952, P6953, 
15591-F, 15596-K and P6968. This is approximately a 20-fold improvement in 
terms of affinity on the inhibition reported earlier in this chapter by the inositol 
phosphate and peptide chimera inhibitors (Sections 5.2.1 and 5.2.2). Compound 
13755, which contains stibonate, nitro and carboxylic acid functionality, was 
found to be the most potent inhibitor of IPPc activity.  
 All of the six compounds that were found to inhibit the Sac phosphatase 
activity by more than 30%, contained nitrogen-based functionality, in the form of 
either nitro, amine or amide groups.  This indicates that nitrogen functionality is 
important for Sac inhibition. As with the IPPc domain, 13755 proved to be the 
most potent inhibitor of Sac activity, although this compound was a less potent 
inhibitor of Sac at 5 µM than IPPc.  
A variety of compounds gave excellent inhibition of PTP-β, with twenty 
six compounds from the thirty nine member aryl stibonate library showing more 
than 30% inhibition. Twenty one of these inhibited PTP-β by more than 60%. 
Twelve out of the thirteen carboxylic acid functional arylstibonates inhibited 
PTP- β more than 60%. This can be attributed to the close resemblance of the 
compounds to the in vivo substrate of PTP-β, tyrosine phosphate. Again, 13755 
was a potent inhibitor of PTP-β, showing that this compound is unselective 
towards the phosphatases tested here.   
 
 
  
 
  
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.18: Inhibition of IPPc, Sac and PTP-β towards their respective substrates by 5 µM of each member of  the arylstibonate library. The activity 
of the Sac and IPPc domain were measured towards 50 µM of I(1,4,5)P3 and PI(4)P respectively. Error bars represent the standard error of triplicate 
repeats.  The activity of PTP- β was measured towards 1 mM of pNPP, presented in order of IPPc effectiveness.  
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5.2.3.4 Selectivity of the Aryl Stibonates as IPPc Inhibitors 
Any in vivo IPPc inhibitor would be required to act selectively on the IPPc domain and 
not inhibit other cellular phosphatases. However, to probe the Sac/IPPc domain 
dependency in vitro, it was only necessary to find an inhibitor that was selective for the 
IPPc domain in Sac/IPPc.  From the initial screening results, five of the compounds 
which inhibited the IPPc domain showed good selectivity for the IPPc domain over Sac. 
(Table 5.2).  P6952 and P6953 showed selectivity for the IPPc domain over both Sac and 
PTP-β.  
 
Table 5.2 : Selectivity of selected arylstibonates for the IPPc domain over Sac and PTP. At a time 
point of 30 minutes. The concentration of inhibitor and substrate  was 5 µM and 50 µM 
respectively. The activity of IPPc was measured towards I(1,4,5)P3 , the activity of Sac measured to 
PI(4)P and the activity of PTP towards pNPP 
 
 
 
 
 
 
 
 
 
 
It was also necessary to find an inhibitor that inhibited close to 100% of IPPc’s 
activity.  To assess the degree of inhibition at higher doses of compound, dose response 
curves of the four most selective IPPc domain inhibitors, P6952, P6953, 15591-F and 
15596-K, were constructed (Fig.5.19). It can be seen that 15596 and P6953 are the most 
potent IPPc inhibitors, with only P6953 giving near 100% IPPc inhibition within the 
concentration range examined. 
It was essential to check whether the compounds were able to inhibit the Sac 
domain at higher concentrations. Therefore the degree of Sac inhibition was evaluated 
at 30 µM (Fig.5.20). It can be seen that the extent of Sac inhibition is increased at this 
Compound IPPc Inhibition 
(%) 
Sac Inhibition  
(%) 
PTP Inhibition 
(%) 
P6952 48 9 -12 
P6953 47 9 91 
15591-F 46 -3 -10 
15596-K 38 -23 59 
P6987 32 5 75 
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concentration. Interestingly, in contrast to the IPPc inhibition, all compounds were able 
to virtually wipe out the Sac phosphatase activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.19: Activity of IPPc in Sac/IPPc towards 100 µM of  I(1,4,5)P3 in the presence of increasing 
concentrations of  P6952, P6953, 15591-F and 15596-K. Phosphate levels were measured through 
the malachite green assay (Section 2.1.7). Assay time was 30 minutes. Error bars represent the 
standard error of triplicate repeats. 
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Fig.5.20: Activity of Sac in Sac/IPPc towards 50 µM of PI(4)P in 0.25% octylglucoside in the 
presence of 30 µM of  P6952, P6953, 15591-F and 15596-K. Phosphate levels were measured 
through the malachite green assay (Section 2.1.7). Assay time was 30 minutes. Error bars 
represent the standard error of triplicate repeats. 
 
 
As compound 15596 was identified as the most potent IPPc inhibitor at 5µM, a 
dose response curve of the Sac domain inhibition by 15596 was constructed and 
compared to that of the IPPc domain (Fig.5.21). However, it can be seen that the 
selectivity of this compound remains poor at all concentrations examined.  
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Fig. 5.21:Inhibiton of the Sac hydrolysis in Sac/IPPc of PI(4)P and the IPPc hydrolysis in Sac/IPPc  
of I(1,4,5)P3 by increasing concentrations of 15596. Phosphate levels were measured through the 
malachite green assay (Section 2.1.7). Assay time was 30 minutes. Error bars represent the 
standard error of triplicate repeats. 
 
 
To investigate the inhibition mechanism of the stibonate inhibitors, the extent of 
inhibition by 5 µM of 15596 was tested at different substrate concentrations. The 
resulting data were plotted in Lineweaver-Burk plots (Fig.5.22). It can clearly be seen 
that the mechanism is competitive, implying that 15596 binds to the active site of the 
IPPc domain.    
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Fig. 5.22: Lineweaver-Burke plots of the Sac/IPPc catalysis of 50 µM of I(1,4,5)P3 (black)and 
Sac/IPPc in the presence of  5 µM of 15596 (red). Phosphate levels were measured through the 
malachite green assay (Section 2.1.7). Assay time was 30 minutes. Error bars represent the 
standard error of triplicate repeats. 
 
 
Having shown that a variety of stibonate compounds were able to significantly 
inhibit PTP-β, dose response curves of the extent of inhibition towards increasing levels 
of the four most potent inhibitors were constructed (Fig 5.23). It can be seen that 
significant inhibition is achieved by P6949, 13778 and P6953, with 13778 exhibiting 
inhibition at nanomolar concentrations. Thus, these compounds are a novel class of PTP 
inhibitor.  
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Fig 5.23: Inhibition of the activity of PTP-β towards 1mM of pNPP by increasing 
concentrations of stibonate compounds. The pNPP assay method is outlined in Section 2.1.7.2. 
Assay time was 30 minutes. Error bars represent the standard error of triplicate repeats. 
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5.2.4 Inhibition of the Sac Domain in Sac/IPPc by BpV(OH)pic 
To determine if Synaptojanin operates via a substrate channelling mechanism, it was 
also necessary to identify a selective inhibitor of the Sac phosphatase. BpV(OH)pic has 
previously been reported by Rosivatz et al to be a potent inhibitor of the Sac domain 
within Sac/IPPc (IC50 0.06 µM)[223]. However, the selectivity of the compound to Sac 
over the IPPc domain was not determined.  
               Selectivity was assessed by comparing the extent of inhibition of both the IPPc 
and Sac domains within Sac/IPPc by BpV(OH)pic (Fig.5.24). In addition, inhibition was 
measured for the Sac and IPPc domains within Sac/IPPc- and Sac-/IPPc respectively. 
Any differences in inhibition between the mutants and Sac/IPPc would indicate the 
location of inhibitor binding. Fig. 4.23 shows that 1µM of BpV(OH)pic gives 100% 
inhibition of the Sac domain in both Sac/IPPc and Sac/ IPPc-.  It can be seen that at 1µM 
the IPPc domain is not inhibited and therefore it can be concluded that BpV(OH)pic 
shows good selectivity for the Sac domain in this concentration regime. However, at a 
concentration of 20 µM and above, BpV(OH)pic starts to have an inhibitory effect on the 
IPPc domain. No differences were observed between the Sac/IPPc- and Sac-/IPPc 
mutants and Sac/IPPc, indicating that the Sac inhibition is not caused by binding to the 
IPPc domain.  
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Fig. 5.24: Comparison of the inhibition of the Sac and IPPc domains by increasing concentrations of 
BpV(OH)pic. The activity of the IPPc domain in Sac/IPPc and Sac-/IPPc was measured towards 50 
µM of I(1,4,5)P3. The activity of the Sac domain in Sac/IPPc and Sac/IPPc- was measured towards 
50 µM of PI(4)P. Phosphate levels were measured through the malachite green assay (Section 
2.1.7). Assay time was 30 minutes. Error bars represent the standard error of triplicate repeats. 
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5.3 DISCUSSION 
 4-C-pentyl IP3 and 2-O-hydroxyethyl IP4 were found to be the most potent of the 
inositol phosphate analogue IPPc inhibitors. Ideally, an inhibitor will act at a nanomolar 
concentration. However, only approximately 50% inhibition was observed for these 
compounds at 100 µM. The compounds also showed poor selectivity towards the IPPc 
domain over the Sac phosphatase, which makes them unsuitable inhibitors with which 
to probe the presence of a substrate channelling mechanism within Synaptojanin.  
It was found that two of the five inositol peptide compounds had the ability to 
inhibit the IPPc domain (KRRSG-Ins and FYRRG-Ins see Fig 5.11) and this shows that 
the inhibition is sensitive to the sequence of amino acids in the peptide backbone. 
Although the selectivity of the compounds could not be characterized due to the limited 
amounts that were synthesized, further investigation into these compounds as Sac 
inhibitors would be interesting due to their similarity to the product of PI(4)P 
hydrolysis, PI.  In the future, the peptide chain composition could be designed to impart 
selectivity into the compounds. However, it will be necessary in the future to test the 
peptide components alone for their ability to inhibit the IPPc domain non-specifically. 
This is because it is possible that the peptides could bind to I(1,4,5)P3 substrate thereby 
hindering the enzymes access to substrate. Combining the 4-C-pentyl IP3 and 2-O-
hydroxyethyl IP4 headgroups with the peptide chains could also offer possible options 
for 5-phosphatase inhibitor development.  
             The aryl stibonates were found to be more potent IPPc inhibitors than both the 
inositol phosphate analogues and inositol peptides. Six members of the library gave 
more than 30% inhibition at a concentration of 5 µM, indicating that stibonate 
functionality may be better at inhibiting IPPc than phosphate. However, due to the 
limitations of the structures of the compounds in each library, it is impossible to make a 
direct comparison of the two functionalities.  
Even so, it may well be that stibonate functionality can form stronger 
interactions with the residues on the IPPc site surface.  Antimony is a Group V element 
and has the same number of outer shell electrons as phosphorus. However, its ionic 
radius is larger than that of phosphorus. MM2 energy-minimization [249] shows that 
the lower electronegativity of Sb(V) compared with P(V) increases the Sb-O bond length 
compared to that of P-O (Fig.5.25). This means that a larger negative charge will be 
present on the oxygen in Sb-O with which to interact with the IPPc active site[247, 250].  
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Fig.5.25 MM2 Minimised structures of (a) H2O3P-Phenyl and (b) H2O3Sb-Phenyl. 
The bond length of Sb-O (1.758 Å) is longer than that of P-O (1.49 Å). Structures were 
minimised using ChemBioOffice 2010 (Cambridge Soft)  
 
  The pure arylstibonate, 13744, did not inhibit Sac, IPPc or PTP-β, showing that 
additional functionality is required for inhibition of these phosphatases. This added 
functionality will determine the selectivity and potency of the compounds to each of the 
enzymes. Because the aryl stibonate library is made up of compounds which have 
discrete structural differences, this allows the assessment of structure-function 
relationships. The relationships discussed here onward are derived from the initial 
screening results in Fig. 5.18 and do not take into account the extent of inhibition found 
at higher concentrations of compound.  
 Table 5.3 gives the extent of inhibition by a series of selected stibonate 
compounds, towards IPPc, Sac and PTP-β.  The compound 13755 is a potent but 
unselective phosphatase inhibitor, inhibiting Sac, IPPc and PTP-β with similar potency. 
Kim et al showed that 13755 is also an inhibitor of the DNases; vTopo and Ape 1. 
However, it was found not to inhibit hTopo[248].  However, the inhibition of the three 
phosphatases is influenced by the different functionalities found within 13755.  
For the IPPc domain, removal of either the nitro (13760) or carboxylic acid 
group (13743) from the di-substituted aryl ring disrupts inhibition. Replacement of the 
nitro group with a second carboxylic group (P6966) also abolishes inhibition.  This 
shows that stibonate, nitro and carboxylic acid functionality at the 1,4, and 5 positions 
in 13755 is vital for IPPc inhibition.  
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Table 5.3: Summary of the inhibition of the IPPc, Sac and PTP phosphatases by a selection 
of arylstibonate compounds. 
Compound Structure IPPc 
Inhibition 
(%) 
Sac 
Inhibition 
 (%) 
PTP-β 
Inhibition 
 (%) 
 
13755 
 
13760 
 
 
13743 
 
 
P6966 
 
 
 
61.5 
 
 
8 
 
 
0 
 
 
0 
41 
 
 
9 
 
 
34 
 
 
9 
92 
 
 
72 
 
 
54 
 
 
51 
 
P6952 
 
 
13740 
 
  
48 
 
 
10 
 
9 
 
 
14 
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Table 5.3 Continued 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure IPPc 
Inhibition 
(%) 
Sac 
Inhibition 
(%) 
PTP-β 
Inhibition 
(%) 
 
13742 
 
 
13743 
 
 
 
 
15 
 
 
0 
 
40 
 
 
34 
 
28 
 
 
55 
 
P6982 
 
 
P6981 
 
  
25 
 
 
0 
 
 
0 
 
 
7 
 
 
67 
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P6954 
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This can perhaps be explained by the fact that the IPPc domain only seems to be 
able to hydrolyse inositols with vicinal phosphate groups, such as PI(4,5,)P2 and 
I(1,4,5)P3. It could be that compounds with vicinal functional groups are more effective 
at inhibiting IPPc than compounds with non-vicinal functionality.  The stibonate, nitro 
and carboxylic groups were also required to achieve inhibition of the homologous 
enzyme, topoisomerase, indicating that 13755 binds in a similar manner to both these 
enzymes[248].  
In contrast to IPPc, removal of the carboxylic acid group (13743) did not cause 
significant disruption to the inhibitory potency of 13755 on the Sac domain. This can be 
explained by considering that in contrast to the IPPc domain, the Sac phosphatase 
prefers non-vicinal inositol phosphate functionality.   Interestingly, the replacement of 
the nitro group with carboxylic acid (p6966) or its removal (13760) lowers the 
inhibition, indicating that the nitro group is more important than carboxylic acid for Sac 
inhibition.  
It would be expected that Sac and PTP-β would share similar structure-function 
relationships due to their homology and membership of the CX5R family. However, in 
contrast to Sac, carboxylic acid rather than nitro functionality seems to be more 
important for PTP-β inhibition. Removal of the nitro group lessened inhibition (13760) 
but the decrease in inhibition observed when the carboxylic acid is removed is more 
severe (13743). Twelve out of the thirteen carboxylic acid functional compounds in the 
library inhibited PTP-β by more than 60% again highlighting the dependence of PTP 
inhibition on carboxylic acid functionality. It could be that the carboxylic acid acts as a 
surrogate phosphate group. Many already established PTP inhibitors contain carboxylic 
acid functionality [251, 252] [253].  
The Iodide aryl stibonate, P6952, was found to inhibit the IPPc domain to a 
greater extent than the more electronegative analogous bromine compound (13740). 
This can be explained by the fact that the C-I bond is longer than the C-Br bond (C-I = 
2.149 C-Br=1.88 Å), meaning that there is more negative charge on the iodine atom with 
which to interact with IPPc and inhibit. It is interesting that in contrast, the bromide 
halide stibonate was found to give more inhibition of PTP-β.   
There does not seem to be a clear pattern when looking at the preference of 
aromatic substitution for IPPc, Sac or PTP-β inhibition. Since the substrate specificity of 
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these phosphatases is influenced more by the vicinity of the phosphate groups rather 
than by their positioning, this is not surprising.   
      Although the positioning of aromatic substitution does not have an effect on 
PTP-β inhibition, mono-substituted arylstibonates seem to have greater inhibitory 
potency towards PTP-β.  Addition of a para (P6966) or meta (P6954) COOH 
functionality to a meta COOH aryl stibonate (13759) disrupts the enzyme-inhibitor 
interaction, decreasing the inhibition. It should be noted that meta-meta positioning 
was preferred over meta-para. The interaction between the stibonates and PTP-β 
compound is clearly controlled by electrostatics.  If the carboxylic acid COOH group is 
replaced by the less electronegative hydroxyl group (compare 13745 with 13760), then 
inhibition is reduced.  Replacing the COOH with ester functionality also abolishes the 
inhibition (compare 13771 with 13759).  
The fact that a variety of compounds in the library gave excellent inhibition of 
PTP-β shows that Stibonates could provide an alternative to the array of phosphate, 
vanadate and peptidomimetic-based PTP inhibitors that have been developed[233, 234, 
236, 238, 252, 254, 255]. It is likely that the stibonates act competitively as substrate 
mimics, due to the close resemblance of the compounds to the natural substrate of PTPs, 
tyrosine phosphate.  
The aromatic nature of the stibonates is likely to increase the binding affinity of 
the stibonates for the PTP-β active site. Aromatic–aromatic interactions have been 
implicated in the binding of tyrosine phosphate to the active site. In PTP1B it has been 
shown that the aryl side chains of two aromatic resides, Tyr 46 and Phe 182 sandwich 
the phosphotyrosine ring (Fig 5.26)[252, 256].  
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Fig 5.26: PTP-β residues critical for the binding of tyrosine phosphate and catalysis. 
Figure taken from Jia et al [256] 
 
PTP inhibitors have long been of attention due to the role of PTPs in numerous 
cell functions including growth, mitogenesis, motility, cell-cell interactions, metabolism, 
gene transcription and the immune reponse[252].  As described previously, inhibitors 
based on vanadium are well established inhibitors of PTP’s. However, they are often 
found to be unselective with regard to other CX5R phosphatases and in particular 
PTEN[223]. However, work by Lok Hang Mak (Imperial College London) has shown that 
a variety of the stibonate compounds that potently PTP, do not act on PTEN. Therefore, 
a novel class of low molecular weight, selective PTP inhibitors has been identified. 
It is interesting that the large di-phenyl compounds, 15596 with 15591 inhibited 
the IPPc domain but not Sac.  The headgroup surface area of the Sac lipid substrate 
PI(4)P is likely to be smaller than that of the IPPc domain substrates PI(4,5)P2 and 
PI(3,4,5)P3. Although there are no Sac phosphatase crystallography data in the 
literature, it is not unreasonable to assume that the active site of Sac is smaller than that 
of IPPc. This may mean that the Sac active site cannot accommodate the larger 
molecules 15596 and 15591 whilst the IPPc domain can. Therefore, a potential method 
of imparting selectivity into IPPc inhibitors could be to modify the size of the molecules. 
In the future, it would be advantageous to calculate the inhibition constants, Ki, 
of the compounds investigated in this work. Ki values represent the dissociation 
constant for the enzyme-inhibitor complex (Ki = [E][I]/[EI]). The lower the Ki of an 
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inhibitor, the lower the concentration of inhibitor required to decrease the rate of 
enzyme catalysis.     
                The selectivity of the IPPc inhibitors identified in this work is not sufficient with 
which to examine the possibility of substrate channelling occurring within 
Synaptojanin. The poor selectivity can be attributed to the similarity of the substrate 
specificity of the Sac and IPPc domains. Nevertheless, this work has highlighted a 
number of structures and functionalities that could be utilized in the future 
development of selective phosphatase and kinase inhibitors. 
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Chapter 6 
 
Investigation into the Mechanism of 
Sac-IPPc Domain Dependence  
CHAPTER ABSTRACT 
Interfacial recognition and substrate channelling were proposed in Chapter 4 as 
mechanisms by which the functioning of the Sac and IPPc domains could be dependent. 
Here it was found that substrate channelling between the Sac and IPPc domains is 
unlikely to occur within Synaptojanin and that interfacial recognition is not a 
contributing factor to the domain dependency. Instead the Sac-IPPc domain dependency 
is likely to be controlled by protein-lipid interactions. In addition, it was found that 
increasing levels of DOPE in DOPC vesicles stimulated the activity of the IPPc domain 
providing the first evidence that Synaptojanin is sensitive to the lipid environment in 
which it works.  
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6.1 INTRODUCTION 
A series of models and mechanisms to explain the observed dependence were proposed 
in Chapter 4 (Section 4.4). They included substrate channelling, interfacial recognition 
and the possibility that Synaptojanin adopts a conformation where the Sac and IPPc 
domains “share” their substrates. The mechanism by which the IPPc and Sac domain are 
co-dependent is probed in this chapter. 
As described previously, substrate channelling can be described as the process of 
direct transfer of an intermediate between the active sites of two enzymes that catalyze 
sequential reactions in a biosynthetic pathway[217]. The active sites can be located on 
separate domains in multifunctional enzymes or separate sub-units in a multi-enzyme 
complex. The transfer of intermediate from one site to another can occur in several 
ways, including tunnelling, electrostatic transfer and through the action of “swinging” 
arms[178]. In pyruvate decarboxylase, the substrate is transferred between several 
sites by a flexible arm [257, 258]. However, in tryptophan synthase and carbamoyl 
phosphate synthase, the active sites are connected by a tunnel through the protein 
through which the substrate travels [166, 168, 259, 260]. In dihydrofolate reductase-
thymidylate synthase, meanwhile, a charged region on the surface of the enzyme acts a 
pathway to guide the substrate from the active site to another [220, 261].  
As described previously, the 5-phosphatase IPPc domain in Synaptojanin can 
hydrolyse PI(4,5)P2  to PI(4)P whilst the Sac phosphatase can hydrolyse PI(4)P to PI . 
Therefore, it could be that Synaptojanin operates via a substrate channelling mechanism 
and converts PI(4,5)P2 directly to PI without release of the intermediate PI(4)P into the 
bulk (Fig.4.12). If this mechanism were to occur, then mutating the Sac or IPPc domains 
could act to lower the levels of phosphate produced from the hydrolysis of PI(4,5)P2. 
This means that the observed differences in activities between the double Synaptojanin 
phosphatase and the mutant and single phosphatases could be due to a disruption of the 
substrate channelling mechanism.  
Substrate channelling mechanisms have been identified through the use of 
chemical inhibitors[222]. To apply this approach to Synaptojanin, work in Chapter 5 
aimed to identify chemical inhibitors of the Sac and IPPc domains.  Although  selective 
chemical inhibitor of the IPPc domain was not found, the bisperoxovanadium 
compound, BpV(OH)pic was found confirmed to be a potent and selective inhibitor of 
the Sac domain in Sac/IPPc[223](Fig. 5.24). This allowed the effect of the chemical 
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inhibition of the Sac domain on the activity of the IPPc domain to be evaluated. If the 
phosphate levels detected from the Sac/IPPc hydrolysis of PI(4,5)P2 were to decrease, 
then this would indicate that significant levels of PI are produced from the action of the 
Sac domain, thus implying that substrate channelling occurs within Synaptojanin. In this 
way the chemical inhibition of the Sac domain effectively acts as a control to the 
possibility that the disruption of a substrate channelling mechanism the cause of the 
observed changes in VMax. 
 Of course, there is a possibility that the Sac domain can hydrolyse the PI(4)P 
product that is released from the IPPc domain into the bulk (see Fig 4.12 (b)). However, 
as described previously the rate of Sac hydrolysis of bulk PI(4)P is comparably slow and 
given the levels of PI(4)P that would be present in the assay, this would not be expected 
to have an influence on the total levels of phosphate produced.   
If substrate channelling occurs via a binding moiety such as a swinging arm or 
electrostatic surface, then the channelling can be described as being “tight” (Fig 6.1). 
The intermediate will be transferred directly from one active site to another. If 
Synaptojanin were to operate via such a mechanism, then inhibiting the Sac domain 
would be expected to cause a significant decrease in the total levels of phosphate 
produced.   Alternatively, a “loose” mechanism of substrate channelling could exist 
whereby the passage of intermediate from the Sac to IPPc domain is controlled by 
diffusion. The effect of Sac inhibition on the levels of total phosphate produced in this 
instance would be expected to be less, but nevertheless observable. An example of an 
enzyme that operates via a “loose” or “leaky” channelling mechanism is the Lumazine 
Synthase/Riboflavin synthase complex of Bacillus subtilis[262].     
Also, one cannot exclude the possibility that interfacial recognition could 
contribute towards the IPPc-Sac domain dependency. VMax dependency was observed 
with the interfacial substrates PI(4,5)P2 and PI(4)P but not with the soluble substrates 
I(1,4,5)P3 and OMFP. As aforementioned, it has previously been reported that 
octylglucoside micelles inhibit the IPPc domain’s VMax activity towards I(1,4,5)P3 [79], 
suggesting that octylglucoside micelles are able to bind to the IPPc domain. In order to 
establish whether interfacial recognition plays a role in the domain dependency, it was 
necessary to confirm that the functioning of the domains is sensitive to the presence of 
an interface.  
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Fig. 6.1: Mechanisms of substrate channelling. If substrate channelling occurs with 
Synaptojanin, then the Sac domain will take the PI(4)P hydrolysed by the IPPc domain from 
PI(4,5)P2 and hydrolyse it further to PI. If the mechanism is “tight”, then the IPPc domain would 
directly transfer the PI(4)P to the  Sac domain by for example, an “arm” . In a “loose” mechanism, 
the PI(4)P would be transferred by diffusion.  If substrate channelling occurs, inhibiting the Sac 
domain should disrupt the process and less total phosphate would be expected to be produced. This 
would be expected to be most severe if Synaptojanin operates via a tight substrate channelling 
mechanism.  
 
 
“Tight” Substrate Channelling  
“Loose” Substrate Channelling  
Disruption of channelling by chemical 
inhibition of the Sac domain 
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6.1.1 Phospholipids and Membrane Curvature 
Fig.6.2 shows the structures of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-sn-glycero-3-
phosphoserine (DOPS).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6.2: 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), and 2-dioleoyl-sn-glycero-3-phosphoserine (DOPS).  
 
 
 
DOPC 
DOPE 
DOPS 
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Particular compositions of lipids adopt characteristic spontaneous curvatures, 
which can be described as the curvature at which the monolayer stress is at a 
minimum[263, 264]. The spontaneous curvature of a monolayer is largely dependent 
upon the shape of the lipid molecule under consideration.  Phospholipids can be 
described as being Type 0, Type I or Type II[264, 265] . Cylindrical lipids, such as DOPC 
and DOPS exhibit negligible spontaneous curvature[266-268]. Type II lipids, such as 
DOPE exhibit negative spontaneous curvature[269], whilst Type I lipids, such as lyso-
PC, form membranes with positive spontaneous curvature [270](Fig. 6.3). The 
spontaneous curvature of lipids will dictate the particular type of mesophase that the 
lipids form.  For example, Type II lipids have a preference for non-bilayer structures 
such as the inverted hexagonal and inverse bicontinuous cubic phases[271, 272].   
 
 
Fig. 6.3: Membrane Curvature. Type I lipids exhibit positive curvature whilst type II lipids 
show negative curvature.  
 
 
The dependence of curvature on lipid composition can be explained by 
examining a lateral stress profile of the membrane (Fig.6.4)[273]. Forces, which dictate 
the membrane curvature, arise because of imbalances that develop in the lateral 
stresses that occur in the head act at different levels within the lipid layer.  These 
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stresses will have a bending effect on the planar sheet group region, the polar/non-
polar interface and the hydrocarbon chain region.  
 
 
 
Fig. 6.4: Lateral Pressure as a function of depth (x) of the membrane. 
 
 
The repulsive lateral pressure in the chain region is due to the thermally 
activated cis-trans rotations in the C-C bonds which impart momentum to the 
neighbouring amphiphiles during collisions. The hydrocarbon effect results in an 
interfacial tension, which minimises the aliphatic-water contact area. The headgroup is 
thought to undergo repulsive pressure due to steric, hydrational and electrostatic 
interactions, while hydrogen bonding might provide an attractive force.  
When the lateral stress in the headgroup region outweighs that in the chain 
region the curvature of the monolayer will be negative, for example like the curvature in 
a pure PE monolayer. However, if the chain pressure is dominant then the curvature 
will be positive, like that in a lyso-PC monolayer. 
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Curvature can be quantified as either the total (J), the mean (H) or Gaussian (K), 
where c1 and c2 are the principle curvatures of the membrane[263]: 
 
 
J = c1 + c2 
 
H = ½(c1+c2)                              
 
K = c1c2 
 
  A membrane will contain levels of stored curvature elastic stress (SCES) if it 
consists of Type I or Type II lipids that spontaneously form curved monolayers. 
(Fig.6.5). Type II lipids increase the propensity of each monolayer to curve towards the 
water. However, due to hydrophobic constraints, the two leaflets in the bilayer cannot 
separate, leading to an increase in curvature elastic stress. This is accompanied by an 
increase in lateral pressure in the central region of the membrane as a result of 
increased collisions between acyl chains. 
The stored curvature elastic stress per amphiphile in a monolayer can be 
quantified using the Helfrich Hamiltonian where A is the cross sectional area per 
molecule, c1 and c2 are the principal curvatures at the interface, co is the spontaneous 
curvature of the monolayer, κ is the bending rigidity of the monolayer and κG is the 
Gaussian curvature modulus[274, 275]:  
 
 
 
 
                     gc = ½ κ A (c1 + c2 - 2co)2 + κG A c1 c2                           
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Fig. 6.5: Stored curvature elastic stress. (a )Non-lamellar lipids increase the tendency for 
the monolayer to curve towards water. (b) the two leaflets are forced to flatten in a bilayer, 
increasing stored curvature elastic stress and lateral pressure in the chain region.  
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6.2 RESULTS 
6.2.1 Investigation of Substrate Channelling as a Mechanism of Domain Dependence 
within Synaptojanin 
To investigate whether Synaptojanin operates via a substrate channelling mechanism, 
the effect of chemical inhibition on the IPPc domain activity was evaluated. To start, as a 
control, the effect of Sac inhibition on the IPPc-mediated hydrolysis of I(1,4,5)P3 was 
assessed. It was shown earlier (see Fig. 3.5) that the product of the IPPc catalysis of 
I(1,4,5)P3, I(1,4)P2, is not a substrate for the Sac phosphatase. Therefore substrate 
channelling would be unlikely to occur for the hydrolysis of I(1,4,5)P3 by Sac/IPPc and 
inhibiting the Sac domain would be expected not to influence the total levels of 
phosphate produced by the phosphatase.  
Fig.6.6 shows the Michaelis-Menten plots generated from the Sac/IPPc catalysis of 
I(1,4,5)P3 both in the absence and presence of 1 µM  BpV(OH)pic. Phosphatase activity 
was measured through monitoring levels of free phosphate through the malachite green 
assay. Evidently, the concentration of BpV(OH)pic used to inhibit the Sac domain 
needed to be such that it did not affect IPPc domain activity. In Chapter 5, it was shown 
that at a concentration of 1 µM, BpV(OH)pic is able to ablate Sac activity (in Sac/IPPc) 
but to not inhibit the IPPc domain. It can be seen that from Fig.6.2 that chemical 
inhibition of the Sac domain does not affect the kinetic parameters of the IPPc 
hydrolysis of I(1,4,5)P3. This indicates that, as expected, the levels of phosphate 
produced from the Sac hydrolysis of I(1,4)P2 are insignificant.  
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Fig6.6: Michaelis-Menten plots of the Sac/IPPc catalysis of increasing concentrations of I(1,4,5)P3  
in the absence (black)  and presence (red) of 1 µM of BpV(OH)pic. Levels of phosphate were 
measured through the malachite green assay (Section 2.1.7).  Kinetic parameters were calculated 
as follows: absence of inhibitor KM = 122±47 µM, VMax = 0.00996 ± 0.00086 nmolphosphate/min, in 
the presence of BpV(OH)pic KM = 145±46 µM, VMax = 0.00973 ± 0.001. Error bars represent the 
standard error of three repeats. 
 
 
Next, the effect of Sac inhibition on the Sac/IPPc-mediated catalysis of PI(4,5)P2 
was evaluated. The Michaelis-Menten plots for the IPPc-catalysed hydrolysis of PI(4,5)P2 
in the presence and absence of 1 µM BpV(OH)pic can be seen in Fig 6.6.  Interestingly, 
inhibition of the Sac domain does not lower the total levels of phosphate produced, 
indicating that Synaptojanin does not operate through either tight or loose substrate 
channelling mechanisms. These results also confirm the earlier suggestion that levels of 
Sac/IPPc hydrolysis of bulk PI(4)P are insignificant.   
 
  
150 
 
 
Fig 6.6: Michaelis-Menten plots of the Sac/IPPc catalysis of increasing concentrations of PI(4,5)P2 
(in 0.25% octylglucoside)  in the absence (black)  and presence (red) of 1 µM of BpV(OH)pic. Levels 
of phosphate were measured through the malachite green assay( Section 2.1.7). Kinetic 
parameters were calculated as follows: absence of inhibitor KM = 165±49 µM, VMax = 0.01996 ± 
0.023 nmolphosphate/min, in the presence of BpV(OH)pic KM = 168±46 µM, VMax = 0.01973 ± 
0.0014. Error bars represent the standard error of three repeats.     
   
 
The single phosphatases, IPPc and Sac were produced by “cutting” the 
appropriate domain from the full length Synaptojanin. Enzymes that have been “cut” by 
molecular biology into separate entities can sometimes reunite back into the original 
enzyme when incubated with each other. This is because the interactions between the 
residues on the entities are often sufficient to reunite the enzyme. Therefore incubating 
the single IPPc and Sac domains could “reunite” the Sac and IPPc enzymes.  
It was found that the VMax of the Sac phosphatase towards PI(4)P is much lower 
when the IPPc domain is not functional. If physical interactions between the Sac and 
IPPc domains are responsible for this effect, then reuniting the single Sac and IPPc 
phosphatases would be expected to restore the VMax  activity to that observed for the 
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double phosphatase. Fig.6.7 shows the activity of the single Sac phosphatase towards 
PI(4)P in the presence of increasing levels of the single IPPc phosphatase. Somewhat 
surprisingly, the activity of the Sac domain decreases in the presence of the IPPc 
phosphatase. A possible explanation is that the IPPc domain can bind PI(4)P and in 
doing so decreases the substrate available to the Sac domain.  Of course, however, there 
is no evidence to confirm that the single phosphatases reunited into the double 
phosphatase.  
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Fig.6.7: The activity of the single Sac phosphatase towards 100 µM PI(4)P in the presence of 
increasing levels of  IPPc. Sac: IPPc ratio refers to mass ratio of IPPc:Sac. The concentration of Sac 
was 0.05 mg/mL. Levels of phosphate were measured through the malachite green assay(2.1.7).  
Assay time was 30 minutes. Error bars represent the standard error of three repeats. 
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To investigate further whether the binding of PI(4)P by IPPc is responsible for 
the observed decrease in Sac activity, active IPPc enzyme was replaced with denatured 
enzyme to act as a control. Fig 6.8 shows the effect of increasing levels of denatured 
IPPc on the activity of the Sac domain towards PI(4)P. It can be seen that the inhibition 
of the Sac phosphatase is abolished, indicating that the presence of the IPPc structure 
may be responsible for the inhibition.   
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Fig.6.8: The activity of the single Sac phosphatase towards 100 µM PI(4)P in the presence of 
increasing levels of denatured IPPc. Sac: IPPc ratio refers to mass ratio of IPPc:Sac. The 
concentration of Sac was 0.05 mg/mL. Levels of phosphate were measured through the malachite 
green assay (2.1.7). Assay time was 30 minutes. Error bars represent the standard error of three 
repeats.     
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6.2.2 Investigation into Interfacial Recognition as a Mechanism of Domain 
Dependence 
The VMax Sac and IPPc domains were found to be co-dependent when they acted on 
lipids suspended in octylglucoside, but not when they acted on soluble non-lipid 
molecules. It is therefore possible that interfacial recognition is a contributing factor to 
the domain dependency.  
If Synaptojanin were to operate via such a mechanism, then the influence of a 
surface must have the ability to modulate the behaviour of the domains within 
Synaptojanin. It has been reported previously that octylglucoside inhibits the activity of 
the single IPPc phosphatase towards I(1,4,5)P3[79] and it was thus suggested that the 
IPPc domain exhibits interfacial recognition towards the detergent. Therefore, it was 
first necessary to confirm that the IPPc domain exhibits interfacial recognition towards 
octylglucoside. To do this, the activity of the IPPc domain in Sac/IPPc, IPPc and Sac-
/IPPc was measured towards a fixed concentration of the soluble substrate I(1,4,5)P3 in 
the presence of increasing concentrations of octylglucoside (Fig.6.9). To evaluate the 
effect of octylglucoside on the kinetic parameters of the IPPc domain hydrolysis of 
I(1,4,5)P3, the activity of the IPPc domain was also measured towards increasing 
concentrations of I(1,4,5)P3 in the absence and presence of octylglucoside (Fig 6.10).  
The Critical Micelle Concentration (CMC) of octylglucoside is 25-30 mM[276-
278]. It can be seen from Fig 6.9 that octylglucoside does not inhibit the activity of the 
IPPc domain either both below or above its CMC.  Fig 6.10 also shows the presence of 
octylglucoside does not affect the kinetic parameters of the IPPc domain towards 
I(1,4,5)P3.  Importantly, these results indicate that the IPPc domain does not exhibit 
interfacial recognition towards octylglucoside micelles and that the presence of 
octylglucoside alone does not contribute to the Sac-IPPc domain dependency.  
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Fig.6.9: Effect of increasing concentrations of octylglucoside on the functioning of the IPPc 
domain in Sac/IPPc, Sac-/IPPc and IPPc after 15 minutes pre-incubation. Levels of phosphate were 
measured through the malachite green assay (2.1.7) after 30 minutes incubation with 100 µM 
I(1,4,5)P3 substrate.   8.56 mM of octylglucoside corresponds to 0.25% (w/v) octylglucoside. Error 
bars represent the standard error of three repeats.     
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Fig.6.10: Effect of  0.25% (w/v)octylglucoside on the KM and VMax of the IPPc domain 
towards I(1,4,5)P3  after 15 minutes pre-incubation. Levels of phosphate were measured through 
the malachite green assay (2.1.7).  Assay time was 30 minutes. Error bars represent the standard 
error of three repeats.     
 
However, it could be that the precise interfacial nature of the phosphoinositide 
lipids in combination with octylglucoside fosters the Sac IPPc domain dependency as it 
is likely that the presence of the lipids will change the interfacial nature of the system. 
Alternatively, it could be the phosphoinositide molecule itself that influences the 
functioning of the phosphatases, through direct lipid-protein interactions. In fact, it has 
been suggested in the literature that the lipid PI(4)P is able to inhibit the IPPc domain 
with inhibition reported to occur at 500 µM of PI(4)P[90]. However, this was shown in a 
qualitative fashion and as of yet, unknown whether the lipid can inhibit the IPPc domain 
at lower concentrations.  
If PI(4)P were to inhibit the IPPc domain, then this could have important 
implications for the functioning of Synaptojanin because PI(4)P is the product of the 
IPPc catalysis of PI(4,5)P2.  The action of many enzymes are regulated by product 
inhibition an example of which is the hepatitis C virus NS3 protease[279].  
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If a product inhibition mechanism were to exist in Synaptojanin, then this could 
have important implications for the observed domain dependency. In the Sac-/IPPc 
mutant, the Sac domain is not functional and it could be that when the domain is 
mutated, the PI(4)P is not released from the IPPc active site. An accumulation of PI(4)P 
could inhibit the IPPc domain hydrolysis of further PI(4,5)P2 molecules and lower the 
levels of phosphate produced.  However, taking into account earlier data, this is unlikely 
to be as a result of a substrate channelling mechanism.   
To assess the effect of PI(4)P in octylglucoside on the functioning of the IPPc 
domain, increasing concentrations of PI(4)P in octylglucoside were incubated with Sac-
/IPPc and IPPc and the activity of the IPPc domain measured towards I(1,4,5)P3 
(Fig.6.11). The influence of PI(4)P on the IPPc domain in the double Sac/IPPc 
phosphatase was not explored as PI(4)P is a Sac substrate. It can be seen from Fig 6.11 
that the presence of PI(4)P decreases the activity of the IPPc domain towards I(1,4,5)P3, 
suggesting that PI(4)P in octylglucoside is able to inhibit the IPPc domain. These results 
can also be interpreted as PI(4)P having a higher affinity towards the IPPc domain than 
I(1,4,5)P3. PI(4)P is able to inhibit the IPPc domain at low micro molar concentrations 
whereas the KM of the IPPc domain towards I(1,4,5)P3 is approximately 140 µM (see 
Chapter 4.  
  
157 
 
0 2 4 6 8 10
0
20
40
60
80
100
120
 
 
A
c
ti
v
it
y
 (
%
 o
f 
C
o
n
tr
o
l)
PI(4)P(
 Sac-/IPPc
 IPPc
 
Fig.6.11: Inhibition of the IPPc domain in Sac-/IPPc and IPPc towards 50 µM of I(1,4,5)P3 by 
increasing concentrations of PI(4)P in 0.25% octylglucoside. Levels of phosphate were measured 
through the malachite green assay (2.1.7). Error bars represent the standard error of three 
repeats.     
 
  
                 To investigate the mechanism of IPPc inhibition by PI(4)P, the extent of IPPc 
inhibition was compared at two different concentrations of I(1,4,5)P3 substrate (Fig. 
6.12). Raising the substrate concentration reduces the extent of inhibition, indicating 
that the inhibition of PI(4)P is a competitive process and that PI(4)P acts by binding to 
the active site of the IPPc domain.  
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Fig.6.12: Extent of IPPc inhibition by PI(4)P in 0.25% octylglucoside towards 50 and 220 
µM I(1,4,5)P3. The control represents the hydrolysis of either concentration of I(1,4,5)P3 in the 
absence of PI(4)P in 0.25% octylglucoside. Levels of phosphate were measured through the 
malachite green assay (2.1.7). Error bars represent the standard error of three repeats.      
 
If PI(4)P were to inhibit the IPPc domain via a product inhibition mechanism, 
then PI(4)P would also be expected to inhibit the activity of the enzyme towards the 
PI(4,5)P2 substrate. In fact, the extent of product inhibition would be expected to be 
even more severe than when I(1,4,5)P3 is used as a substrate, as the concentration of 
PI(4)P would be raised through the IPPc catalysis of PI(4,5)P2. 
Fig.6.13 compares the extent of inhibition of the IPPc domain by PI(4)P towards 
I(1,4,5)P3 and PI(4,5)P2. It can be seen that PI(4)P does not inhibit the IPPc domain 
when PI(4,5)P2 is used as a substrate. This shows that the inhibition is specific to 
I(1,4,5)P3 and indicates that product inhibition does not occur.  
It is therefore likely that the observed decrease in IPPc activity with I(1,4,5)P3 as 
a substrate is a result of interfacial recognition or direct protein-lipid interactions. 
However, at a concentration of 10 µM PIP or below, the system is below its CMC. This 
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means that it is most probable that the inhibition is due to interactions between the 
IPPc active site and lipid molecule. To confirm whether the fatty acid chain of the lipid is 
required for this interaction, the extent of inhibition by the corresponding PI(4)P 
headgroup, I(1,4)P2 was compared to that of PI(4)P. It can be seen from Fig.6.14 that 
I(1,4)P2 does not inhibit IPPc in the same way as PI(4)P, indicating that the presence of 
a fatty acid chain is required for inhibition.  
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Fig. 6.13: Inhibition of IPPc by 8 µM PI(4)P in 0.25% octylglucoside with 50 µM of PI(4,5)P2 and 
I(1,4,5)P3 as substrates. Levels of phosphate were measured through the malachite green 
assay(2.1.7). Error bars represent the standard error of three repeats.      
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Fig 6.14: A comparison of the activity of the IPPc domain towards 50 µM I(1,4,5)P3 in the 
presence of increasing concentrations of I(1,4)P2 and PI(4)P. Both substrates were presented in 
0.25% octylglucoside.  Levels of phosphate were measured through the malachite green assay 
(2.1.7).  Assay time was 30 minutes. Error bars represent the standard error of three repeats.     
 
It has also been suggested in previous studies that PI is able to activate the IPPc 
domain[90]. However, this was reported at a single concentration of 500 µM PI and it is 
unknown whether smaller concentrations are able to influence the activity of the 
phosphatase. Fig.6.15 shows a comparison of the effect of increasing levels of both PI 
and PI(4)P on the activity of the IPPc domain towards I(1,4,5)P3. It can be seen that the 
presence of PI activates the IPPc domain by approximately 40%. This is significantly 
lower than the extent to which PI(4)P inhibits the IPPc domain towards I(1,4,5)P3.       
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Fig.6.15: Comparison of the effect of increasing concentrations of PI in 0.25% 
octylglucoside on the activity of IPPc towards 50 µM I(1,4,5)P3 with that of PI(4)P. Levels of 
phosphate were measured through the malachite green assay(2.1.7). Error bars represent the 
standard error of three repeats.     
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5.3.3 Effect of Vesicles of Differing Compositions on the Activity of Synaptojanin 
Having established that PI(4)P in octylglucoside interacts with the IPPc domain, the 
influence of PI(4)P, suspended in artificial lipid vesicles was investigated. This would 
further clarify whether the effect of PI(4)P on the enzyme is sensitive to the 
presentation of the lipid. Also, phospholipid vesicles are a better mimic of the biological 
cell membrane than detergent molecules and are therefore often used as biomimetic 
systems with which to investigate protein-lipid interactions. They can be classified as 
being giant (>1 µM), large (50-100nm) or small (10-50nm). There are hundreds of 
varying lipids in the cellular membranes and the individual nature of these lipid 
molecules confers different physical and electrostatic properties to the membranes that 
they inhabit.   
Furthermore, the functioning of numerous proteins has been shown to be 
modulated by the behaviour of the lipids in cellular membranes. For example, enzymes 
such as CTP:phosphocholine cytidyltransferase (CCT), protein kinase C and 
DiacylGlycerol Kinase (DGK) have been shown to be sensitive to the levels of DOPE 
[280-282]. The inositol phosphatases PTEN and SHIP2 have been shown to be activated 
by anionically charged lipids[216, 226, 283]. However, it is as yet unknown whether the 
functioning of Synaptojanin is modulated by the properties of the membrane. Therefore, 
before the effect of vesicular PI(4)P on the functioning of the IPPc domain was 
evaluated, an investigation into the response of the Synaptojanin to the presence of lipid 
vesicles was undertaken. DOPC was selected as a carrier lipid. DOPE and the anionic 
lipid DOPS were evaluated for their ability to influence the behaviour of Synaptojanin 
due to their aforedescribed effect on the functioning of other cellular enzymes. DOPE is 
a particularly interesting lipid because of its ability to impart stored curvature elastic 
stress into membranes. This property has been shown to modulate the behaviour of 
CCT[280].                                                                                    
To assess the response of the IPPc domain towards DOPE, 100 nm vesicles 
containing increasing levels of DOPE in DOPC were incubated with the Sac/IPPc, IPPc 
and Sac-/IPPc phosphatases and the activity of the IPPc domain measured towards the 
soluble substrate I(1,4,5)P3 (Fig.6.16). Interestingly, it can be seen that raising the levels 
of DOPE significantly increases the activity of the IPPc domain towards I(1,4,5)P3 in all 
three of the Synaptojanin phosphatases. Taking into account that the response of the 
double phosphatase, Sac/IPPc and IPPc were similar, it seems that the influence of 
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DOPE on the IPPc domain does not result from interactions with the Sac domain. A 
slight increase in the activity of Synaptojanin in the presence of DOPC vesicles was also 
observed.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6.16: Effect of increasing levels of DOPE in DOPC Large Unilamellar Vesicles (LUVs), 100 nm in 
size, on the activity of the IPPc domain towards 200 µM I(1,4,5)P3.The concentration of substrate 
was 100 µM. Levels of phosphate were measured through the malachite green assay (2.1.7). The 
control refers to the activity of the enzyme towards 200 µM I(1,4,5)P3  in the absence of vesicles.  
Interference of the absorbance of the malachite green dye by vesicles was removed as described in 
Section 2.1.11. Error bars represent the standard error of three repeats.     
 
Next, the mechanism by which the IPPc domain is activated by DOPE was 
investigated. To do this, the Michaelis-Menten plot of the Sac/IPPc hydrolysis of I(1,4,5)P3 
in the presence of 60:40 DOPC:DOPE vesicles was compared to that in the absence of 
vesicles(Fig.6.17). It can be seen that the effect is predominantly a VMax effect. This 
indicates that the presence of DOPE modifies the conformation of Synaptojanin in such a 
way that it increases the activity of the IPPc domain towards I(1,4,5)P3. 
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Fig.6.17: KM/VMax curves of the Sac/IPPc mediated hydrolysis of I(1,4,5)P3  in the presence and 
absence of 200 µM of 100 nm 60:40 DOPC:DOPE vesicles. The KM was determined by fitting as 
115±37 µM and the VMax 0.0251±0.0034 nmol phosphate/min in the presence of DOPC:DOPE 
vesicles.  In the absence of vesicles the KM was 122±47 µM and the VMax 0.009±0.00130 nmol 
phosphate/min. Levels of phosphate were measured through the malachite green assay (2.1.7). 
Interference of the absorbance of the malachite green dye by vesicles was removed as described in 
Section 2.1.11. Error bars represent the standard error of three repeats.     
 
 
To evaluate the effect of anionic lipids on the IPPc domain, the lipid DOPS was 
assessed for its ability to modulate the functioning of the enzyme. Vesicles containing 
increasing levels of DOPS in DOPC were evaluated for their ability to influence the 
activity of the IPPc domain in the Sac/IPPc, IPPc and Sac-/IPPc phosphatases. It can be 
seen from Fig.6.18 that in contrast to DOPE, DOPS does not have the ability to increase 
the activity of the IPPc domain.    
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Fig.6.18: Effect of increasing levels of DOPS in DOPC Large Unilamellar Vesicles (LUVs), 100 nm in 
size, on the activity of the IPPc domain towards I(1,4,5)P3 .The concentration of substrate was 100 
µM.  Levels of phosphate were measured through the malachite green assay (2.1.7). Interference of 
the absorbance of the malachite green dye by vesicles was removed as described in Section 2.1.11. 
Error bars represent the standard error of three repeats.     
 
It was proposed in Chapter 4 that the Sac domain might be responsible for the 
recruitment of Synaptojanin to the membrane. If this is the case then it might be 
expected that the presence of vesicles would modulate the behaviour of the enzyme in 
the same way as the IPPc domain. Fig. 6.19 shows the effect of increasing levels of 
DOPE/ DOPC vesicles on the Sac domain activity towards 25 µM OMFP. It can be seen 
that the activity of the Sac domain decreases in the presence of DOPC/DOPE vesicles 
indicating that the vesicles can bind the Sac domain active site. However this is 
observed at relatively large concentrations of vesicles, compared with the concentration 
required to give activation of IPPc by DOPE.  
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Fig 6.19: The effect of increasing concentrations of DOPE/ DOPC vesicles on the Sac domain 
activity towards 250 µM OMFP. Details of the OMFP assay can be found in Section 2.19. 
Assay time was 30 minutes. Error bars represent the standard error of three repeats.     
 
 
 It was shown earlier that DOPC does not influence the activity of the IPPc 
domain. Therefore, this lipid was chosen as a suitable lipid with which to incorporate 
PI(4)P. Fig.6.20 shows the effect of increasing levels of PI(4)P in DOPC vesicles on the 
activity of the IPPc domain towards 50 µM of I(1,4,5)P3. It can be seen that the PI(4)P 
does not inhibit the IPPc domain when it is presented in vesicles.  Inhibition was 
observed at 0.01% mol PI(4)P in octylglucoside.  It could be that the PI(4)P headgroup 
is less accessible in the relatively flat surface of a vesicle.  
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Fig.6.20: Effect of increasing levels of PI(4)P in DOPC vesicles on the activity of Sac-/IPPc towards 
I(1,4,5)P3. Vesicles were extruded to be 100 nm in size. Total lipid concentration was 100 µM. 
Levels of phosphate were measured through the malachite green assay (2.1.7). Error bars 
represent the standard error of three repeats. Interference of the absorbance of the malachite 
green dye by vesicles was removed as described in Section 2.1.11.  Assay time was 30 minutes.  
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6.4 DISCUSSION 
Chemical inhibition of the Sac domain does not affect the activity of the IPPc domain 
towards PI(4,5)P2 indicating that “tight” or “loose” substrate channelling mechanisms 
are unlikely to occur within Synaptojanin. These results also confirm that levels of 
phosphate produced from the bulk PI(4)P hydrolysis by  Sac/IPPc during the hydrolysis 
of PI(4,5)P2 are negligible.    
However, the results presented here are likely to dependent upon the 
presentation of the lipid substrate.  It was reported by Chung et al that when PI(4,5)P2 
was incorporated into vesicles containing DOPE and DOPC, then the predominant 
product formed was PI. However, when a micellar format was used, levels of PI(4)P 
were found to be larger than that of PI[105]. This suggests that the Sac domain activity 
is dependent upon the surface on which it acts. Therefore, the possibility that substrate 
channelling might occur when other substrate presentations are used cannot be ruled 
out. It could be that the presence of a vesicle membrane is required to induce the 
formation of a substrate channel.    
Given that in the present work, it was shown that DOPE is able to significantly 
increase the activity of the IPPc domain, it is interesting that Chung et al found that 
increased levels of PI were produced when PI(4,5)P2 was incorporated into vesicles 
containing DOPE[105]. It could be that the presence of DOPE in the PI(4,5)P2 vesicles 
stimulates the IPPc hydrolysis of PI(4,5)P2 and in doing so creates higher levels of the 
Sac substrate PI(4)P. This in turn would generate higher levels of PI.  
The fact that the presence of DOPE increases activity of the IPPc domain provides 
direct evidence that the conformation of Synaptojanin is sensitive to the lipid 
environment in which it works. Given the role of Synaptojanin in the uncoating of 
synaptic vesicles, it is perhaps not surprising that the activity of the enzyme is sensitive 
to the lipid environment in which it works[63, 76].  
Increasing levels of type II lipids such as DOPE in a bilayer are known to increase 
the levels of membrane stored curvature elastic stress (see Section 6.16)[264, 280]. 
Therefore, it could be that Synaptojanin can sense levels of membrane stored curvature 
elastic stress. As described previously, a variety of proteins, including CCT, PLA2 and 
DGK have been shown to respond to increasing levels of DOPE in membranes [280-282]. 
However, one cannot exclude the possibility that the DOPE headgroup activates the IPPc 
domain through electrostatic interactions with the enzyme.  
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A membrane docking model of S.pombe Synaptojanin as proposed by Tsujishita 
et al is shown in Fig. 6.21[128]. As previously described, the enzyme CCT responds to 
levels of DOPE in the membrane. It is thought that CCT enzyme responds to levels of 
membrane DOPE by inserting its alpha helix into the membrane. As can be seen from 
Fig 6.22, it is unlikely that such a binding mode exists in Synaptojanin as the molecular 
surface surrounding the active site is relatively flat.  
It is thought that steric considerations rather than electrostatic interactions are 
likely to control the translocation of Synaptojanin to the membrane as other than the 
active site, there is relatively little concentration of positive charge in the flat membrane 
binding surface. Data in the present work indicate that the binding of the DOPE/DOPC 
vesicles is allosteric, as the effect was mainly a VMax one.  Therefore, it is likely that the 
vesicles act on a binding site exterior to the active site and in doing so cause a 
conformational change which in turn activates the enzyme. Such a binding site would 
ensure that full activation of the IPPc domain only occurs at the membrane surface. 
 
 
Fig 6.21: Membrane docking of S.pombe Synaptojanin. Red areas correspond to acidic 
regions, blue = basic, green= hydrophobic and white= uncharged polar. Figure is taken from 
Tsujishita et al [128] 
 
 
 
Interface 
Hydrocarbon Core PI(4)P molecule 
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 Although the activity of Synaptojanin is clearly modulated by its lipid 
environment, no evidence was found to suggest that interfacial recognition is 
responsible for the observed co-dependence. In contrast to previous work, 
octylglucoside was found not to inhibit the IPPc domain activity towards I(1,4,5)P3.  
It is instead likely that direct protein-lipid interactions control the domain 
dependency. PI(4)P in octylglucoside was shown to have the ability to competitively 
inhibit the IPPc domain activity towards I(1,4,5)P3. Seeing as the system was below its 
CMC, it is likely that this effect is due to direct binding of the PI(4)P molecule to the IPPc 
active site. The fact that I(1,4)P2 does not inhibit the IPPc domain shows that the 
interaction with PI(4)P and IPPc requires the presence of a fatty acid chain or surface. 
Seeing as PI(4)P is the product of the IPPc catalysis of PI(4,5)P2, it was proposed 
that Synaptojanin could operate via a product inhibition mechanism. However, PI(4)P 
was shown not to inhibit the IPPc phosphatase in the presence of PI(4,5)P2 implying 
that this is not the case. The inhibition of IPPc by PI(4)P was found to be competitive. 
However, if the binding was to be competitive, then inhibition surely should be 
observed with PI(4,5)P2 as a substrate. Therefore, another possibility is that PI(4)P 
binds specifically to the same lipid binding site as DOPE which excludes water soluble 
substrates through steric hindrance or via conformational change.  
  Overall, it has been found that Synaptojanin does not operate via a substrate 
channelling mechanism and that interfacial recognition does not contribute to the 
observed domain dependency. Instead it is likely that the domain-dependency is likely 
to be controlled by protein-lipid interactions. In addition, the first direct evidence that 
Synaptojanin responds to its lipid environment has been presented.        
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7.  SUMMARY AND CONCLUDING REMARKS 
Synaptojanin is unique in that it contains two distinct catalytic domains; an IPPc domain 
and a Sac phosphatase. The domains in bi-and multi- functional enzymes are often 
found to act in a co-operative manner in order to optimise the output of the enzyme 
[172, 193, 194, 284]. However, the reasons as to why nature has evolved a bi-functional 
inositol phosphatase have as of yet, remained unclear. To elucidate whether the Sac and 
IPPc phosphatases in Synaptojanin act in a co-dependent manner, an analysis of the 
enzymological properties of the Sac and IPPc domains in a series of Synaptojanin 
phosphatases was carried out. This involved an assessment of the KM and VMax 
parameters of the Sac- and IPPc- mediated catalysis of their corresponding substrates in 
a double phosphatase Sac/IPPc, an IPPc mutant, Sac/IPPc-, a Sac mutant Sac-/IPPc, and 
single IPPc and Sac phosphatases.   
 The VMax of the IPPc domain towards the lipid substrate PI(4,5)P2 was found to 
be reduced in Sac-/IPPc and the single IPPc phosphatase compared with that of the IPPc 
domain in Sac/IPPc (see Section 4.2.1). This shows that the functioning of the Sac 
domain has an influence on the ability of the IPPc domain to turn over PI(4,5)P2. The KM 
was found not to differ between the three phosphatases indicating that the functioning 
of the Sac domain does not influence the KM of the IPPc domain towards PI(4,5)P2. The 
kinetic parameters of the IPPc domain towards the soluble substrate I(1,4,5)P3 were 
found not to be influenced by the Sac domain.  
Interestingly, the VMax parameters of the Sac domain hydrolysis of PI(4)P were 
also found to be lower in the single Sac phosphatase and in the IPPc mutant Sac/IPPc- 
compared with the Sac domain in Sac/IPPc (see Section 4.2.2). The VMax activities of the 
Sac and IPPc domains can therefore be described as being co-dependent when they act 
on their lipid substrates (Table 7.1). These results provide the first evidence that the 
functioning of the catalytic domains within Synaptojanin are dependent upon one 
another. In addition, the KM of the Sac domain towards PI(4)P was found to be 
influenced by the functioning of the IPPc phosphatase. The IPPc domain was found not 
to have an effect of the kinetic parameters of the Sac domain in the double phosphatase 
towards the soluble substrate OMFP, indicating that the IPPc and Sac domains are not 
co-dependent when they act on non-lipid substrates. In contrast, the activity of the 
single Sac phosphatase towards OMFP was lower than that of the Sac domain in the 
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double phosphatase. However, one can not rule out the possibility that this enzyme is 
misfolded.  
It is unlikely that the VMax differences between the IPPc domain in the single and 
double phosphatases are due to protein misfolding. If the single IPPc phosphatase were 
to be misfolded, then the domain dependence would be expected to occur with its 
soluble as well as its lipid substrates. Also, the boundaries of the single IPPc 
phosphatase extend beyond the boundaries defined in the literature and are roughly the 
same that were used by Tsujishita et al for the crystal structure determination of the 
IPPc domain[63, 79, 125-128].  
 
Table 7.1: Summary of the VMax activities of the Sac and IPPc domains in each of the phosphatases. 
The activities of the Sac and IPPc domains were significantly higher in the double phosphatase 
than in the mutant and single phosphatases when they acted on lipid substrates. However, the VMax 
of the Sac and IPPc domains were comparable when they acted on soluble substrates.   
 
 VMax 
 
Activity 
 
 
 
 
 
 
 
Lipid 
 
 
 
HIGH 
 
REDUCED 
 
REDUCED 
 
Headgroup/ 
Soluble 
Substrate 
 
 
 
 
NO EFFECT 
 
 
NO EFFECT 
 
 
NO EFFECT 
 
 
The magnesium dependencies of the Sac and IPPc domains in the double 
phosphatase were contrasted and compared (Figs 4.10 and 4.11).  It was found that in 
accordance with the results observed by Chi et al for SP Synaptojanin[80], that in the 
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absence of magnesium, the IPPc domain is unable to hydrolyse I(1,4,5)P3. Addition of 
magnesium raises the activity to a maximum at 2 mM after which the activity slowly 
decreases. Chi et al suggested that the decline in activity in the presence of larger levels 
of magnesium is due to magnesium ions binding to a secondary metal binding site that 
is inhibitory. However, the location of such a site remains to be identified. It was also 
found that the activity of the IPPc domain towards PI(4,5)P2 was also magnesium 
dependent.  
CX5R phosphatases are often reported as being magnesium independent[72]. 
Interestingly, in contrast, it was shown in the present work that the Sac domain in 
Sac/IPPc cannot hydrolyse PI(4)P in the absence of magnesium. The response of Sac to 
increasing levels of magnesium seems to mirror that of the IPPc domain, with the 
characteristic decrease in activity observed at higher magnesium concentrations.  
It was found that the magnesium response of the single Sac domain differs to 
that of Sac in Sac/IPPc (Fig.4.11). The activity of the single Sac phosphatase was found 
not to reach a maximum within the magnesium concentration range examined. 
Therefore, it is likely that the decrease in Sac activity at large magnesium 
concentrations in the double phosphatase, Sac/IPPc, is a direct result of a binding event 
on the IPPc domain.  This provides yet more evidence that the IPPc domain functioning 
influences the activity of the Sac phosphatase. It is possible that the binding of 
magnesium causes a conformational change to the enzyme that controls the functioning 
of both the Sac and IPPc domains. It is not unusual for cations such as magnesium to 
induce changes to an enzyme’s conformation. For example, the interfacial binding of the 
diacylglycerol(DAG)kinase DgKB has been shown to be dependent on a magnesium- 
dependent conformational change[230].  
However, it is unlikely that magnesium effects are the cause of the observed 
domain dependency. At the magnesium concentration (4 mM) used to evaluate the 
kinetic parameters of the domains, binding of magnesium to this putative inhibitory 
binding site is likely to be insignificant. Also, the IPPc domain was rendered inactive 
through the mutation of Asp to Ala. This mutation would not be expected to interfere 
with magnesium binding at the active site of the IPPc domain because the Glu residue in 
the IPPc active site has been shown to be responsible for the binding of the active site to 
the metal cation[104].  
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One can think of several mechanisms that could account for the observed 
enzymological changes with respect to lipid substrates.  Substrate channelling can be 
described as the process of direct transfer of an intermediate between the active sites of 
two enzymes that catalyze sequential reactions in a biosynthetic pathway[217]. The 
product of the IPPc catalysis of PI(4,5)P2, PI(4)P, is a substrate of the Sac domain and it 
has therefore been suggested that Synaptojanin could hydrolyse PI(4,5)P2 directly to PI, 
without accumulation of the PI(4)P intermediate [75, 105]. If Synaptojanin were to 
operate via such a mechanism, then this would have implications for the observed 
domain dependency.  Inactivating the Sac or IPPc domains in the double phosphatase 
would be expected to disrupt the channelling mechanism. For example, mutating or 
removing the Sac domain from the double phosphatase would mean that the PI(4)P, 
produced from the IPPc catalysis of PI(4,5)P2 would not be converted to PI. This in turn 
would be expected to lower the total levels of phosphate produced in the assay.  
Substrate channelling mechanisms in multifunctional enzymes can be identified 
by chemically inhibiting one particular domain and monitoring the effect on the activity 
of the other domains [222]. Therefore, to investigate the possibility that Synaptojanin 
operates via a substrate channelling mechanism, the use of chemical inhibitors was 
employed. If “tight” substrate channelling were to occur within Synaptojanin (see 
Fig.6.1), then chemically inhibiting the Sac domain in Sac/IPPc, would be expected to 
lower the activity of the IPPc domain towards PI(4,5)P2.  Likewise, inhibiting the IPPc 
domain would be expected to lower the activity of the Sac domain towards PI(4)P. In 
this way, the chemical inhibitors effectively act as a chemical control with which to 
investigate whether substrate channelling is responsible for the observed changes in 
VMax between the Synaptojanin phosphatases.   
It was first necessary to identify selective inhibitors of both the IPPc and Sac 
domains. The bisperoxovanadium inhibitor BpV(OH)pic was previously reported as an 
inhibitor of the Sac domain [223] and the compound was confirmed in this work to be a 
potent and selective inhibitor of the Sac domain within Synaptojanin (Fig 5.24).  Due to 
the lack of reported IPPc domain inhibitors in the literature, a variety of compounds 
were tested for their ability to selectively inhibit the IPPc domain. These included 
inositol phosphate analogues, inositol peptide compounds and stibonate compounds. 
Compounds within all of these classes were found to inhibit the IPPc domain, with the 
stibonates proving to be the most potent inhibitors. However, the selectivity of these 
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inhibitors towards the IPPc over Sac domain was found to be too low to be used to 
assess the domain dependency.  
To probe whether substrate channelling occurs within Synaptojanin, the effect of 
Sac inhibition on the activity of the IPPc domain towards PI(4,5)P2 was measured.  
Chemical inhibition of the Sac domain was found not to affect either the KM or VMax of 
the IPPc domain towards PI(4,5)P2. This shows that significant levels of PI are not 
produced by the action of the Sac domain during the IPPc catalysis of PI(4,5)P2. In turn, 
this indicates that substrate channelling does not occur within Synaptojanin. However 
in order to fully confirm that substrate channelling does not occur within Synaptojanin, 
the effect of IPPc inhibition on Sac activity needs to be assessed.   
As described previously, the VMax of the Sac and IPPc domains were found to be 
co-dependent when they acted on the lipid substrates PI(4,5)P2 and PI(4)P suspended 
in octylglucoside. However the functioning of the domains was found to be independent 
when they acted upon the soluble substrates I(1,4,5)P3 and OMFP. Therefore, interfacial 
recognition was investigated as a possible mechanism of domain dependency (Section 
6.2.2). If interfacial recognition were to contribute to the observed domain dependency, 
then the activity of the phosphatases would be expected to be modulated by the 
presence of an interface. It was shown in previous work that octylglucoside inhibits the 
VMax activity of the single IPPc domain towards I(1,4,5)P3[79], and it was therefore 
suggested that the phosphatase could exhibit interfacial recognition towards the 
detergent. However, no such inhibition was observed in the present work and no 
evidence was found to indicate that interfacial recognition contributes to the domain 
dependency. 
However, it was found that the molecule PI(4)P in octylglucoside was able to 
competitively inhibit the IPPc domain activity towards I(1,4,5)P3. At the concentrations 
used in the assay, the system is below its CMC, indicating that the inhibition is a result of 
direct lipid-protein interactions between PI(4)P and the IPPc active site. This is 
supported by data by Woscholski et al that showed that PI(4)P inhibits the IPPc domain 
activity towards PI(3,4,5)P3[90]. Lipid protein interactions have been shown to be 
crucial for the functioning of another inositol phosphatase, PTEN. PI(4,5)P2 has been 
shown to bind to the PTEN and initiate a conformational change that activates the 
enzyme [226].   
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Therefore it seems likely that the domain dependency is controlled by protein-
lipid interactions. However, one cannot rule out the possibility that a conformation 
exists by which the active site of the Sac and IPPc domains are brought together to form 
an enclosure (see Section 4.3.3).     
 Interestingly, the Sac and IPPc domains seem to influence each other in different 
ways. There is no VMax difference between Sac-/IPPc and the single IPPc phosphatase for 
the hydrolysis of PI(4,5)P2. Therefore, the removal of the Sac domain seems to have the 
same effect as its mutation. This implies that the physical presence of the Sac domain 
does not influence the functioning of the IPPc domain. Instead, it is likely that the 
activity of the Sac domain in some way contributes to the VMax of the IPPc domain. 
However, as described earlier, no evidence was found to support the notion that 
substrate channelling occurs within Synaptojanin.  
 The IPPc domain seems to have a different influence on the Sac domain. The VMax 
of the single Sac domain was significantly lower than that of the IPPc mutant Sac/IPPc-. 
This shows that both the activity and physical presence of the IPPc domain are required 
for the normal functioning of the Sac phosphatase. Taking into account the boundaries 
of the individual Sac and IPPc enzymes (See Fig 3.1), the region that contributes to the 
Sac phosphatase enzymes functioning is likely to be between the amino residues 494-
1016. The way in which this section of the phosphatase contributes to the activity of the 
Sac domain could involve the presence of a lipid binding site or that of a conformational 
contribution. 
In addition to establishing that the functioning of the Sac and IPPc domains are 
co-dependent and probing the mechanism by which this occurs, this thesis described 
other insights into the enzymological functioning of Synaptojanin. It was found that 
increasing levels of the lipid DOPE within DOPC vesicles increased the activity of the 
IPPc domain, providing the first direct evidence that Synaptojanin responds to the lipid 
environment in which it works. The effect was found to be primarily on VMax, indicating 
that DOPE interacts in an allosteric manner with the enzyme. Given the role of 
Synaptojanin in the uncoating of synaptic vesicles[63, 76], it is perhaps not surprising 
that the activity of the enzyme is sensitive to the presence of certain lipids in the bilayer. 
As described previously, a variety of proteins, including CCT, PLA2 and DGK have been 
shown to respond to increasing levels of DOPE in membranes [280-282]. 
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Increasing levels of type II lipids such as DOPE in a bilayer are known to increase 
the levels of membrane stored curvature elastic stress (see Section 6.16)[264, 280]. 
Therefore, it could be that Synaptojanin can sense levels of membrane stored curvature 
elastic stress. However, the possibility that the increase in IPPc activity is due to 
electrostatic interactions with the DOPE headgroup cannot be ruled out.  
A variety of stibonate compounds were tested for their ability to inhibit PTP-β.   
PTPs are widely regarded as an important drug target[285, 286] due to their role in 
numerous cell functions including growth, mitogenesis, motility, cell-cell interactions, 
metabolism, gene transcription and the immune response[252]. A number of carboxy-
stibonate compounds were found to potently inhibit PTP-β, with compound 13778 (Fig 
5.17) achieving inhibition at nanomolar concentrations.  Therefore a novel class of low 
molecular weight PTP inhibitors has been identified.  
 
In summary, the main conclusions of this thesis are as follows: 
 
 The functioning of the Sac and IPPc domains in Synaptojanin are co-dependent 
 Protein-lipid interactions are likely to control this co-dependency 
 The activity of Synaptojanin is sensitive to the lipid environment in which it 
works 
 Carboxy-stibonates are a novel class of PTP inhibitor    
 
  These findings have crucial implications for the understanding of the biological 
functioning of Synaptojanin. Synaptojanin has been implicated in both Alzheimer's 
disease and Down ’s syndrome [67, 69, 114, 132] and the knowledge presented here 
will surely aid the understanding and treatment of these disorders.  
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8. FUTURE WORK 
The functioning of the catalytic domains in Synaptojanin were found to be co-dependent 
when they acted on lipid substrates, but independent when they hydrolysed soluble 
non-lipid substrates. Substrate channelling and interfacial recognition were 
investigated as possible mechanisms of domain dependency but were found to be 
responsible for controlling the domain interaction.  There are a number of experiments 
that could be conducted in future work that would aid the understanding of the 
mechanism of the Sac-IPPc domain dependency.  
Further mutagenesis experiments could be used to identify the critical amino 
acids required for the dependency. By making successive single amino acid 
substitutions in the Sac and IPPc domains and monitoring their effect on the functioning 
of the enzyme, the regions of the protein that are necessary for the domain dependency 
could be determined. In particular it would be interesting to mutate the amino acids in 
the region of residues between 494-1016, as this portion of the enzyme seems to be 
critical for the functioning of the Sac domain.   
It was suggested in Section 7 that it is likely that protein-lipid interactions induce 
the domain dependency. Seeing that the dependency was a VMax effect, these 
interactions are likely to change the conformation of the enzyme. It would therefore be 
interesting to investigate if the conformation of Synaptojanin is modulated in the 
presence of its lipid substrates.  
Intra-molecular conformational changes in proteins can be detected in various 
ways. Forster Resonance Energy Transfer (FRET) is a widely used technique that is 
based on the transfer of energy from a donor fluorescence molecule to an acceptor[287-
291]. By attaching a donor molecule to one terminus of Synaptojanin and an acceptor 
molecule to the other, any significant changes to their conformation in the presence of 
their lipid substrates could be detected.  Another method that could be used to detect 
conformational changes within Synaptojanin is Circular Dichroism (CD), which is a 
technique that allows the assessment of the secondary structure of proteins[291-294].  
Inhibition of the Sac domain did not affect the ability of the IPPc domain to 
catalyse its substrates, implying that substrate channelling does not occur within 
Synaptojanin.  However in order to fully confirm that substrate channelling does not 
occur within Synaptojanin, the effect of IPPc inhibition on Sac activity should be 
assessed. To do this, a selective inhibitor of the IPPc domain in the double phosphatase 
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needs to be identified. A strategy that could be used to find an IPPc inhibitor is to 
combine the inositol phosphate analogue compounds (Fig 5.3) with the peptide 
backbones of the inositol peptides (Fig.5.11). The design of the amino acids in the 
peptide backbone could be optimised so that the interactions between the IPPc domain 
and inhibitor are selective to the IPPc domain active site. The inositol peptide 
compounds are currently being resynthesized so that further testing can take place. 
Also, in the future, it would be advantageous to calculate the inhibition constants, Ki, of 
the compounds investigated in this work  
DOPE is a Type II lipid and levels of the lipid in DOPC vesicles were found to 
increase the levels of stored curvature elastic stress.  An array of experiments could be 
carried out to further investigate the effect of the physical properties of the bilayer on 
Synaptojanins functioning. These include the measurement of Synaptojanin’s activity 
towards substrates suspended in vesicles in the presence of varying lipid compositions. 
It would also be interesting to evaluate whether the functioning of 5-phosphatase 
domains in other inositol phosphatases, such as OCRL, SHIP and SKIP, are modulated by 
the presence of DOPE.  Also, instead of the use of spherical vesicles supported lipid 
bilayers could be used [295-299]. This would solve the issues surrounding the use of 
spherical vesicles in absorbance measurements.  
Further work will include an in vivo assessment of the levels of tyrosine 
phosphorylation in cells in the presence of the carboxy-stibonate inhibitors. If these 
compounds were to inhibit PTPs in vivo, then they could provide a potential therapeutic 
option for type II diabetes[300-302].      
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